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Point	  mutations	  in	  the	  isocitrate	  dehydrogenase	  (IDH)	  genes	  are	  an	  early,	  if	  not	  the	  earliest	  
event	  during	  the	  development	  of	  gliomas	  and	  other	  tumors,	  such	  as	  acute	  myeloid	  leukemia	  
(AML).	  Among	  grade	  II	  and	  grade	  III	  gliomas,	  more	  than	  80	  %	  carry	  an	  IDH	  mutation.	  In	  these	  
entities,	  mutations	  almost	  exclusively	  affect	  the	  catalytically	  critical	  arginine	  residue	  of	   the	  
cytoplasmic	   IDH1,	   leading	  to	  the	  amino	  acid	  exchange	  to	  histidine	  (R132H).	  This	  and	  other	  
IDH	   mutations	   result	   in	   a	   neomorphic	   enzyme	   function	   and	   the	   production	   of	   the	  
oncometabolite	   2-­‐hydroxyglutarate	   (2-­‐HG)	   and	   thus	   genome-­‐wide	   hypermethylation	   and	  
malignant	  transformation.	  
The	  work	  at	  hand	  demonstrates	  the	  suitability	  of	  IDH1R132H	  as	  a	  target	  for	  immunotherapy	  
in	   an	  MHC-­‐humanized	  mouse	  model,	   A2.DR1.	   Peptides	   encompassing	   the	  mutated	   region	  
bound	  MHC	  class	  II	   in	  vitro	  and	  induced	  a	  mutation-­‐specific	  CD4+	  T	  helper	  (Th)	  response	  in	  
vivo,	   whose	   antigen-­‐specificity	   persisted	   in	   a	   specific	   T	   cell	   line	   and	   clone	   and	  which	  was	  
accompanied	  by	  IDH1R132H-­‐specific	  antibody	  production.	  To	  detect	  IDH1R132H-­‐specific	  IgG	  
in	  mouse	  and	  human	  serum,	  a	  peptide-­‐coated	  ELISA	  was	  established.	  Several	  tested	  patients	  
with	  IDH1R132H+	  gliomas	  showed	  spontaneous	  IDH1R132H-­‐specific	  antibody	  and	  CD4+	  Th1	  
cell	   responses.	  Preventive	  and	  therapeutic	   IDH1R132H	  peptide	  vaccination	  of	  A2.DR1	  mice	  
bearing	   syngeneic	   IDH1R132H+	   sarcomas	   resulted	   in	   an	   effective	   mutation-­‐specific	  
antitumor	   immune	   response	   capable	   of	   controlling	   tumor	   growth	   in	   a	   CD4+	   T	   and	   B	   cell-­‐
dependent	   manner.	   Functionality	   of	   the	   vaccine	   was	   evidenced	   by	   loss	   of	   IDH1R132H	  
expression	  in	  IDH1-­‐transduced	  sarcomas	  and	  infiltration	  of	  IDH1R132H-­‐specific	  CD4+	  T	  cells	  
into	  the	  tumor	  bulk.	  Compared	  to	  therapeutic	  MHC	  II-­‐mediated	  peptide	  vaccination	  against	  
the	  well-­‐established	   cancer	   testis	   antigen	   1	   (CTAG1B,	  NY-­‐ESO-­‐1),	   IDH1R132H	   is	   a	   relevant	  
neoantigen	  of	  comparable	  efficacy.	  
Given	   the	   IDH1R132H-­‐mediated	   accumulation	   of	   2-­‐HG,	   the	   effect	   of	   this	   metabolite	   on	  
human	   T	   cells	   is	   of	   potential	   relevance	   during	   IDH1R132H-­‐targeted	   immunotherapy.	  
However,	  neither	  human	  peripheral	  CD4+	  nor	  CD8+	  T	   cell	   functions	   from	  healthy	   subjects	  
were	  affected	  by	  2-­‐HG.	  
In	   conclusion,	   IDH1R132H	   represents	   a	   potentially	   clinically	   meaningful	   tumor-­‐specific	  
neoantigen.	   Conceptually,	   patients	   with	   low-­‐grade	   and	   anaplastic	   gliomas	   with	   a	   high	  
 II	  
prevalence	   of	   the	   IDH1R132H	   mutation	   represent	   a	   patient	   population,	   which	   may	  
particularly	   benefit	   from	   a	   tumor	   vaccine,	   as	   there	   is	   currently	   no	   therapy	   preventing	  
recurrence	   in	   this	   relatively	   young	   and	   immunologically	   competent	   patient	   population.	  
Moreover,	   patient	   groups	   with	   other	   IDH1R132H-­‐mutated	   tumors	   might	   potentially	   also	  




Während	  der	  Entwicklung	  von	  Gliomen	  und	  anderer	  Tumore,	  wie	   z.	  B.	  akuter	  myeloischer	  
Leukämie	   (AML),	   sind	   Punktmutationen	   in	   den	   Isozitrat-­‐Dehydrogenase	   (IDH)	   Genen	   ein	  
frühes,	   wenn	   nicht	   das	   früheste	   Ereignis.	  Mehr	   als	   80	   %	   der	   Grad	   II	   und	   Grad	   III	   Gliome	  
tragen	  eine	  IDH	  Mutation.	  In	  diesen	  Entitäten	  betreffen	  Mutationen	  fast	  ausschließlich	  den	  
katalytisch	   kritischen	   Argininrest	   des	   zytoplasmatischen	   IDH1	   und	   führen	   zum	  
Aminosäureaustausch	  zu	  Histidin	  (R132H).	  Diese	  und	  andere	  IDH	  Mutationen	  resultieren	  in	  
einer	   neomorphen	   enzymatischen	   Funktion	   und	   der	   Produktion	   des	   Onkometaboliten	   2-­‐
Hydroxyglutarat	   (2-­‐HG).	   Die	   Akkumulation	   von	   2-­‐HG	   führt	   zu	   genomweiter	  
Hypermethylierung	  und	  maligner	  Transformation.	  
Die	  vorliegende	  Arbeit	  befasst	  sich	  mit	  der	  Eignung	  der	  IDH1R132H	  Mutation	  als	  Zielstruktur	  
für	  Immuntherapien	  in	  einem	  MHC-­‐humanisierten	  Mausmodell,	  in	  A2.DR1-­‐Mäusen.	  Peptide,	  
die	   die	  Mutationsregion	   enthalten,	   banden	   an	  MHC	  Klasse	   II	   in	   vitro	   und	   induzierten	   eine	  
mutationsspezifische	   CD4+	   T	   Helfer	   (Th)	   Antwort	   in	   vivo,	   deren	   Antigenspezifität	   auch	   in	  
einer	  spefischen	  T-­‐Zelllinie	  und	  einem	  Klon	  persistierte	  und	  die	  von	  IDH1R132H-­‐spezifischer	  
Antikörperproduktion	   begleitet	   war.	   Um	   IDH1R132H-­‐spezifische	   IgG	   in	   murinem	   und	  
humanem	  Serum	  zu	  detektieren,	  wurde	  ein	  Peptid-­‐beschichteter	  ELISA	  etabliert.	  Ein	  Teil	  der	  
untersuchten	  Patienten	  mit	   IDH1R132H+	  Gliomen	  wurde	  positive	  auf	  spontane	  IDH1R132H	  
spezifische	   Antikörper	   und	   CD4+	   Th1	   Zellen	   getestet.	   Präventive	   und	   therapeutische	  
Peptidvakzinierung	  mit	  IDH1R132H	  von	  A2.DR1	  Mäusen,	  die	  syngene	  IDH1R132H+	  Sarkome	  
trugen,	   resultierte	   in	   einer	   effektiven	   mutationsspezifischen	   anti-­‐Tumor	   Immunantwort.	  
Abhängig	  von	  CD4+	  T-­‐Zellen	  und	  B-­‐Zellen	  konnte	  das	  Tumorwachstum	  durch	  die	  induzierte	  
Immunantwort	  kontrolliert	  werden.	  Die	  Funktionalität	  der	  Vakzine	  wurde	  durch	  den	  Verlust	  
der	   IDH1R132H	   Expression	   in	   transduzierten	   Tumoren	   und	   der	   Infiltration	   IDH1R132H-­‐
spezifischer	  CD4+	  T-­‐Zellen	  in	  die	  Tumormasse	  gezeigt.	  Verglichen	  mit	  therapeutischer	  MHC	  II	  
vermittelter	   Peptidvakzinierung	   gegen	   das	   etablierte	   Tumor-­‐Hoden-­‐Antigen	   CTAG1B	   (NY-­‐
ESO-­‐1),	  ist	  IDH1R132H	  ein	  relevantes	  Neoantigen	  vergleichbarer	  Wirksamkeit.	  
Aufgrund	   der	   IDH1R132H-­‐vermittelten	   Akkumulation	   von	   2-­‐HG	   ist	   der	   Effekt	   dieses	  
Metaboliten	  auf	  humane	  T-­‐Zellen	  von	  potenzieller	  Relevanz	  für	  eine	  IDH1R132H-­‐gerichtete	  
 IV	  
Immuntherapie.	   Jedoch	   waren	   weder	   periphere	   CD4+	   noch	   CD8+	   T-­‐Zellfunktionen	   von	  
Probanden	  durch	  2-­‐HG	  beeinträchtigt.	  
Schlussfolgernd	   lässt	   sich	   sagen,	   dass	   die	   IDH1R132H	   Mutation	   ein	   potentziell	  
bedeutungsvolles,	   tumorspezifisches	   Neoantigen	   ist.	   Konzeptuell	   repräsentieren	   Patienten	  
mit	  niedriggradigen	  und	  anaplastischen	  Gliomen	  mit	  einer	  hohen	  Prävalenz	  der	  IDH1R132H	  
Mutation	  eine	  Patientenpopulation,	  die	  besonders	  von	  einer	  Tumorvakzine	  profitieren	  kann,	  
da	   es	   derzeit	   keine	   Therapie	   gibt,	   die	   ein	   Rezidiv	   in	   dieser	   relativ	   jungen,	   immunologisch	  
kompetenten	   Patientenpopulation	   verhindert.	   Darüber	   hinaus	   könnten	   Patientengruppen	  
mit	   anderen	   IDH1R132H-­‐mutierten	   Tumoren	   möglicherweise	   von	   solch	   einer	   Vakzine	  
profitieren.	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1	  INTRODUCTION	  
	  
1.1	  Cancer	  Immunotherapy	  
	  
Since	  the	  first	  description	  of	  cancer	  as	  a	  disease	  some	  thousands	  of	  years	  ago,	  in	  3000	  BC	  [1],	  
and	   despite	   of	   considerable	   progress	   in	   development	   of	   treatment	   and	   therapy,	   in	   most	  
solid	  tumor	  entities	  consisting	  of	  surgery,	  radiotherapy,	  and	  chemotherapy,	  cancer	  remains	  
the	   second-­‐leading	   cause	  of	   death	   in	   the	   industrialized	  world	   (World	  Health	  Organization.	  
The	   Global	   Burden	   of	   Disease:	   2004	   Update.	   Geneva:	   World	   Health	   Organization;	   2008.	  
www.who.int).	  The	  idea	  of	  harnessing	  the	  immune	  system	  to	  target	  tumor	  cells	  dates	  back	  
to	  over	  a	  century	  ago	  when	  bacterial	  toxins	  were	  injected	  into	  cancer	  patients	  for	  treatment	  
[2,	  3].	   Since	   then,	   the	   reasons	  why	  cancer	   therapy	  by	  employment	  of	   the	   immune	  system	  
has	  gained	  so	  much	  interest	  and	  raised	  hope	  have	  become	  more	  profound.	  The	  concept	  of	  
cancer	   immunotherapy	  relies	  on	   immunosurveillance	  mechanisms,	  which	  are	  hypothesized	  
to	  naturally	  prevent	  development	  of	  a	  tumor	  from	  transformed	  cells,	  and	  immune	  escape	  by	  
transformed	   cells	   that	   are	   able	   to	   evade	   the	   surveillance	   by	   the	   immune	   system,	   thereby	  
being	   able	   to	   form	   a	   tumor.	   Hence,	   immunotherapy	   aims	   at	   manipulating	   the	   immune	  
system	  to	  enhance	  anti-­‐tumor	  immunity	  and	  at	  preventing	  immune	  escape	  by	  the	  tumor.	  
Hints	  for	  natural	  tumor	  immunity	  comes	  from	  observations	  that	  after	  transplantation,	  which	  
goes	  along	  with	  therapeutic	  immunosuppression,	  patients	  have	  a	  higher	  risk	  for	  developing	  
tumors	   [4,	   5].	   In	   addition,	   it	   has	   been	   shown	   that	   in	   many	   tumor	   entities,	   infiltration	   of	  
lymphocytes	  into	  the	  tumor	  is	  associated	  with	  a	  better	  prognosis	  [6-­‐12].	  Direct	  evidence	  for	  
the	   role	   of	   the	   immune	   system	   in	   controlling	   tumor	   growth	   came	   from	   experiments	  with	  
immunodeficient	   mice,	   which	   developed	   tumors	   faster	   and	   at	   a	   higher	   frequency	   than	  
immunocompetent	   mice	   after	   chemical	   induction	   [13].	   Furthermore,	   when	   tumors	   from	  
immunodeficient	   mice	   were	   implanted	   into	   immunocompetent	   wildtype	   (wt)	   mice,	   they	  
were	   completely	   rejected,	   suggesting	   that	   the	   immune	   system	   is	   not	   only	   capable	   of	  
preventing	   tumor	   development,	   but	   also	   to	   eliminate	   established	   tumors	   that	   have	   not	  
grown	  under	  immunosurveillance.	  
However,	   in	   the	  patient,	   tumor	   immunoediting	  eventually	   leads	   to	   immune	  escape.	  When	  
transformation	   of	   cells	   first	   occurs	   and	   a	   tumor	   forms,	   cells	   of	   both	   the	   innate	   immune	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system,	  such	  as	  dendritic	  cells	  (DC)	  and	  natural	  killer	  (NK)	  cells,	  and	  adaptive	  immune	  system,	  
such	   as	   T	   cells,	   are	   activated	   and	   eliminate	   tumor	   cells	   [14,	   15].	   Yet,	   because	   of	   genetic	  
instability	  and	  heterogeneity	  of	  tumor	  cells,	  immune	  selection	  leads	  to	  equilibrium	  between	  
anti-­‐tumor	   immunity	   and	   immunosuppressive	   mechanisms	   and	   eventually	   to	   immune	  
escape	   and	   tumor	   progression.	   Under	   immune	   selection,	   tumors	   regulate	   a	   variety	   of	  
pathways	   to	   evade	   immunosurveillance.	   These	   include	   inhibition	   of	   DC	   maturation	   and	  
functions,	  leading	  to	  inhibited	  immune	  response	  or	  T	  cell	  tolerance	  [16],	  downregulation	  of	  
receptors	   that	   are	   required	   for	   targeted	   NK	   cell	   functions	   [17],	   downregulation	   of	   MHC	  
receptors	  that	  are	  essential	  for	  antigen	  presentation	  and	  therefore	  recognition	  by	  cytotoxic	  
T	   cells	   (CTL)	   [15],	   recruitment	   of	   immunosuppressive	   components	   of	   the	   immune	   system	  
such	  as	  regulatory	  T	  cells	   (Treg)	   [18]	  and	  myeloid-­‐derived	  suppressor	  cells	   (MDSC)	  [19],	  and	  
induction	   of	   an	   immunosuppressive	  microenvironment,	   e.	   g.	   by	   secretion	   of	   transforming	  
growth	  factor	  β	  (TGF-­‐β)	  and	  interleukin	  (IL)-­‐10	  [20].	  
Cancer	   Immunotherapy	   follows	   two	   distinct	   strategies	   to	   exploit	   the	   immune	   system	   for	  
targeted	   cancer	   treatment.	   Passive	   immunotherapies	   target	   tumor	   cells	   specifically	   and	  
exert	   immunological	   anti-­‐tumor	   effects	   by	   themselves.	   These	   include	   tumor-­‐specific	  
monoclonal	  antibodies	  or	  administration	  of	  specific	  T	  cells	  by	  adoptive	  T	  cell	  transfer.	  Tumor	  
cell	   killing	  mechanisms	   range	   from	  direct	   action	   over	   immune-­‐mediated	   killing	   to	   payload	  
delivery	   [21].	  Prominent	  examples	   for	  passive	   immunotherapy	   targets	   that	   are	   involved	   in	  
immune	   responses	   are	   cytotoxic	   T	   lymphocyte-­‐associated	   antigen	   4	   (CTLA-­‐4)	   and	  
programmed	  cell	  death	  protein	  1	   (PD1).	  Both	  are	  proteins	   involved	   in	   immune	  checkpoint	  
mechanisms	  that	  diminish	  T	  cell	  activation	  or	  lead	  to	  tolerance	  induction	  and	  are	  expressed	  
on	  activated	  T	  cells	  [22,	  23].	  Both	  can	  be	  inhibited	  with	  monoclonal	  antibodies.	  Ipilimumab,	  
which	   is	  specific	  for	  CTLA-­‐4,	  has	  proved	  to	  strengthen	  cellular	   immune	  responses	  and	  anti-­‐
tumor	   activity	   [24],	   and	   has	   therefore	   been	   approved	   by	   the	   U.S.	   Food	   and	   Drug	  
Administration	   (FDA)	   for	   melanoma.	   In	   patients	   with	   advanced	   melanoma,	   ipilimumab	  
enhances	   overall	   survival	   compared	   to	   standard	   care	   with	   long-­‐term	   effects	   [25,	   26],	  
suggesting	   the	   generation	   of	   an	   immunological	   memory	   as	   a	   major	   advantage	   of	  
immunotherapy.	   Likewise,	   an	   inhibitory	   antibody	   targeting	   PD1	   amplified	   T	   cell	   function,	  
thereby	  reducing	  tumor	  growth	  in	  mouse	  models	  for	  melanoma	  and	  colon	  carcinoma	  [27].	  
Moreover,	  in	  a	  Phase	  I	  clinical	  trial,	  blockade	  of	  PD1	  showed	  promising	  results	  [28].	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Adoptive	  T	  cell	  transfer	  is	  the	  re-­‐infusion	  of	  autologous	  or	  allogeneic	  tumor	  antigen-­‐specific	  
T	  cells	  into	  the	  patient.	  These	  T	  cells	  can	  be	  genetically	  engineered	  e.g.	  to	  express	  chimeric	  
antigen	  receptors	  (CARs)	  serving	  as	  artificial	  T	  cell	  receptors,	  or	  expanded	  ex	  vivo	   from	  the	  
patient	  (reviewed	  by	  [29]).	  In	  clinical	  trials,	  adoptive	  transfer	  of	  CD8+	  as	  well	  as	  CD4+	  T	  cells	  
specific	  for	  NY-­‐ESO-­‐1	  (see	  below)	  into	  melanoma	  patients	  has	  proven	  to	  be	  effective	  [30,	  31].	  
Active	  immunotherapy	  intends	  to	  tip	  the	  balance	  between	  immunosurveillance	  and	  immune	  
escape	   towards	   successful	   eradication	   of	   the	   tumor	   by	   stimulation	   of	   the	   host’s	   immune	  
system	   to	   generate	   a	   tumor	   antigen-­‐specific	   cellular	   and	   humoral	   response.	   Strategies	   to	  
achieve	   an	   antigen-­‐specific	   T	   cell-­‐mediated	   anti-­‐tumor	   immune	   response	   involve	   cDNA	   or	  
peptide	   vaccination	   and	   dendritic	   cell	   vaccination	   using	   whole	   tumor	   lysates	   or	   specific	  
antigenic	   proteins.	   For	   all	   approaches,	   the	   presentation	   of	   a	   tumor-­‐specific	   or	   tumor-­‐
associated	  antigen	  as	  target,	  leading	  to	  the	  induction	  of	  antigen-­‐specific	  and	  tumor-­‐reactive	  
T	  cell	  responses,	  is	  required	  in	  order	  to	  achieve	  specificity	  for	  tumor	  cells.	  Typically,	  targeted	  
antigens	   can	   be	   unaltered	   tissue	   differentiation	   antigens	   that	   are	   overexpressed	   in	  
corresponding	   tumor	   entities,	   such	   as	   gp100,	   melanoma	   antigen	   recognized	   by	   T	   cells	   1	  
(MART1),	   and	   tyrosinase-­‐related	   protein	   1	   and	   2	   (TYRP1/2),	   which	   are	   overexpressed	   in	  
melanoma	  [32-­‐34],	  tumor	  stroma	  and	  vasculature	  antigens,	  viral	  antigens	  e.g.	  from	  human	  
papillomavirus	   (HPV),	   gene	   mutation	   products	   such	   as	   epidermal	   growth	   factor	   receptor	  
variant	  III	  (EGFRvIII),	  which	  has	  been	  targeted	  in	  phase	  II	  clinical	  trials	  [35],	  and	  antigens	  that	  
are	  derived	  from	  epigenetic	  changes	  which	  trigger	  the	  expression	  of	  so-­‐called	  cancer-­‐testis	  
antigens	   that	   are	  usually	   only	   expressed	   in	   the	   germline,	   including	   cancer	   testis	   antigen	  1	  
(CTAG1,	  or	  New	  York	  esophageal	  squamous	  cell	  carcinoma	  (NY-­‐ESO-­‐1)	  (reviewed	  by	  [29]).	  In	  
contrast	  to	  overexpressed	  antigens,	  gene	  mutation	  products	  may	  induce	  reactive	  T	  cells	  that	  
have	   not	   been	   subjected	   to	   tolerance	   during	   thymic	   development	   hence	   may	   induce	  
stronger	   responses.	   The	   advantage	   of	   cancer	   testis	   antigens	   is	   that	   they	   are	   expressed	   in	  
many	  tumor	  entities	  but	  not	  in	  normal	  non-­‐germline	  tissue.	  Specific	  T	  cells	  do	  not	  recognize	  
the	  antigen	  on	  male	  germline	  cells	  because	  these	  lack	  expression	  of	  major	  histocompatibility	  
complexes	  (MHC)	  and	  therefore	  do	  not	  present	  the	  antigen	  [36].	  
The	  most	  prominent	  and	  very	  potent	  cancer	  testis	  antigen	  NY-­‐ESO-­‐1	  has	  been	  identified	  in	  
esophageal	   squamous	   cell	   carcinoma	   and	   is	   expressed	   in	   a	   variety	   of	   cancers	   such	   as	  
melanoma,	   breast,	   bladder	   and	   prostate	   cancer,	   and	   hepatocellular	   carcinoma	   [37]	   and	   is	  
one	   of	   the	   most	   immunogenic	   tumor	   antigens,	   inducing	   both	   spontaneous	   humoral	   and	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cellular	   immune	   responses	   in	   mice	   and	   patients.	   T	   cell	   responses	   to	   NY-­‐ESO-­‐1	   are	   not	  
restricted	  to	  CTL,	  but	  NY-­‐ESO-­‐1	  also	  elicits	  CD4+	  T	  cell	  reactivity	  and	  humoral	  responses	  [38-­‐
43].	   In	   clinical	   trials,	   NY-­‐ESO-­‐1-­‐specific	   immunotherapy	   has	   led	   to	   profound	   immune	  
responses	  even	  in	  NY-­‐ESO-­‐1-­‐negative	  patients,	  with	  a	  benefit	  for	  NY-­‐ESO-­‐1-­‐positive	  patients	  
[31,	  44,	  45].	  
For	   an	   efficient	   anti-­‐tumor	   immunity	   against	   a	   particular	   antigen,	   antigen-­‐presenting	   cells	  
(APC),	  mostly	  DC,	  need	  to	  take	  up	  tumor	  antigens,	  process	  them	  and	  present	  them	  on	  MHC	  
molecules	  to	  CD4+	  or	  CD8+	  T	  cells.	  Antigen-­‐specific	  T	  cells	  need	  to	  differentiate	  into	  effector	  
T	   cells	   by	   engagement	   of	   peptide-­‐MHC	   complexes	   by	   the	   T	   cell	   receptor	   (TCR),	   by	   co-­‐
stimulatory	   signals	   delivered	   to	   CD28,	   and	   by	   stimulatory	   cytokines.	   In	   Immunotherapy,	  
antigen	   presentation	   can	   be	   achieved	   by	   protein	   or	   mostly	   peptide	   vaccination	   using	   an	  
effective	  epitope,	  during	  which	  DC	  take	  up	  the	  antigenic	  peptide	  inside	  the	  patient.	  This	  type	  
of	   vaccination	   is	   the	   easiest	   and	   most	   cost-­‐effective	   vaccination.	   Several	   studies	   have	  
targeted	  NY-­‐ESO-­‐1	  by	  vaccination	  with	  protein	  [44]	  or	  peptide	  [45].	  For	  peptide	  vaccination,	  
the	  use	  of	  an	  immune-­‐stimulatory	  adjuvant	  is	  required	  in	  order	  to	  establish	  innate	  immune	  
responses.	  This	  is	  usually	  achieved	  by	  administration	  of	  pattern	  recognition	  receptor	  ligands,	  
mostly	   for	   toll-­‐like	   receptors	   (TLRs)	   (reviewed	   in	   [46]).	   The	   TLR-­‐7	   agonist	   imiquimod	   has	  
proven	  a	  potent	  adjuvant,	  which	  enhanced	   immune	  responses	   in	  a	  clinical	   trial	   in	  prostate	  
cancer	   patients	   [47].	   Another	   example	   are	   synthetic	   oligodeoxynucleotides	   containing	  
unmethylated	  CG	  dinucleotides	  (CpG),	  which	  bind	  TLR-­‐9	  and	  have	  proven	  efficacious	  against	  
melanoma,	  renal	  cell	  carcinoma	  [48],	  and	  cutaneous	  T	  cell	  lymphoma	  [49]	  in	  clinical	  studies.	  
Alternatively	  to	  peptide,	  autologous	  DC	  from	  the	  patient	  can	  be	  isolated	  and	  loaded	  ex	  vivo	  
with	  defined	  antigen	  or	  autologous	   tumor	   lysate	   to	  allow	  optimal	  DC	  priming	  and	  patient-­‐
specific	  immunity.	  During	  DC	  vaccination,	  these	  primed	  DC	  are	  infused	  back	  into	  the	  patient.	  
As	  an	  example,	  the	  DC	  vaccine	  sipuleucel-­‐T	  stimulates	  T	  cells	  specific	  for	  the	  overexpressed	  
prostate	  carcinoma	  antigen	  prostatic	  acid	  phosphatase	  (PAP)	  and	  has	  been	  approved	  by	  the	  
FDA	  for	  prostate	  cancer	  patients	  [50],	  significantly	  increasing	  overall	  survival	  by	  four	  months.	  
Since	   most	   tumors	   are	   strongly	   immunosuppressive,	   it	   is	   acknowledged	   that	   overcoming	  
these	   conditions	   at	   the	   tumor	   site	   and	  breaking	   immune	   tolerance	  mostly	   in	   combination	  
with	   vaccination	   are	   required	   for	   induction	   of	   potent	   anti-­‐tumor	   immunity.	   Strategies	   for	  
immunomodulation	   include	   the	   inhibition	   of	   immunosuppressive	   cell	   populations	   such	   as	  
Treg.	  In	  colorectal	  cancer	  patients,	  Treg	  depletion	  led	  to	  elevated	  antigen-­‐specific	  T	  helper	  cell	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responses	  [51];	  however,	  inhibition	  of	  Treg	  bears	  the	  risk	  of	  autoimmune	  induction	  [52,	  53].	  
Immunomodulatory	  antibodies	  for	  passive	  immunotherapy	  as	  discussed	  above	  are	  also	  used	  
in	  combination	  with	  active	  vaccination.	  
	  
	  
Fig.	   1.1.	   Generation	   of	   effective	   tumor-­‐specific	   immune	   responses	   depends	   on	   antigen	  
presentation	   to	   and	   stimulation	   of	   T	   cells,	   enhancement	   of	   T	   cell	   functions,	   and	   inhibition	   of	  
immunosuppression.	   a,	   DC	   priming	   of	   tumor	   antigen-­‐specific	   T	   cells	   can	   be	   accomplished	   by	  
injection	  of	  irradiated	  whole	  tumor	  cells,	  which	  are	  phagocytosed	  by	  DC.	  DC	  present	  tumor	  antigens	  
to	   T	   cells.	   Alternatively,	   DC	   are	   isolated	   from	   the	   patient,	   loaded	  with	   autologous	   tumor	   lysate	   or	  
specific	   antigen,	   matured	   ex	   vivo	   and	   re-­‐implanted	   into	   the	   patient.	   Besides,	   chemotherapy	   or	  
targeted	   therapy	   leads	   to	   apoptotic	   tumor	   cells	   that	   can	   be	   phagocytosed	   by	   DC.	   b,	   Passive	  
immunotherapy	  can	  enhance	  T	  cell	  function	  through	  co-­‐stimulation	  or	  block	  of	   inhibitory	  signals	  by	  
agonistic	   or	   antagonistic	   antibodies,	   respectively.	   c,	   Immunosuppressive	   Treg	   and	   MDSC	   inhibit	  
immune	   responses	   by	   release	   of	   cytokines	   IL-­‐10	   and	   TGF-­‐β.	   Inhibition	   of	   cytokine	   secretion	   or	  
depletion	  of	  these	  cell	  populations	  can	  boost	  anti-­‐tumor	  effective	  T	  cell	  responses.	  [54]	  
	  
Taken	   together,	   cancer	   immunotherapy	   aims	   at	   the	   generation	   of	   a	   potent	   anti-­‐tumor	  
immune	   response.	   This	   includes	   (a)	   DC	   priming	   for	   an	   efficient	   antigen-­‐presentation	   to	   T	  




1.2	  Classification,	  clinical	  and	  molecular	  characteristics,	  and	  standard	  therapy	  
of	  glioma	  
	  
Gliomas	  belong	   to	   the	   two	  most	   abundant	   types	  of	   tumors	  of	   the	   central	  nervous	   system	  
(CNS),	   constituting	  29	  %	  of	  primary	  CNS	   tumors,	   the	  other	  group	  being	  meningiomas	  with	  
35.5	   %.	   Notably,	   gliomas	   account	   for	   80	   %	   of	   malignant	   primary	   CNS	   tumors	   [55].	   CNS	  
tumors	   are	   among	   the	   rather	   rare	   tumor	   entities	  with	   an	   incident	   rate	   of	   20.6	   cases	   per	  
100.000	   people	   in	   the	   U.S.	   in	   2012,	   but	   belong	   to	   the	   most	   malignant	   tumors	   with	   low	  
median	  survival	  rates	  [56].	  
Gliomas	  were	  named	  according	  to	  histopathological	  similarities	  of	  tumor	  cells	  with	  glial	  cells,	  
which	   are	   non-­‐neuronal	   cells	   of	   the	   central	   and	   peripheral	   nervous	   systems	   (CNS,	   PNS,	  
respectively)	   that	   support	   and	  protect	   neurons	   by	   physical	   support,	   nutritient	   and	  oxygen	  
supply,	  myelin	  formation,	  immune	  functions,	  and	  homeostasis.	  Glial	  cells	  are	  classified	  into	  
macroglia	   and	   microglia.	   In	   the	   CNS,	   macroglia	   consist	   of	   astrocytes,	   oligodendrocytes,	  
ependymal	   cells,	   and	   radial	   glia.	   The	   most	   common	   macroglial	   cell	   types	   in	   the	   CNS	   are	  
astrocytes,	  which	  are	  mainly	   involved	   in	  regulation	  of	  blood	  flow	  and	  the	  formation	  of	  the	  
blood-­‐brain-­‐barrier	   (BBB),	   and	   oligodendrocytes,	   which	   form	   myelin	   sheaths	   to	   coat	   the	  
neuronal	   axons,	   allowing	   efficient	   propagation	   of	   electrical	   signals	   along	   the	   axons.	  
Ependymal	   cells	   line	   the	  ventricle	  walls	  and	   secrete	   the	  cerebrospinal	   fluid	   (CSF),	  whereas	  
radial	   glia	   are	   the	   glia	   cells	   of	   the	   retina.	   As	   opposed	   to	   macroglia,	   microglia	   during	  
development	  originate	  in	  the	  embryonic	  yolk	  sac	  and	  arise	  from	  the	  hematopoietic	  system	  in	  
the	  bone	  marrow	  during	  inflammation	  [57,	  58].	  They	  function	  as	  brain	  resident	  macrophages	  
as	  they	  fulfill	  phagocytotic	  functions	  as	  part	  of	  the	  innate	  immune	  system	  in	  the	  brain.	  Since	  
glial	  cells	  are	  most	  abundant	  in	  the	  brain,	  this	  is	  the	  most	  common	  site	  where	  gliomas	  occur.	  
In	   fact,	   gliomas	   are	   the	  most	   common	   brain	   tumors	   in	   adults,	   constituting	   12-­‐15	  %	   of	   all	  
intracranial	  neoplasms,	  30	  %	  of	  all	  CNS	  and	  brain	  tumors,	  and	  even	  80	  %	  of	  all	  primary	  brain	  
tumors	  [55].	  
Gliomas	   can	   be	   classified	   according	   to	   the	   histologically	   corresponding	   normal	   cell	   type,	  
malignancy,	   or	   location.	   In	   accordance	   with	   glial	   cell	   types,	   gliomas	   are	   grouped	   into	  
astrocytomas,	  oligodendrogliomas,	  ependymomas,	  mixed	  gliomas	  such	  as	  oligoastrocytomas,	  
and	  neuroepithelial	  tumors.	  Whether	  gliomas	  indeed	  arise	  from	  glial	  cells	  remains	  a	  matter	  
of	  debate.	  Recent	  in	  vivo	  studies	  suggest	  that	  the	  cell	  of	  origin	  can	  be	  a	  committed	  glial	  cell	  
like	  an	  astrocyte	  and	  oligodendrocyte,	  a	  more	  immature	  precursor	  cell	  or	  a	  neural	  stem	  cell	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[59].	  According	  to	  malignancy,	  gliomas	  are	  classified	  into	  World	  Health	  Organization	  (WHO)	  
grades	  I	  to	  IV,	  whereas	  grade	  I	  tumors	  are	  slowly	  proliferating	  tumors	  with	  a	  high	  probability	  
of	   cure	   by	   surgical	   resection.	   Low-­‐grade	   gliomas	   (WHO	   °II)	   are	   well-­‐differentiated,	   also	  
slowly	  proliferating	  but	  infiltrate	  the	  brain	  parenchyma,	  which	  impairs	  resection	  [60].	  Diffuse	  
astrocytoma,	   oligodendroglioma	   and	   the	   mixed	   subtype	   oligoastrocytoma	   belong	   to	   low-­‐
grade	   gliomas	   and	   patients	   suffering	   from	   these	   subtypes	   have	   a	  median	   survival	   of	   7-­‐10	  
years.	   However,	   despite	   resection	   and	   several	   years	   of	   tumor-­‐free	   survival,	   these	   glioma	  
types	   are	   prone	   to	   recurrence	   and	   malignant	   progression	   to	   a	   higher	   grade	   and	   thus	  
eventually	   also	   lethal	   [60,	   61].	   High-­‐grade	   glioma	   grades	   III	   and	   IV	   are	   anaplastic,	   i.e.	   de-­‐
differentiated,	  and	  more	  malignant,	  requiring	  aggressive	  adjuvant	  therapies	  after	  resection	  
[62].	   Grade	   III	   gliomas	   are	   histologically	   characterized	   by	   nuclear	   atypia	   and	   enhanced	  
proliferation	   [60].	   The	   median	   survival	   for	   patients	   with	   grade	   III	   gliomas	   like	   anaplastic	  
astrocytoma	  is	  highly	  variable	  between	  2	  and	  5	  years	  [62].	  Glioblastoma	  multiforme	  (GBM)	  is	  
the	  most	  malignant	   glioma	   (WHO	  grade	   IV),	   highly	   proliferative	  with	   presence	   of	   necrotic	  
areas,	  and	  accounts	  for	  about	  50	  %	  of	  brain	  tumor	  cases.	  Maximal	  median	  survival	  for	  GBM	  
in	  study	  cohorts	  receiving	  therapy	  is	  only	  14-­‐17	  months	  [63,	  64].	  
Glioma	  patients	  initially	  present	  in	  the	  clinic	  with	  symptoms	  like	  seizures,	  headaches	  caused	  
by	   increased	   intracranial	   pressure,	   and	   focal	   neurologic	   deficits	   or	   altered	   mental	   status	  
because	  of	  mass	  effect,	  infiltration	  or	  destruction	  of	  the	  affected	  part	  of	  the	  brain.	  Primarily,	  
diagnosis	  is	  done	  by	  magnetic	  resonance	  imaging	  (MRI),	  which	  demonstrates	  tumor	  lesions.	  
However,	  a	   conclusive	  and	  differential	  diagnosis	  depends	  on	  histological	  analysis	  of	   tumor	  
tissue	  obtained	  from	  biopsy	  or	  resection	  [56].	  
Surgery	  with	  maximal	  possible	  resection	  is,	   if	  feasible,	  the	  first	  therapeutic	  intervention	  for	  
glioma.	   Standard	   of	   care	   subsequent	   to	   surgery	   depends	   on	   tumor	   type	   and	   grade	   of	  
resection.	   Adjuvant	   therapy	   mostly	   consists	   of	   radiotherapy,	   frequently	   accompanied	   or	  
followed	   by	   chemotherapy	   using	   the	   alkylating	   agent	   temozolomide	   (TMZ)	   [61,	   65,	   66].	  
However,	  with	  respect	  to	  low-­‐grade	  gliomas,	  wait-­‐and-­‐watch	  after	  surgery	  might	  be	  the	  best	  
strategy	  for	  some	  patients.	  
Especially	   high-­‐grade	   gliomas	   are	   characterized	   by	   areas	   of	   necrosis	   and	   hypoxia	   and	   are	  
therefore	   highly	   angiogenic	   tumors	   that	   are	   heavily	   vascularized.	   In	   addition,	   they	   are	  
infiltrative	   tumors	  with	   distinct	   single	   cells	   that	   can	   be	   found	   apart	   from	   the	   tumor	   bulk,	  
making	  a	  complete	   resection	  difficult.	  However,	  gliomas	  are	  not	  mitogenic,	  although	  high-­‐
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grade	  gliomas	  are	  associated	  with	  a	  breakdown	  of	  the	  blood-­‐brain	  barrier	  (BBB).	  Gliomas	  are	  
generally	  immunosuppressive,	  especially	  due	  to	  the	  secretion	  of	  immunosuppressive	  factors	  
such	  as	  TGF-­‐β	  (see	  1.4).	  
On	   a	   molecular	   level,	   gliomas	   are	   hallmarked	   by	   a	   variety	   of	   genetic	   and	   epigenetic	  
alterations,	   and	   the	   mutational	   signature	   of	   a	   tumor	   has	   been	   identified	   to	   distinguish	  
glioma	  subtypes	  and	   to	   shed	   light	  on	   the	  development	  and	  progression	  of	   the	   tumor	   (Fig.	  
1.2).	   Astrocytomas	   in	   general	  mostly	   carry	   a	  mutation	   in	   the	   tumor	   suppressor	   gene	   p53	  	  
(TP53,	   65	   %)	   whereas	   oligodendrogliomas	   frequently	   show	   co-­‐deletion	   of	   chromosomes	  
1p/19q	   (>75	   %).	   With	   respect	   to	   glioblastoma,	   different	   genetic	   and	   epigenetic	   profiles	  
distinguish	  primary	  and	  secondary	  glioblastoma.	  The	  most	  common	  genetic	  alteration	  in	  all	  
glioblastomas	   is	   the	   loss	  of	  heterozygosity	   (LOH)	  on	  chromosome	  10	   found	   in	  primary	  and	  
secondary	  glioblastomas	  [67].	  The	  majority	  of	  glioblastomas	  (>90	  %)	  develops	  de	  novo	  and	  is	  
named	  primary	  glioblastomas.	  Typical	  for	  these	  tumors	  are	  epidermal	  growth	  factor	  receptor	  
(EGFR)	   amplification	   (35	   %)	   [68]	   or	   overexpression	   (63	   %)	   and	   loss	   or	   mutations	   of	  
phosphatase	   and	   tensin	   homologue	   (PTEN,	   25	   %).	   On	   the	   other	   hand,	   secondary	  
glioblastomas	   progress	   from	   diffuse	   or	   anaplastic	   astrocytoma	   and	   therefore	   show	  
astrocytoma-­‐specific	  mutations	  including	  the	  TP53	  mutation.	  In	  addition,	  they	  have	  acquired	  
accessory	   alterations,	   including	   LOH	   of	   19q.	   An	   important	   hallmark	   that	   distinguishes	  
primary	   glioblastoma	   from	   other	   gliomas	   including	   astrocytoma,	   oligodendroglioma,	   and	  
secondary	  glioblastoma,	  is	  the	  mutation	  of	  the	  isocitrate	  dehydrogenase	  1	  (IDH1)	  [69-­‐71]	  in	  
88	  %	  of	  gliomas	  except	  primary	  gliobastomas	  (see	  1.3).	  [67]	  
Based	  on	  their	  molecular	  and	  genetic	  alterations,	  gliomas	  have	  been	  classified	  into	  four	  main	  
subgroups	   by	   integrated	   genomic	   analysis,	   explicitly	   proneural,	   neural,	   classical,	   and	  
mesenchymal	   classes	   [72].	   Proneural	   class	   gliomas	   are	   characterized	   by	   two	   major	   but	  
mutually	  almost	  exclusive	  alterations,	   first	  concomitant	   focal	  amplifications	  with	  high	  gene	  
expression	   levels	   of	   platelet-­‐derived	   growth	   factor	   receptor	   alpha	   (PDGFRA),	   and	   second	  
point	  mutations	  in	  the	  IDH1	  gene	  (see	  1.3).	  Moreover,	  TP53	  alterations	  are	  frequent	  in	  this	  
group.	  Most	  of	  secondary	  GBM	  are	  classified	  into	  the	  proneural	  class.	  The	  neural	  subtype	  is	  
classified	   by	   neuronal	   marker	   gene	   expression,	   such	   as	   neurofilament	   light	   polypeptide	  
(NEFL),	   and	  gamma-­‐aminobutyric	   acid	   (GABA)	  A	   receptor,	   alpha	   1	   (GABRA1).	   The	   classical	  
class	  exhibits	  a	  significant	  increase	  in	  EGFR	  expression	  accompanied	  by	  frequent	  mutations	  
in	   this	   gene.	  Mesenchymal	   gliomas	   are	   identified	   by	   neurofibromin	   1	   (NF1)	   mutations	   or	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deletions	   and	   mesenchmymal	   and	   astrocytic	   marker	   expression	   such	   as	   CD44	   and	   c-­‐mer	  
proto-­‐oncogene	  tyrosine	  kinase	  (MERTK).	  [72]	  
	  
	  
Fig.	  1.2	  Genetic	  pathways	  to	  primary	  and	  secondary	  glioblastomas.	  [67]	  
	  
Epigenetically,	  gliomas	  can	  be	  catagorized	  according	  to	  promotor	  methylation	  patterns	  since	  
the	  discovery	  of	  the	  glioma	  CpG	  island	  methylator	  phenotype	  (G-­‐CIMP),	  which	  is	  defined	  by	  
hypermethylated	   regions	   (CpG	   islands)	   throughout	   a	   large	   number	   of	   loci	   [73].	   G-­‐CIMP	  
gliomas	  belong	  to	  the	  proneural	  class	  and	  are	  tightly	  associated	  with	  IDH1	  mutations,	  which	  
are	  causative	  for	  the	  hypermethylation	  (see	  1.3).	  Due	  to	  the	  hypermethylation	  phenotype,	  
G-­‐CIMP	  gliomas	  (as	  well	  as	  some	  others)	  exhibit	  methylation	  of	  the	  O6-­‐methylguanine-­‐DNA	  
methyl-­‐transferase	   (MGMT)	   promotor,	   thereby	   silencing	   MGMT,	   a	   DNA	   mismatch	   repair	  
enzyme,	  leading	  to	  increased	  sensitivity	  towards	  alkalyting	  chemotherapy	  such	  as	  TMZ	  [74].	  
More	   recently,	   six	   different	   epigenetic	   subgroups	   among	   gliomas	   have	   been	   suggested,	  
characterized	  by	  two	  mutations	  in	  the	  gene	  for	  histone	  H3.3	  (H3F3A)	  occuring	  at	  young	  age	  
(K27	   belonging	   to	   the	   proneural	   class,	   and	   G34),	   IDH	   mutation	   (IDH,	   proneural	   class),	  
PDGFRA	  amplification	  (RTK	  I	  PDGFRA,	  proneural	  class),	  mesenchymal	  and	  classical	  [75].	  
With	  this	  deeper	  understanding	  of	  heterogeneity	  and	  tumorigenic	  pathways	  of	  gliomas,	  not	  
only	  biomarkers	  for	  diagnosis	  and	  prognosis	  have	  been	  identified,	  but	  also	  potential	  targets	  
for	  specific	  treatment.	  Targeted	  therapy,	  however,	  will	  possibly	  remain	  a	   long-­‐term	  goal	   in	  




1.3	  The	  IDH	  mutations	  
	  
Mutations	  in	  the	  isocitrate	  dehydrogenase	  1	  (IDH1)	  gene	  located	  on	  chromosome	  2q33	  were	  
originally	  identified	  by	  an	  integrated	  genomic	  screen	  of	  glioblastoma	  multiforme	  [70].	  Point	  
mutations	   in	   the	   active	   site	   of	   the	   enzyme	   were	   found	   in	   12	   %	   of	   GBM	   patients	   and	  
correlated	  with	  mutations	  in	  TP53,	  but	  not	  with	  PTEN,	  retinoblastoma	  1	  (RB1),	  EGFR,	  or	  NF1	  
mutations,	   supporting	   the	   notion	   of	   distinct	   glioma	   subclasses	   (see	   1.2).	   Isocitrate	  
dehydrogenase	  isoforms	  are	  homodimeric	  enzymes	  catalyzing	  the	  oxidative	  decarboxylation	  
of	   isocitrate	   to	   α-­‐ketoglutarate	   (α-­‐KG),	   producing	   nicotinamide	   adenine	   dinucleotide	  
phosphate	   (NAD[P]H)	   [76].	   Unlike	   the	   other	   isoforms,	   IDH1	   is	   not	   located	   in	   the	  
mitochondria,	  but	  in	  the	  cytoplasm	  and	  peroxisomes	  [77],	  where	  it	  plays	  an	  essential	  role	  in	  
cellular	  regulation	  of	  oxidative	  stress	  by	  the	  generation	  of	  NADPH	  [78,	  79].	  IDH	  types	  2	  and	  3	  
are	   located	   in	   the	  mitochondria	  and	   involved	   in	   the	  citric	  acid	  cycle	  and	   the	  generation	  of	  
ATP.	  
IDH1	   mutations	   occur	   in	   more	   than	   70	   %	   of	   diffuse	   and	   anaplastic	   astrocytomas,	  
oligodendrogliomas,	   oligoastrocytomas,	   and	   secondary	   glioblastomas	   progressing	   from	  
anaplastic	   astrocytomas	   [69,	   71]	   and	   in	   all	   entities	   are	   associated	   with	   increased	  
progression-­‐free	  and	  overall	  survival	  and	  can	  thus	  be	  used	  as	  a	  prognostic	  marker	  for	  glioma	  
patients.	   [70,	   71,	   75,	   80].	   However,	   no	   predictive	   value	   for	   treatment	   decisions	   has	   been	  
shown	  for	  IDH1	  mutations	  [80].	  	  
IDH	  mutations	  are	  an	  early	  –	  if	  not	  the	  earliest	  –	  event	  in	  gliomagenesis	  and	  probably	  occur	  
before	  TP53	  mutations	  or	  1p/19q	   loss,	  because	  gliomas	  carrying	  only	  an	   IDH	  mutation	  are	  
more	   frequent	   than	   those	  with	  only	  TP53	  mutation	  or	  1p/19q	  codeletion	   [67,	  81].	   Loss	  of	  
1p/19q	  appears	  later	  and	  may	  be	  the	  driving	  force	  toward	  oligodendroglioma	  differentiation	  
[82-­‐84].	  
Mutations	   in	   IDH1	   almost	   uniformly	   affect	   amino	   acid	   132,	   leading	   to	   an	   exchange	   of	  
histidine	   to	  arginine	   (R132H),	  a	  critical	   residue	   in	   the	  catalytic	   site	  of	   the	  enzyme,	   forming	  
salt	  bridges	  with	  the	  substrate	   isocitrate	  and	  mediating	  the	  hinge	  movements	  towards	  the	  
active	   conformation	   [85].	   The	   replacement	   with	   histidine	   leads	   to	   inability	   to	   bind	   the	  
natural	  substrate.	  Most	  grade	  II	  and	  III	  gliomas	  as	  well	  as	  secondary	  glioblastomas	  which	  are	  
negative	  for	  IDH1	  mutations,	  harbor	  mutations	  in	  the	  IDH2	  gene,	  uniformly	  affecting	  amino	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acid	   arginine	   172,	   which	   is	   the	   analogous	   amino	   acid	   to	   132	   of	   IDH1	   [71].	   Since	   their	  
discovery	  not	  only	  in	  gliomas,	  but	  also	  other	  tumor	  entities	  such	  as	  acute	  myeloid	  leukemia	  
(AML)	   [86-­‐88],	   sarcomas	   like	   chondrosarcoma	   [89,	   90],	   and	   intrahepatic	  
cholangiocarcinomas	   [91],	   a	   large	   body	   of	   evidence	   has	   accumulated	   delineating	   the	  
metabolic	   consequences	   of	   these	   monoallelic	   point	   mutations	   and	   their	   implications	   in	  
tumorigenesis	   [92].	   The	   amino	   acid	   exchange	   within	   the	   catalytic	   sites	   results	   in	   the	  
inhibition	  of	  wt	  enzymatic	  function	  [93]	  and	  a	  neomorphic	  dominant	  enzymatic	  function	  that	  
is	  associated	  with	  the	  reduction	  of	  α-­‐KG	  to	  and	  the	  accumulation	  of	  the	  oncometabolite	  (R)-­‐
2-­‐hydroxyglutarate	  (2-­‐HG)	  (Fig.	  1.3)	  [85,	  88,	  94].	  
IDH	   type	   1	   and	   2	   mutations	   and	   the	   consequences	   of	   2-­‐HG	   accumulation	   have	   been	  
extensively	   studied.	   2-­‐HG	   accumulation	   is	   sufficient	   to	   alter	   the	   epigenome	   of	   glial	   and	  
hematopoietic	   cells	   [95,	   96]	   resulting	   in	   a	   hypermethylation	   phenotype	   [97,	   98]	   by	  
competitively	   inhibiting	   α-­‐KG-­‐dependent	   dioxygenases	   such	   as	   the	   methylcytosine	  
hydroxylase	  TET2,	  which	  mediates	  DNA	  demethylation,	   and	   the	  histone	  demethylase	   JmjC	  
[99].	  These	   inhibitory	  mechanisms	   lead	   to	  DNA	  hypermethylation	  and	  therefore	   to	   the	  so-­‐
called	  G-­‐CIMP.	  The	  IDH	  mutation	  is	  sufficient	  for	  establishment	  of	  this	  epigenetic	  phenotype	  
[95],	  which	   leads	   to	  genetic	   instability,	   the	   subsequent	  acquisition	  of	  additional	  mutations	  
and	  ultimately	  malignant	  transformation	  [100].	  
	  
	  
Fig.1.3.	  Chemical	   reactions	  catalyzed	  by	   IDH	  wt	  and	   IDH	  mutant	  enzymes.	   IDH1	  and	  IDH2	  convert	  
isocitrate	  α-­‐ketoglutarate	  by	  oxidative	  decarboxylation	  under	  the	  concomitant	  reduction	  of	  NADP	  to	  
NADPH.	  Of	  note,	   IDH3	  utilizes	  NAD+	  to	  produce	  NADH.	  α-­‐ketoglutarate	  serves	  as	  substrate	   for	   IDH	  
mutant	   enzymes	   IDH1R132C,	   IDH1R132H,	   and	   IDH2R172K,	   which	   in	   turn	   reduce	   it	   to	   2-­‐
hydroxyglutarate	  with	  accompanying	  oxidation	  of	  NADPH	  to	  NADP.	  The	  heterozygous	  nature	  of	  the	  
mutation	  ensures	  sufficient	  α-­‐KG	  levels.	  (Adapted	  from	  [94])	  
	  
The	  identification	  of	  IDH1R132H	  has	  led	  to	  the	  epigenetic	  classification	  of	  gliomas	  according	  
to	   promoter	   methylation	   patterns.	   Most	   GBM	   of	   the	   proneural	   subgroup	   carry	   the	   IDH1	  
mutation,	   which	   defines	   the	   G-­‐CIMP	   methylation	   phenotype.	   The	   definition	   of	   six	  
methylation	  clusters	  includes	  one	  so-­‐called	  IDH	  subgroup	  (see	  1.2)	  [75,	  101].	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The	  IDH1	  mutation	  has	  been	  identified	  as	  a	  prognostic	  but	  not	  predictive	  marker	  in	  grade	  II	  –	  
IV	  gliomas	  [80,	  101-­‐103].	  Patients	  with	  IDH1R132H-­‐mutated	  anaplastic	  glioma	  benefit	  from	  a	  
better	  progression-­‐free	  survival	   independent	  of	  treatment	  compared	  to	  patients	  with	  IDH1	  
wt	  anaplastic	  gliomas	   [104],	   together	  with	  the	  causality	  of	  mutation	  events	  supporting	  the	  
notion	  that	  IDH1	  mutation	  defines	  a	  distinct	  glioma	  entity.	  
In	   gliomas	   and	   other	   solid	   tumors	   the	   development	   of	   an	   antibody	   detecting	   IDH1R132H	  
[105,	  106]	  has	  not	  only	  been	  implemented	  in	  clinical	  routine	  diagnostics	  of	  gliomas	  [66]	  but	  
also	   guided	   the	   concept	   that	   IDH1R132H	   is	   expressed	   in	   all	   tumor	   cells	   constituting	   this	  
mutation	   an	   early	   event	   in	   gliomagenesis	   [107].	   Beyond	   expanding	   the	   knowledge	   on	   the	  
metabolic	   and	  epigenetic	   control	  of	   tumorigenesis,	   the	  discovery	  of	   IDH1	  mutations	  bears	  
important	   therapeutic	   implications.	  One	   route	   is	   the	   development	   of	   specific	   inhibitors	   of	  
the	   neomorphic	   enzymatic	   function	   of	   IDH1	   and	   IDH2,	   which	   are	   capable	   of	   suppressing	  
tumor	  growth	  in	  preclinical	  cancer	  models	  of	  glioma	  and	  AML	  [108,	  109].	  As	  a	  specific	  and	  
uniform	  hallmark	  of	  many	  gliomas	  and	  other	  tumors,	  IDH	  mutations	  might	  pave	  the	  way	  to	  a	  
more	  targeted	  therapy	  for	  the	  hitherto	  believed	  to	  be	  highly	  heterogeneous	  glioma.	  
	  
1.4	  Immunotherapy	  for	  glioma	  patients	  
	  
Improvements	   in	   standard	   therapy	  have	  not	   yet	   led	   to	  markedly	  enhanced	   survival,	  much	  
less	   to	   cure	   of	   gliomas.	   In	   search	   of	   alternative	   and	   novel	   therapies	   to	   combat	   gliomas,	  
immunological	   approaches,	   which	   have	   proven	   efficacious	   for	   other	   entities,	   have	   gained	  
interest	  [110].	  
Gliomas	  are	  in	  general	  immunosuppressive	  tumors.	  Brain	  parenchyma	  as	  well	  as	  the	  tumor	  
itself	   are	   characterized	   by	   soluble	   immunoinhibitory	   factors	   derived	   from	   microglia,	  
astrocytes,	  and	  tumor	  cells,	  such	  as	  transforming	  growth	  factor	  β	  (TGF-­‐β),	  which	  suppresses	  
T	   cell	   proliferation	   and	   NK	   cell	   activity	   and	   induces	   T	   cell	   apoptosis	   [111],	   vascular	  
endothelial	  growth	  factor	  (VEGF),	  and	  IL-­‐10,	  as	  well	  as	  the	  expression	  of	  inhibitory	  enzymes,	  
e.g.	   indoleamine	   2,3-­‐dioxygenase	   (IDO)	   by	   dendritic	   cells	   and	   tryptophan-­‐2,3-­‐dioxygenase	  
(TDO)	   [112],	   impairing	   T	   cell	   functions,	   arginase,	   and	   nitric	   oxide	   synthase	   2	   (NOS-­‐2)	   by	  
tumor	   cells.	   In	   this	   regard,	   constitutive	   STAT-­‐3	   activation	   by	   tumor	   cells	   seems	   to	   be	   a	  
central	  regulator	  in	  suppressing	  anti-­‐tumor	  immune	  responses	  [113].	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These	   immunosuppressive	   factors	   lead	   to	   impaired	   effector	   T	   cell	   (Teff)	   proliferation	   and	  
enhanced	  proliferation	  and	  recruitment	  of	  Treg.	  Glioma	  cell	  expression	  of	   inhibitory	  surface	  
molecules	  such	  as	  Fas	  ligand	  (FasL)	  and	  PD-­‐1L	  (B7-­‐H1)	  as	  well	  as	  the	  downregulation	  of	  MHC	  
molecules	  contribute	  to	  weakened	  T	  cell	  proliferation	  and	  the	  induction	  of	  apoptosis	  [114].	  
The	   immunomedulatory	   microenvironment	   in	   glioma	   convert	   microglia	   and	   glioma-­‐
infiltrating	   monocytes	   to	   immunosuppressive	   phenotypes	   [115]	   and	   immunosuppressive	  
monocytic	   cells,	   which	   have	   been	   termed	   myeloid-­‐derived	   suppressor	   cells	   (MDSC)	   are	  
found	  to	  inhibit	  T	  cell	  functions	  in	  glioma	  [116-­‐119].	  Hence,	  gliomas	  both	  directly	  inhibit	  Teffs	  
and	  act	  immunosuppressive	  on	  other	  components	  of	  the	  immune	  system	  (Fig.	  1.4)	  
	  
	  
Fig.	  1.4.	  Immunosuppressive	  mechanisms	  in	  glioma.	  [120]	  
	  
The	  healthy	  brain	   is	  no	   longer	   regarded	  as	  a	  completely	   immunologically	  privileged	  organ,	  
despite	  its	  intact	  BBB	  and	  lack	  of	  lymphatic	  vessels.	  Rather,	  the	  BBB	  allows	  tight	  regulation	  of	  
immune	  responses	  in	  the	  brain	  by	  controlling	  the	  selective	  trafficking	  of	  immune	  infiltrates	  
into	  the	  brain.	  Hence,	  under	  physiological	  conditions,	  the	  brain	  contains	  microglia,	  which	  are	  
the	  brain-­‐resident	  APCs	  contributing	  to	  20%	  of	  CNS	  cells,	  macrophages	  and	  DCs	   [121].	  The	  
intact	  BBB	  results	  in	  the	  impairment	  of	  immune-­‐mediated	  rejection	  at	  the	  time	  of	  malignant	  
transformation	  and	  beginning	  of	  glioma	  growth.	  However,	  the	  necessity	  for	  a	  disruption	  of	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the	  BBB	  for	  immune	  responses	  in	  the	  brain	  is	  a	  prevalent	  misconception	  that	  can	  be	  refuted	  
by	   the	   fact	   that	   autoimmunity	   occurs	   in	   the	   brain	  without	   a	   primary	   BBB	   disruption,	   e.g.	  
multiple	   sclerosis	   (MS)	   [122].	   Actually,	   T	   cells	   constantly	   infiltrate	   and	   survey	   the	   brain	   to	  
prevent	   inflammation	   of	   the	   CNS	   potentially	   caused	   by	   viral	   infections	   [123].	   Moreover,	  
during	  the	  course	  of	  tumor	  progression,	  the	  BBB	  becomes	  disrupted,	  making	  gliomas	  even	  
more	  accessible	  for	  immune	  cell	  infiltrates	  and	  leading	  to	  chemokine-­‐mediated	  attraction	  of	  
immune	  cells	  into	  the	  brain	  tumor,	  including	  macrophages,	  DCs,	  and	  T	  cells	  [114],	  the	  latter	  
consisting	  of	  both	  CD4+	  and	  CD8+	  T	  cells	  and	  constituting	  up	  to	  3.2	  %	  of	  tumor	  cells	  in	  high	  
grade	   glioma	   [124,	   125].	   The	   finding	   that	   immunological	   synapses	   between	   T	   cells	   and	  
glioma	  cells	  can	  form	  in	  the	  patient	  [126]	  leads	  to	  the	  assumption	  that	  infiltrating	  T	  cells	  are	  
functional,	  targeting	  glioma	  cells.	  
Evidence	  that	  T	  cell-­‐mediated	  immunitiy	  can	  play	  a	  role	  for	  glioma	  regression	  came	  from	  rat	  
models	  of	  glioma,	  in	  which	  genetically	  modified	  glioma	  cells	  expressing	  IFN-­‐γ	  implanted	  into	  
the	   brain	   caused	   microglia	   priming	   with	   T	   cell	   infiltration	   and	   tumor	   rejection	   [127].	   In	  
glioma	  patients,	  tumor-­‐infiltrating	  lymphocytes	  (TILs)	  are	  associated	  with	  longer	  survival	  and	  
the	   extent	   of	   T	   cell	   infiltration	   correlates	   with	   a	   better	   outcome	   [128-­‐131].	   Importantly,	  
glioma-­‐infiltrating	  T	  cells	  were	  shown	  to	  be	  functional	  in	  exert	  tumor	  cell	  lysis	  in	  vitro	  [132],	  
indicating	   that	  cytotoxic	  T	  cells	  are	  not	  only	  able	   to	   infiltrate	  gliomas,	  but	  also	  retain	   their	  
functionality	  when	  not	  exposed	  to	  the	  immunosuppressive	  microenvironment	  of	  gliomas.	  
T	   cell-­‐mediated	   anti-­‐glioma	   immunity	   requires	   the	   presence	   of	   glioma-­‐specific	   antigens.	  
Although	  gliomas	  are	  heterogeneous	  tumors,	  several	  antigens	  have	  been	  identified,	   in	  part	  
by	  mass	  spectrometry-­‐based	  identification	  of	  HLA-­‐bound	  epitopes,	  some	  of	  which	  shown	  to	  
be	  immunogenic,	  such	  as	  IL13Rα2,	  EGFRvIII,	  gp100,	  and	  TRP2	  [133],	  as	  well	  as	  survivin,	  SOX2,	  
and	  MAGE1,	  [134-­‐136].	  Yet,	  a	  lot	  of	  clinical	  immunotherapy	  studies	  for	  glioma	  patients	  apply	  
DC	   vaccination	  using	   autologous	   tumor	   lysate.	   In	   a	   study	  enrolling	  23	  patients	  with	   newly	  
diagnosed	   glioblastoma,	   autologous	   tumor	   lysate	   loaded	   onto	   autologous	   and	   ex	   vivo	  
matured	  DC,	  which	  were	  reinjected	   into	  the	  patient,	   led	  to	  CD8+	  T	  cell	   infiltration	   into	  the	  
recurrent	   tumor	   and	   –	   compared	   to	   historical	   controls	   –	   increased	   overall	   survival.	   Even	  
more,	   this	   study	   identified	   glioblastoma	   of	   the	   mesenchymal	   subtype	   as	   the	   responding	  
group	  susceptible	  to	  this	  type	  of	  immunotherapy,	  while	  patients	  with	  proneural	  GBM	  did	  not	  
benefit	  from	  vaccination	  and	  did	  not	  show	  enhanced	  CD8+	  T	  cell	  infiltration	  [137].	  However,	  
the	   uncontrolled	   and	   one-­‐armed,	   non-­‐blinded	   nature	   of	   this	   study	  makes	   conclusions	   on	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effectiveness	   of	   such	   a	   vaccine	   difficult.	   In	   terms	   of	   glioma	   antigen-­‐specific	   vaccination,	  
EGFRvIII	  has	  probably	  gained	  most	   interest	   in	   recent	  years.	  Originally	   identified	   in	  primary	  
human	  GBM,	  where	   it	   is	   expressed	   in	   30	  %	  of	   patients,	   EGFRvIII	   is	   a	   constitutively	   active,	  
ligand-­‐independent	   form	   of	   the	   EGFR	   that	   has	   been	   implicated	   in	   tumorigenicity	   via	  
proliferation	  induction	  and	  inhibition	  of	  apoptosis	  [138,	  139]	  as	  well	  as	  in	  resistance	  towards	  
radiotherapy	  [140].	  Thus,	  EGFRvIII	  represents	  a	  promising	  target	  and	  neoantigen,	  one	  of	  the	  
few	  mutation	   antigens.	   Its	   immunogenicity	   arises	   from	   an	   in-­‐frame	   deletion,	   leading	   to	   a	  
truncated	   extracellular	   domain	   with	   creation	   of	   an	   antigenic	   junction	   harboring	   a	   novel	  
glycine	  residue,	  and	  has	  led	  to	  the	  development	  of	  an	  EGFRvIII-­‐specific	  peptide	  vaccine	  that	  
has	  been	  extensively	  studied	  preclinically	  and	  clinically	   [141].	   In	  a	  one-­‐armed	  phase	  II	  trial,	  
vaccination	   led	   to	   enhanced	   progression-­‐free	   and	   overall	   survival	   compared	   to	   historical	  
controls.	   Within	   the	   vaccinated	   patient	   group,	   responders	   measured	   by	   delayed-­‐type	  
hypersensitivity	   response	   and	   antibody	   development	   had	   a	   higher	   benefit	   than	   non-­‐
responding	   patients.	   However,	   patients	   eventually	   suffered	   from	   recurrence,	   which	   was	  
associated	  with	  a	   loss	  of	  EGFRvIII	  expression	   [35].	  Although	   this	   immunologic	  escape	   is	  an	  
indicator	  for	  biological	  activity,	  these	  results	  might	  also	  be	  explained	  by	  the	  heterogeneity	  of	  
gliomas,	  i.e.	  the	  presence	  of	  EGFRvIII-­‐negative	  cells	  within	  the	  tumor,	  which	  are	  selected	  by	  
immunotherapy.	  
With	   improved	   understanding	   of	   glioma	   immunobiology	   and	   immunosuppression,	  
immunomodulation	  and	  targeting	  glioma-­‐specific	  antigen	  might	  become	  part	  of	  combination	  
therapy	   for	   glioma	   patients.	   In	   this	   regard,	   the	   homogeneous	   expression	   of	   the	   target	   is	  
critical	  in	  a	  tumor	  entity	  that	  is	  characterized	  by	  regression	  and	  progression.	  
	  
1.5	  Objectives	  of	  this	  thesis	  
	  
IDH1	  mutations	  have	  proven	  to	  be	  effectively	  targeted	  by	  specific	   inhibitors,	  which	  change	  
epigenetic	  characteristics	  and	  result	  in	  growth	  suppression	  [108,	  109].	  A	  different	  potential	  
strategy	   may	   be	   to	   explore	   mutated	   IDH1	   as	   a	   cancer	   immunotherapy	   target.	   From	   an	  
immunological	  perspective	  the	  IDH1R132H	  mutation	  represents	  a	  potential	  target	  for	  active	  
immunotherapy	   particularly	   of	   low	   grade	   and	   anaplastic	   gliomas	   as	   it	   is	   tumor	   specific,	  
represents	  a	  potential	  neoantigen	  with	  high	  uniformity	  and	  penetrance	  and	  is	  expressed	  in	  
all	   tumor	   cells	   [84,	   106].	   In	   addition,	   the	   development	   of	   a	  mutation-­‐specific	   antibody	   in	  
INTRODUCTION	  
 16	  
mice	   [106]	   suggests	   that	   the	   immune	   system	   is	   –	   in	   principle	   –	   capable	   to	   discriminate	  
between	  mutant	  and	  wt	  IDH1.	  
	  
The	   present	   study	   aimed	   at	   evaluating	   the	   suitability	   of	   the	   IDH1R132H	   mutation	   as	   an	  
immunotherapeutic	  target	  for	  gliomas	  and	  potentially	  other	  IDH1R132H-­‐mutated	  tumors.	  To	  
this	  end,	  analyses	  on	  the	  mutation-­‐specific	  immunogenicity	  of	  potential	  epitopes	  in	  an	  MHC-­‐
humanized	  mouse	  model	   in	   vivo,	   spontaneous	   immune	   responses	   in	   glioma	   patients	  with	  
IDH1R132H-­‐mutated	  tumors,	  and	  the	  antitumor	  functionality	  of	  a	  peptide	  vaccine	   in	  MHC-­‐
humanized	  mice	  as	  well	  as	  the	  characterization	  of	  the	  immune	  response	  and	  possible	  effects	  
of	  2-­‐HG	  on	  human	  T	  cells	  were	  included.	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2	  MATERIALS	  AND	  METHODS	  
	  
2.1	  Special	  materials	  
	  
2.1.1	  Mice	  
A2.DR1	   mice	   B6.Tg(HLA-­‐DRA*0101,HLA-­‐DRB1*0101)1Dmz	   Tg(HLA-­‐A/H2-­‐D/B2M)	   1Bpe	   H2-­‐
Ab1tm1Doi	  on	  C57BL/6J	  background	  are	  deficient	  for	  mouse	  MHC	  class	  I	  (H-­‐2b)	  and	  class	  II	  
(H-­‐IAb)	  and	  transgenic	   for	  human	  MHC	  class	   I	  HLA-­‐A*0201	  and	  class	   II	  HLA-­‐DRA*0101	  and	  
HLA-­‐DRB1*0101	  and	  were	  kindly	  provided	  by	   [142].	  DR4	   transgenic	  mice	  C57BL/6-­‐Tg(HLA-­‐
IEd	  alpha/HLA-­‐DRB1*0401-­‐I-­‐Ed	  beta)#39-­‐2	  are	  deficient	   for	  mouse	  MHC	  class	   II	   (H-­‐2b)	  and	  
transgenic	   for	   human	   MHC	   class	   II	   HLA-­‐DRA*0101	   and	   HLA-­‐DRB1*0401	   and	   were	   kindly	  
provided	  by	  [143].	  NOD/SCID	  mice	  were	  purchased	  from	  Charles	  River	  (Sulzfeld,	  Germany).	  
Mice	  were	  bred	  according	  to	  local	  regulatory	  authorities.	  
2.1.2	  Patients	  and	  patient	  samples	  
Patients	  were	  diagnosed	  at	  the	  Institute	  of	  Neuropathology,	  University	  Hospital	  Heidelberg.	  
Blood	   samples	   were	   taken	   after	   patient	   agreement	   and	   approval	   of	   the	   local	   regulatory	  
authorities.	  IDH1	  mutation	  status	  was	  routinely	  determined	  by	  immunohistochemistry	  (IHC)	  
and	   in	   exceptional	   cases	   by	   polymerase	   chain	   reaction	   (PCR)	   at	   the	   Institute	   of	  
Neuropathology,	   University	   Hospital	   Heidelberg.	   Buffy	   coats	   of	   healthy	   donors	   were	  
obtained	  from	  IKTZ	  Heidelberg.	  For	  patient	  characteristics,	  see	  6.5,	  Table	  6.1.	  
2.1.3	  Peptides	  
Human	   IDH1wt	   and	   IDH1R132H	   amino	   acid	   sequences	   IDH1	   p118-­‐146	  
PRLVSGWVKPIIIGRHAYGDQYRATDFVV	   (wt)	   and	   PRLVSGWVKPIIIGHHAYGDQYRATDFVV	  
(R132H),	  respectively,	  cover	  the	  amino	  acid	  exchange	  from	  arginine	  to	  histidine	  at	  position	  
132	  and	  include	  all	  possible	  putatively	  processed	  15-­‐mer	  IDH1	  peptides	  containing	  position	  
132	  (Fig.	  3.1).	  Mouse	  and	  human	  sequences	  are	  identical	  in	  this	  region	  except	  for	  amino	  acid	  
122	   (serine	   in	   human,	   threonine	   in	   mouse).	   Peptide	   libraries	   for	   ex	   vivo	   and	   in	   vitro	  
stimulation	  of	  IDH1wt	  and	  IDH1R132H	  of	  10	  amino	  acid	  long	  peptides	  with	  an	  overlap	  of	  9	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amino	  acids	   (10-­‐mers)	  and	  15	  amino	  acid	   long	  peptides	  with	  an	  overlap	  of	  13	  amino	  acids	  
(15-­‐mers)	  contained	  the	  following	  peptides:	  
IDH1wt	  p123-­‐132:	   	   GWVKPIIIGR;	  
IDH1wt	  p124-­‐133:	   	   WVKPIIIGRH;	  
IDH1wt	  p125-­‐134:	   	   VKPIIIGRHA;	  
IDH1wt	  p126-­‐135:	   	   KPIIIGRHAY;	  
IDH1wt	  p127-­‐136:	   	   PIIIGRHAYG;	  
IDH1wt	  p128-­‐137:	   	   IIIGRHAYGD;	  
IDH1wt	  p129-­‐138:	  	   	   IGRHAYGDQ;	  
IDH1wt	  p130-­‐139:	   	   IGRHAYGDQY;	  
IDH1wt	  p131-­‐140:	   	   GRHAYGDQYR;	  
IDH1wt	  p132-­‐141:	   	   RHAYGDQYRA;	  
IDH1wt	  p118-­‐132:	   	   PRLVSGWVKPIIIGR;	  
IDH1wt	  p120-­‐134:	   	   LVSGWVKPIIIGRHA;	  
IDH1wt	  p122-­‐136:	   	   SGWVKPIIIGRHAYG;	  
IDH1wt	  p124-­‐138:	   	   WVKPIIIGRHAYGDQ;	  
IDH1wt	  p126-­‐140:	   	   KPIIIGRHAYGDQYR;	  
IDH1wt	  p128-­‐142:	   	   IIIGRHAYGDQYRAT;	  
IDH1wt	  p130-­‐144:	   	   IGRHAYGDQYRATDF;	  
IDH1wt	  p132-­‐146:	   	   RHAYGDQYRATDFVV;	  
IDH1R132H	  p123-­‐132:	   GWVKPIIIGH;	  
IDH1R132H	  p124-­‐133:	   WVKPIIIGHH;	  
IDH1R132H	  p125-­‐134:	   VKPIIIGHHA;	  
IDH1R132H	  p126-­‐135:	   KPIIIGHHAY;	  
IDH1R132H	  p127-­‐136:	   PIIIGHHAYG;	  
IDH1R132H	  p128-­‐137:	   IIIGHHAYGD;	  
IDH1R132H	  p129-­‐138:	   IIGHHAYGDQ;	  
IDH1R132H	  p130-­‐139:	   IGHHAYGDQY;	  
IDH1R132H	  p131-­‐140:	   GHHAYGDQYR;	  
IDH1R132H	  p132-­‐141:	   HHAYGDQYRA;	  
IDH1R132H	  p118-­‐132:	   PRLVSGWVKPIIIGH;	  
IDH1R132H	  p120-­‐134:	   LVSGWVKPIIIGHHA;	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IDH1R132H	  p122-­‐136:	   SGWVKPIIIGHHAYG;	  
IDH1R132H	  p124-­‐138:	   WVKPIIIGHHAYGDQ;	  
IDH1R132H	  p126-­‐140:	   KPIIIGHHAYGDQYR;	  
IDH1R132H	  p128-­‐142:	   IIIGHHAYGDQYRAT;	  
IDH1R132H	  p130-­‐144:	   IGHHAYGDQYRATDF;	  
IDH1R132H	  p132-­‐146:	   HHAYGDQYRATDFVV.	  
For	   mouse	   vaccination	   and	   restimulation	   experiments,	   20	   amino	   acid	   long	   peptides	  
IDH1R132H	  p123-­‐142	  	   GWVKPIIIGHHAYGDQYRAT	  and	  
IDH1wt	  p123-­‐142	   	   GWVKPIIIGRHAYGDQYRAT	  and	  
25	  amino	  acid	  long	  peptide	  
NY-­‐ESO-­‐1	  p119-­‐143	   	   PGVLLKEFTVSGNILTIRLTAADHR	  
were	  used.	  As	  negative	   control	  peptide	   for	  ex	   vivo	   and	   in	   vitro	   stimulation,	  mouse	  myelin	  
oligodendrocyte	   glycoprotein	   (MOG)	   p35-­‐55	   MEVGWYRSPFSRVVHLYRNGK	   was	   used.	   For	  
ELISA	  establishment	  as	  negative	   control,	  MOG	  p35-­‐55	  and	  human	   immunodeficiency	   virus	  
(HIV)-­‐1	  p17	  gag	  p77-­‐85	  SLYNTVATL	  were	  used.	   In	  T2	  binding	  assay,	  human	  T	   lymphotropic	  
virus	  1	  (HTLV1)	  tax	  p11-­‐19	  LLFGYPVYV	  was	  used.	  MOG	  peptide	  was	  synthesised	  by	  Genscript.	  
Tax,	  HIV,	  NY-­‐ESO-­‐1	  p119-­‐143,	  and	  IDH1	  10-­‐mer	  peptides	  were	  synthesized	  in	  house	  by	  DKFZ	  
proteomics	   and	   genomics	   Core	   Facility,	   15-­‐mer	   and	   20-­‐mer	   peptides	  were	   synthesized	   by	  
Bachem	  Distribution	  Services	  GmbH	  and	  jpt.	  Peptides	  were	  diluted	  in	  PBS	  10%	  DMSO	  at	  2.5	  
mg/ml	  and	  stored	  at	  -­‐80°C.	  
2.1.4	  2-­‐hydroxyglutarate	  




2.2.1	  MHC	  binding	  prediction	  
IDH1R132H	   p122-­‐142	   was	   subjected	   to	   HLA-­‐A*0201	   (HLA-­‐A2)	   peptide	   binding	   prediction	  
using	  NetMHC	  [144].	  Algorithms	  for	  8-­‐mers,	  9-­‐mers,	  10-­‐mers,	  and	  11-­‐mers	  containing	  R132H	  
were	  performed.	  Peptides	  with	  IC50	  below	  500	  nM	  are	  defined	  as	  weak	  binders,	  those	  with	  
IC50	  below	  50	  nM	  are	  defined	  as	  strong	  binders.	  Prediction	  for	  binding	  of	  10-­‐mer	  peptides	  
within	  the	  library	  to	  HLA-­‐A2	  was	  also	  performed	  using	  the	  SYFPEITHI	  algorithm	  [145].	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MHC	  class	  II	  binding	  prediction	  for	  15-­‐mers	  within	  IDH1R132H	  p118-­‐146	  was	  done	  using	  the	  
NetMHCII	  algorithm	  [146]	  to	  HLA-­‐DRB1*0101	  (HLA-­‐DR1).	  Peptides	  with	  IC50	  below	  500	  nM	  
are	  defined	  as	  weak	  binders,	  those	  with	  IC50	  below	  50	  nM	  are	  defined	  as	  strong	  binders.	  
2.2.2	  T2	  binding	  assay	  
T2	  cells,	  which	  are	  HLA-­‐A2+	   transporter	  associated	  with	  antigen	  processing	   (TAP)-­‐deficient	  
cells	  expressing	  HLA-­‐A2	  stably	  on	   their	   surface	  only	  after	  peptide	  binding	   to	  HLA-­‐A2,	  were	  
treated	  with	  5	  µg/ml	  β2-­‐microglobulin	  (BD	  Pharmingen)	  together	  with	  10	  µg/ml	  IDH1R132H	  
peptides	  or	  tax	  as	  positive	  control	  peptide	  for	  3h.	  As	  controls,	  cells	  were	  treated	  with	  equal	  
volume	   of	   DMSO	   as	   vehicle	   with	   or	   without	   β2-­‐microglobulin.	   Cells	   were	   washed	   and	  
surface-­‐stained	  with	  FITC-­‐conjugated	  mouse	  anti-­‐HLA-­‐A2	  antibody	  (BB7.2,	  1	  µl	  per	  test;	  BD	  
Pharmingen)	  for	  30	  min	  and	  analyzed	  by	  flow	  cytometry.	  Binding	  values	  were	  calculated	  by	  
subtraction	  of	  vehicle	  control	  and	  relative	  to	  positive	  control.	  Assay	  performed	  by	  Agnieszka	  
Grabowska	  and	  Angelika	  Riemer.	  
2.2.3	  Class	  II	  REVEAL™	  MHC-­‐Peptide	  Binding	  Assay	  
HLA-­‐DRB1*01:01	  binding	  assay	  was	  performed	  by	  ProImmune	  (quick	  check	  stability	  assay).	  
2.2.4	  Tumor	  induction	  and	  generation	  of	  a	  syngeneic	  tumor	  cell	  line	  
500	  µg	  3-­‐methylcholantrene	  (MCA)	   in	  peanut	  oil	  was	   injected	  s.c.	   into	  the	  flank	  of	  A2.DR1	  
mice.	   Tumor	   growth	   started	   after	   60	   to	   90	   days	   and	  was	  monitored	   daily.	  When	   tumors	  
reached	  a	  maximum	  size	  of	  1.5	  cm,	  tumors	  were	  excised,	  cut	  into	  small	  pieces,	  embedded	  in	  
MatrigelTM	   (BD	  Biosciences)	   and	   s.c.	   injected	   into	   the	  back	  of	  NOD/SCID	  mice.	   Established	  
tumors	  were	  again	  excised,	  cut	  into	  small	  pieces	  and	  cultured	  in	  DMEM	  with	  10%	  FBS	  (both	  
PAA	  Laboratories),	  50	  µg/ml	  gentamycin,	  10	  mM	  HEPES,	  and	  50	  µM	  β-­‐mercaptoethanol	  (all	  
Sigma-­‐Aldrich).	  When	  single	  cells	  grew	  out	  of	  tumor	  tissue,	  tissue	  pieces	  were	  removed	  and	  
adherent	   single	   cells	   were	   obtained	   and	   grown	   as	   established	   cell	   line.	   Cells	   were	   s.c.	  
injected	   into	   the	   flank	   of	   A2.DR1	   mice	   and	   established	   tumors	   were	   excised	   for	  
characterization	   by	   H&E	   staining.	   Tumor	   induction	   was	   done	   by	   Karin	   Müller-­‐Decker,	  
establishment	  of	  tumor	  cell	  line	  was	  done	  by	  Jasmin	  Quandt.	  
2.2.5	  Stable	  overexpression	  of	  IDH1	  and	  NY-­‐ESO-­‐1	  
A2.DR1	   sarcoma	   cells	   were	   transduced	   with	   full-­‐length	   cDNA	   of	   human	   IDH1R132H	   or	  
IDH1wt	   (GenBank	   CR541695.1),	   or	   CTAG1B	   coding	   for	   human	   NY-­‐ESO-­‐1	   (GenBank	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AJ003149.1),	  provided	  by	  the	  DKFZ	  Genomics	  Facility,	  cloned	  in	  the	  retroviral	  vector	  pMXs-­‐
IRES-­‐BsdR	   (Cell	   Biolabs,	   Inc.)	   (IDH1	   by.	   S.	   Pusch,	   NY-­‐ESO-­‐1	   by	   L.	   Bunse)	   using	   FuGene	   HD	  
transfection	  reagent	  (Promega).	  Cells	  were	  selected	  with	  9	  µg/ml	  blasticidin	  (Sigma-­‐Aldrich)	  
72	   h	   after	   transfection.	   For	   therapeutic	   vaccination	   experiments,	   A2.DR1	   IDH1R132H+	  
sarcoma	   cell	   clones	   were	   generated	   by	   limiting	   dilution	   and	   outgrowing	   clones	   were	  
screened	   for	   IDH1R132H	   expression	   by	   2-­‐HG	   measurements	   (see	   2.2.18)	   and	  
immunofluorescent	   staining	   (see	   2.2.22).	   	   Clone	   IVC1	  was	   selected	   according	   to	   high	   and	  
homogenous	  IDH1R132H	  expression.	  Clones	  of	  the	  human	  glioma	  cell	  line	  LN229	  transfected	  
with	   IDH1R132H	   (H3,	   H114)	   or	   IDH1wt	   (86)	   in	   pcDNA.3,	   selected	   with	   1.5	   mg/ml	   G418	  
(Sigma-­‐Aldrich),	   and	   expressing	   endogenous	   IDH1wt	   protein	   levels	   (H114,	   86)	   or	   half	   the	  
amount	  (H3)	  were	  provided	  by	  J.	  Balß.	  
2.2.6	  Peptide	  vaccination	  and	  tumor	  cell	  inoculation	  
A2.DR1	  or	  DR4	  transgenic	  mice	  were	  immunized	  with	  100	  µg	  IDH1R132H	  (p123-­‐142;	  p122-­‐
136;	   p124-­‐138)	   emulsified	   in	   complete	   Freund’s	   adjuvant	   (CFA)	   or	   Montanide-­‐ISA51®	  
(Seppic).	  For	  CFA-­‐vaccination,	  Freund’s	  adjuvant	  was	  supplemented	  with	  mycobacteria	  (both	  
from	  Difco)	  and	  emulsified	  with	  equal	   volume	  of	  peptide	   stock	  diluted	   in	  PBS	  or	  PBS	  with	  
equal	  concentration	  of	  DMSO	  as	  sham	  control	  treatment.	  Final	  peptide	  concentration	  in	  the	  
emulsion	  was	  1	  mg/ml.	  S.	  c.	   injections	  (50	  µl	  each)	  were	   into	  the	   lateral	  pectoral	  region	  at	  
both	  sides.	  For	  Montanide®-­‐vaccination,	  peptide	  or	  DMSO	  at	  concentrations	  as	  above	  were	  
emulsified	   in	   Montanide-­‐ISA51®	   and	   injection	   was	   as	   above.	   In	   addition,	   Aldara®	   cream	  
containing	  5	  %	  imiquimod	  (Meda	  Pharma)	  was	  applied	  at	  injection	  site.	  For	  this,	  mice	  were	  
shaved	  before	   injections.	  300	  ng	  recombinant	  GM-­‐CSF	  (Immunotools)	   in	  50	  µl	  PBS	  was	  s.c.	  
injected	   medio-­‐pectoral	   between	   emulsion	   injection	   sites.	   For	   both	   protocols,	   mice	   were	  
boosted	  after	  10	  days.	  In	  case	  of	  Montanide®-­‐vaccination,	  no	  GM-­‐CSF	  was	  applied	  at	  boost.	  
In	   vaccination	   only	   experiments,	   submandibular	   vein	   blood	   was	   taken	   and	   spleens	   were	  
excised	  after	   21	  days.	   For	   tumor	   cell	   inoculation	  experiments,	   IDH1R132H	   (p123-­‐142)	  was	  
used	  with	  Montanide®/imiquimod.	  
For	  preventive	  vaccination,	  A2.DR1	  mice	  were	  again	  boosted	  on	  day	  21	  by	  s.c.	  injection	  into	  
the	   shaved	   back	   and	   imiquimod	   application.	   On	   day	   25,	   2*106	   syngeneic	   tumor	   cells	  
expressing	  human	  IDH1R132H	  or	  IDH1wt	  were	  embedded	  in	  MatrigelTM	  and	  s.c.	  injected	  into	  
the	   shaved	   right	   flank	   of	   A2.DR1	  mice	   and	   tumor	   growth	  was	  measured	   regularly	   with	   a	  
calliper	   in	   two	   dimensions.	   For	   therapeutic	   vaccination,	   5*105	   syngeneic	   tumor	   cells	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expressing	  human	   IDH1R132H	   (clone	   IVC1)	  were	   injected	  as	  above	  and	   tumor	  growth	  was	  
measured	   regularly	   with	   a	   calliper	   in	   two	   dimensions.	   On	   day	   6,	   when	   tumors	   were	  
detectable	   in	   all	   mice,	   mice	   were	   divided	   into	   two	   groups	   according	   to	   tumor	   size	   and	  
vaccinated	   with	   IDH1R132H	   (p123-­‐142)	   or	   sham-­‐treated	   using	   Montanide®/imiquimod	   as	  
above.	  Mice	  were	  boosted	  on	  day	  13.	  Therapeutic	  vaccination	  against	  NY-­‐ESO-­‐1	  was	  done	  by	  
injection	  of	  8*105	  syngeneic	  tumor	  cells	  expressing	  NY-­‐ESO-­‐1	  and	  vaccination	  with	  NY-­‐ESO-­‐1	  
(p119-­‐143)	  or	  sham-­‐treatment	  on	  day	  6	  using	  Montanide®/imiquimod	  as	  above.	  Mice	  were	  
boosted	  on	  day	  13.	  
Lymphocyte	  depletion	  was	  done	  by	  repeated	  i.	  p.	  injections	  of	  anti-­‐CD4	  (clone	  GK1.5,	  1	  mg	  /	  
dose,	  every	  3	  days),	  anti-­‐CD19	   (clone	  1D3,	  500	  µg	  /	  dose,	  every	  5	  days),	  or	  corresponding	  
isotype	  controls	   (for	  anti-­‐CD4,	  clone	  LTF-­‐2,	  1	  mg	  /	  dose,	  every	  3	  days;	   for	  anti-­‐CD19,	  clone	  
2A3,	  500	  µg	  /	  dose,	  every	  5	  days;	  all	  BioXcell).	  8*105	  syngeneic	  tumor	  cells	  expressing	  human	  
IDH1R132H	  were	   injected	   as	   above.	   On	   day	   4,	   when	   tumors	  were	   detectable	   in	   all	  mice,	  
mice	   were	   divided	   into	   groups	   according	   to	   tumor	   size	   and	   injected	   with	   depleting	  
antibodies	  or	  controls.	  One	  group	   received	  specific	  antibodies	  and	   two	  were	   injected	  with	  
isotype	   controls.	   On	   day	   5,	   mice	   were	   vaccinated	   with	   IDH1R132H	   (p123-­‐142)	   (depletion	  
groups	   and	   one	   isotype	   control	   group)	   or	   sham	   treated	   (isotype	   control	   group)	   using	  
Montanide®/imiquimod	  and	  boosted	  on	  day	  13.	  On	  day	  7	  and	  17,	  submandibular	  vein	  blood	  
was	   taken	   from	   2	  mice	   of	   each	   group	   to	   verify	   depletion	   efficacy	   by	   flow	   cytometry	   (see	  
2.2.17).	  
2.2.7	  Tumor	  cell	  vaccination	  
A2.DR1	  transgenic	  mice	  were	  vaccinated	  by	  s.c.	  injection	  of	  107	  irradiated	  (100	  Gy)	  syngeneic	  
tumor	  cells	  overexpressing	  IDH1wt	  or	  IDH1R132H	  (clone	  IVC1)	  with	  1	  µg	  rGM-­‐CSF	  in	  PBS	  into	  
the	  neck.	   CFA	  was	   injected	   s.c.	   into	   the	   lateral	   pectoral	   region	   at	   both	   sides	   (50	  µl	   each).	  
Injection	  of	  107	  irradiated	  tumor	  cells	  only	  was	  repeated	  4	  times	  every	  10	  days	  and	  spleens	  
were	  excised	  after	  47	  days.	  
2.2.8	  Lymphocyte	  and	  bone	  marrow	  cell	  isolation	  
Spleens	  and	   lymph	  nodes	   (LN)	  were	  excised	   from	  vaccinated	  and	   sham-­‐treated	  A2.DR1	  or	  
DR4	  mice	  and	  bone	  marrow	  was	  isolated	  from	  hind	  limbs	  of	  naïve	  A2.DR1	  mice.	  Organs	  were	  
mashed	   through	   a	   40	   µm	   cell	   strainer.	   Blood	   lymphocytes	   were	   obtained	   from	  
submandibular	   vein	   blood	   of	   lymphocyte-­‐depleted	   mice.	   Erythrocytes	   in	   spleens,	   bone	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marrow	  and	  blood	  were	  lysed	  with	  ACK	  buffer	  –	  containing	  150	  mM	  NH4Cl,	  10	  mM	  KHCO3,	  
and	   100	   µM	   Na2EDTA	   –	   and	   cells	   were	   washed	   twice	   with	   medium	   before	   culturing	   in	  
RPMI1640	  containing	  10%	  FBS	  and	  100	  U/ml	  penicillin	  and	  100	  μg/ml	  streptomycin	  (all	  PAA	  
Laboratories).	  For	  splenocytes	  and	  LN	  cells,	  medium	  was	  supplemented	  with	  1	  mM	  sodium-­‐
pyruvate,	   2	   mM	   glutamine	   (both	   PAA	   Laboratories),	   100	   µM	   non-­‐essential	   amino	   acids	  
(Lonza),	  and	  50	  µM	  β-­‐mercaptoethanol	  (Sigma-­‐Aldrich).	  
2.2.9	  Isolation	  of	  tumor-­‐infiltrating	  lymphocytes	  
Tumors	  were	  excised,	  washed	  in	  HBSS	  (Sigma-­‐Aldrich)	  and	  cut	  into	  small	  pieces	  before	  tissue	  
disruption	  in	  HBSS	  supplemented	  with	  0.05	  %	  collagenase,	  0.1	  µg/ml	  TLCK	  trypsin	  inhibitor,	  
10	  µg/ml	  DNAse	  I,	  and	  10	  mM	  Hepes,	  pH	  7.4,	  for	  1	  h	  under	  slow	  rotation	  at	  37°C.	  Dispersed	  
tissue	  was	  mashed	  through	  a	  70	  µm	  cell	  strainer	  and	  lymphocytes	  were	  isolated	  by	  density	  
gradient	  centrifugation	  using	  Lympholyte®	  Mouse	  (Cedarlane).	  
2.2.10	  Generation	  of	  antigen-­‐specific	  T	  cells	  
Splenocytes	   from	   A2.DR1	   mice	   vaccinated	   with	   IDH1R1232H	   (p123-­‐142)	   in	   Montanide-­‐
ISA51®	  were	  stimulated	  with	  10	  µg/ml	  IDH1R132H	  (p123-­‐142)	  peptide.	  After	  7	  days,	  medium	  
was	  exchanged	  and	  supplemented	  with	  3	  %	  (v/v)	  ConA	  sup	  (kind	  gift	   from	  W.	  Osen)	  as	  an	  
interleukin	   (IL)-­‐2	   source	   and	   15	   mM	   α-­‐methylmannopyranoside	   (α-­‐MM,	   Sigma-­‐Aldrich).	  
Medium	   was	   exchanged	   weekly	   including	   ConA	   sup	   and	   α-­‐MM.	   Cells	   were	   restimulated	  
every	  4	  weeks	  with	  autologous	  splenocytes	   irradiated	  with	  30	  Gy	  and	  loaded	  with	  2	  µg/ml	  
IDH1R132H	   (p123-­‐142)	   in	   ConA	   sup	   and	   α-­‐MM-­‐containing	  medium.	   Cells	  were	   used	   after	  
two	   restimulations	   until	   the	   fifth	   restimulation.	   At	   the	   second	   restimulation,	   T	   cell	   clones	  
were	   generated	   by	   limiting	   dilution	   (0.5	   cells	   per	   well)	   and	   stimulation	   with	   IDH1R132H	  
(p123-­‐142)-­‐loaded	   and	   irradiated	   autologous	   splenocytes.	   Reactive	   clones	   were	   picked	  
according	   to	  polarized	  morphology	  after	   4	  weeks	   and	   restimulated.	  Medium	  was	   changed	  
weekly	  and	  restimulation	  was	  every	  4	  weeks.	  
2.2.11	  Peripheral	  blood	  mononuclear	  cell	  and	  T	  cell	  isolation	  
Peripheral	  blood	  mononuclear	  cells	  (PBMC)	  were	  isolated	  from	  buffy	  coats	  or	  heparin	  blood	  
of	  glioma	  patients	  by	  density-­‐gradient	  centrifugation	  using	   lymphocyte	  separation	  medium	  
(LSM)	  1077	  (PAA	  Laboratories)	  and	  cultured	  in	  RPMI1640	  containing	  10%	  FBS	  or	  autologous	  
serum	  (see	  below)	  and	  100	  U/ml	  penicillin	  and	  100	  μg/ml	  streptomycin,	  supplemented	  with	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1	  mM	  sodium-­‐pyruvate,	  2	  mM	  glutamine,	  100	  µM	  non-­‐essential	  amino	  acids,	  and	  50	  µM	  β-­‐
mercaptoethanol.	  
CD4+	  or	  CD8+	  T	  cells	  were	  isolated	  from	  PBMC	  by	  depletion	  of	  non-­‐T	  cell	  populations	  using	  
the	  CD4+	  T	   cell	   isolation	   kit	   II	   and	  CD8+	  T	   cell	   isolation	   kit	   (both	  Miltenyi	  Biotec,	  Bergisch	  
Gladbach,	   Germany)	   according	   to	   manufacturer’s	   instructions.	   Biefly,	   for	   CD4+	   T	   cell	  
isolation,	   cells	  were	   labeled	  with	   biotinylated	   antibody	   cocktail,	  magnetically	   labeled	  with	  
anti-­‐biotin	  beads,	  and	  subjected	  to	  magnetic	  separation.	  For	  CD8+	  T	  cell	  isolation,	  cells	  were	  
lebeled	   with	   CD8+	   T	   cell	   biotin-­‐antibody	   cocktail,	   magnetically	   labeled	   with	   CD8+	   T	   cell	  
microbead	   cocktail	   and	   subjected	   to	  magnetic	   separation.	   In	   both	   protocols,	   effluent	   cell	  
population	  was	  the	  enriched	  T	  cell	  population.	  Purity	  was	  assessed	  by	  flow	  cytometry	  (see	  
below)	  and	  T	  cells	  were	  cultured	   in	  RPMI1640	  containing	  10%	  FBS	  and	  100	  U/ml	  penicillin	  
and	  100	  μg/ml	  streptomycin,	  supplemented	  with	  1	  mM	  sodium-­‐pyruvate,	  2	  mM	  glutamine,	  
100	  µM	  non-­‐essential	  amino	  acids,	  and	  50	  µM	  β-­‐mercaptoethanol.	  
2.2.12	  IFN-­‐γ	  ELISpot	  
ELISpot	  white	  bottom	  multiwell	  plates	  (Millipore)	  were	  coated	  with	  anti-­‐mouse	  IFN-­‐γ	  (AN18,	  
Mabtech)	   or	   anti-­‐human	   IFN-­‐γ	   (1D1K,	   Mabtech)	   at	   4°C	   overnight	   and	   blocked	   with	  
RPMI1640	  containing	  10	  %	  FBS	  and	  100	  U/ml	  penicillin	  and	  100	  μg/ml	  streptomycin.	  Human	  
PBMC	  or	  mouse	  splenocytes	  or	  LN	  cells	  were	  seeded	  at	  5*105	  to	  106	  per	  well	  and	  stimulated	  
with	  10	  µg/ml	  peptide	   in	  case	  of	  cells	   from	  vaccinated	  mice	  or	  20	  µg/ml	   in	  case	  of	  human	  
PBMC.	  As	  negative	   controls,	  MOG	   (p35-­‐55)	  was	  used	  at	  equal	   concentrations	  and	  peptide	  
diluent	  PBS	  10	  %	  DMSO	  was	  used	  at	  equal	  volume.	  Positive	  control	  was	  20	  ng/ml	  phorbol	  
myristate	   acetate	   (PMA,	   Sigma-­‐Aldrich)	   and	   1	   µg/ml	   ionomycin	   (Sigma-­‐Aldrich).	   For	   T	   cell	  
line	   and	   clone,	   antigen-­‐presenting	   B	   cell	   blasts	  were	   generated	   from	   autologous	   (A2.DR1)	  
splenocytes	   by	   stimulation	   with	   25	   µg/ml	   lipopolysaccharides	   (LPS,	   Sigma-­‐Aldrich)	   and	   7	  
µg/ml	  dextran-­‐sulfate	  (Amersham	  Pharmacia	  Biotech	  AB)	  over	  3	  days,	  loaded	  with	  0.1	  µg/ml	  
or	  1.0	  µg/ml	  peptides	  and	  seeded	  at	  5*104	  cells	  per	  well	  together	  with	  2.5*103	  T	  cells.	  CD4+	  
and	  CD8+	  T	  cells	  from	  splenocytes	  of	  vaccinated	  mice	  were	  isolated	  by	  magnetic	  cell	  sorting	  
(MACS)	   using	   the	   pan	   T	   cell	   isolation	   kit	   II,	   mouse,	   followed	   by	   CD4	   (L3T4)	   MicroBeads,	  
mouse	  (all	  Miltenyi	  Biotec)	  and	  5*103	  T	  cells	  per	  well	  were	  stimulated	  with	  5*104	  peptide-­‐
loaded	   (20	   µg/ml)	   dendritic	   cells	   (DC)	   per	  well	   that	   had	   been	   derived	   from	   bone	  marrow	  
cells	  by	  treatment	  with	  20	  ng/ml	  rGM-­‐CSF	   (Immunotools)	   for	  6	  days.	  Peptide	  presentation	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on	  MHC	  was	  blocked	  with	  blocking	  antibodies	  (1	  µg	  per	  well)	  against	  HLA-­‐A	  (W6/32,	  kindly	  
provided	  by	  A.	  Riemer)	  or	  HLA-­‐DR	  (L243,	  BioLegend).	  
After	  36	  h,	  IFN-­‐γ-­‐producing	  cells	  were	  detected	  with	  biotinylated	  anti-­‐mouse	  IFN-­‐γ	  (R4-­‐6A2)	  
or	   anti-­‐human	   IFN-­‐γ	   (7-­‐B6-­‐1),	   streptavidin-­‐ALP	   (all	   Mabtech)	   and	   ALP	   color	   development	  
buffer	  (Bio-­‐Rad)	  and	  quantified	  using	  an	  ImmunoSpot	  Analyzer	  (Cellular	  Technology	  Ltd.).	  
2.2.13	  Cytokine	  ELISA	  
Splenocytes	   from	   vaccinated	   and	   sham-­‐treated	   mice	   were	   stimulated	   with	   10	   µg/ml	  
IDH1R132H	   (p123-­‐142),	   20	   ng/ml	   phorbol-­‐12-­‐myristate-­‐13-­‐acetate	   (PMA)	   and	   1	   µg/ml	  
ionomycin	   as	   positive	   control,	   or	   peptide	   diluent	   PBS	   10%	   DMSO	   (vehicle)	   as	   negative	  
control	  (see	  above)	  for	  3	  days.	  Supernatants	  were	  used	  on	  cytokine-­‐specific	  antibody-­‐coated	  
ELISA	   plates	   (Corning)	   and	   horseradish-­‐peroxidase	   (HRP)-­‐based	   cytokine	   detection	   was	  
performed	   according	   to	  manufacturer’s	   instructions	   (ebioscience)	   with	   TMB	   (ebioscience)	  
and	   stopped	  with	   1M	  H2SO4.	  OD	  at	   450	  nm	  was	  measured	  with	   an	   ELISA	   reader	   (Thermo	  
Fisher).	   Cytokine	   concentrations	   were	   calculated	   using	   cytokine	   standard	   serial	   dilution.	  
Cytokines	  detected	  were	  IFN-­‐γ,	  TNF-­‐α,	  IL-­‐4,	  IL-­‐6,	  and	  IL-­‐17.	  
2.2.14	  IgG	  ELISA	  
ELISA	   plates	   (Nunc	   or	   Corning)	   were	   coated	   with	   IDH1R132H	   and	   IDH1wt	   p123-­‐142	   for	  
mouse	  IgG	  detection	  and	  p122-­‐136	  for	  patient	  IgG	  detection	  (10	  µg	  per	  well	  in	  PBS),	  washed	  
with	  PBS	  0.05	  %	  Tween	  20,	  and	  blocked	  with	  3	  %	  FBS	  in	  PBS	  0.05	  %	  Tween	  20.	  As	  negative	  
controls,	  MOG	  p35-­‐55	  was	  used	  at	  equal	  concentrations	  and	  peptide	  diluent	  PBS	  10%	  DMSO	  
was	  used	  at	  equal	  volume.	  Positive	  control	  for	  patient	  serum	  was	  tetanus	  toxoid	  (0.25	  µg	  per	  
well;	  Merck	  Chemicals,	  Ltd).	  Mouse	  serum	  was	  obtained	  by	  puncture	  of	  the	  submandibular	  
vein	  and	  centrifugation	  of	  whole	  heparin-­‐mixed	  blood	  and	  diluted	  1:50	  in	  blocking	  solution.	  
Patient	   serum	   was	   obtained	   from	   serum	   tubes	   by	   centrifugation	   and	   used	   undiluted.	  
Monoclonal	   mouse	   anti-­‐IDH1R132H	   (1:1000,	   H09,	   Dianova)	   was	   used	   as	   peptide	   coating	  
control	   in	   human	   serum	   assays	   and	   as	   positive	   control	   in	   mouse	   serum	   assays.	   HRP-­‐
conjugated	  secondary	  antibodies	  were	  sheep	  anti-­‐mouse	  IgG	  (1:5000,	  Amersham),	  goat	  anti-­‐
mouse	   IgG1,	  goat	  anti-­‐mouse	   IgG2a,	  goat	  anti-­‐mouse	   IgG2b,	  and	  goat	  anti-­‐mouse	   IgG3	  (all	  
1:10000,	  Bethyl	  Laboratories,	  Inc.)	  for	  mouse	  serum	  and	  control	  and	  goat	  anti-­‐human	  IgG-­‐Fc	  
(1:10000,	  Bethyl	  Laboratories,	   Inc.),	  mouse	  anti-­‐human	  IgG1,	  anti-­‐human	  IgG2,	  anti-­‐human	  
IgG3,	  and	  anti-­‐human	  IgG4	  (all	  1:500,	  Acris	  Antibodies,	  Inc.)	  for	  patient	  serum.	  Substrate	  was	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TMB	  and	  reaction	  was	  stopped	  with	  1M	  H2SO4.	  OD	  at	  450	  nm	  was	  measured	  with	  an	  ELISA	  
reader.	  Data	  is	  shown	  in	  relation	  to	  MOG	  negative	  control.	  
2.2.15	  IFN-­‐γ	  secretion	  assay	  
PBMC	  isolated	  from	  glioma	  patients	  were	  stimulated	  with	  40	  µg/ml	  IDH1R132H	  (p123-­‐142),	  
equal	   concentration	   of	   MOG	   (p35-­‐55)	   as	   negative,	   or	   1	   µg/ml	   staphylococcus-­‐derived	  
enterotoxin	  B	  (SEB,	  Sigma-­‐Aldrich)	  as	  positive	  control	  and	  co-­‐stimulated	  with	  2	  µg/ml	  anti-­‐
human	  CD28	  (CD28.6,	  ebioscience)	   in	  medium	  containing	  10	  %	  autologous	  serum	  for	  16	  h.	  
Splenocytes	   from	   vaccinated	  mice	  were	   stimulated	  with	   20	  µg/ml	   IDH1R132H	   (p123-­‐142),	  
equal	   volume	   of	   peptide	   diluent	   PBS	   10%	   DMSO	   as	   negative,	   or	   1	   µg/ml	   SEB	   as	   positive	  
control	  as	  above.	  Mouse	  T	  cells	  were	  stimulated	  with	  autologous	  splenocytes	  loaded	  with	  10	  
µg/ml	  IDH1R132H	  (p123-­‐142).	  Positive	  control	  was	  SEB	  (as	  above).	  IFN-­‐γ	  secretion	  assay	  was	  
performed	  according	  to	  manufacturer’s	   instructions	  (IFN-­‐γ	  Secretion	  Assay	  Cell	  Enrichment	  
and	  Detection	  Kit	  (PE),	  human,	  130-­‐054-­‐201;	  mouse,	  130-­‐090-­‐517;	  Miltenyi	  Biotec).	  Briefly,	  
cells	  were	  labelled	  with	  IFN-­‐γ	  catch	  reagent	  and	  after	  secretion	  period	  IFN-­‐γ	  caught	  on	  the	  
cell	  surface	  was	  labelled	  with	  PE-­‐conjugated	  antibody.	  For	  isolation	  and	  enrichment	  of	  IFN-­‐γ-­‐
secreting	   cells,	   cells	   were	   incubated	   with	   anti-­‐PE	   microbeads	   and	   subjected	   to	   magnetic	  
separation.	  Separated	  cell	  populations	  were	  stained	  for	  flow	  cytometry	  (see	  2.2.17).	  Ex	  vivo	  
splenocytes	  were	  stained	  and	  analyzed	  without	  enrichment.	  
2.2.16	  Mixed	  leukocyte	  reaction	  
As	  an	  in	  vitro	  model	  of	  allogeneic	  T	  cell	  stimulation	  in	  response	  to	  (R)-­‐2-­‐HG-­‐treatment,	  mixed	  
leukocyte	  reactions	  (MLR)	  were	  performed.	  PBMCs	  of	  two	  non-­‐related	  donors	  were	  isolated,	  
cells	  from	  one	  donor	  were	  irradiated	  with	  30	  Gy	  and	  mixed	  with	  non-­‐irradiated	  cells	  of	  the	  
second	   donor	   at	   2*105	   cells	   per	   donor	   and	   per	   well.	   Cells	   were	   treated	   with	   increasing	  
concentrations	   of	   (R)-­‐2-­‐HG	   for	   five	   days.	   Alternatively,	   cells	  were	   seeded	   on	   6*103	   LN229	  
overexpressing	  IDH1wt	  or	  IDH1R132H	  per	  well,	  which	  had	  been	  seeded	  one	  day	  before	  for	  
adherent	   growth,	   or	   in	   supernatant	   of	   these	   cells	   For	   collecting	   supernatant,	   LN229	  were	  
cultured	   in	   RPMI1640	   containing	   10%	   FBS	   and	   100	   U/ml	   penicillin	   and	   100	   μg/ml	  
streptomycin	   for	   two	   days.	   MLR	   were	   pulsed	   with	   [3H]-­‐methylthymidine	   (Amersham	  
Radiochemical	   Centre,	   Buckinghamshire,	   U.K.)	   for	   20h	   and	   frozen.	   Incorporated	   [3H]-­‐
methylthymidine	   was	   harvested	   (Tomtec	   Cell	   Harvester,	   Tomtec,	   Hamden,	   CT,	   USA)	   and	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measured	   in	   a	   scintillation	   counter	   (Wallac	   Micro	   Beta	   TriLux	   Scintillation	   Beta	   Counter,	  
Perkin	  Elmer,	  Waltham,	  MA,	  USA).	  Proliferation	  was	  given	  as	  counts	  per	  minute	  (cpm).	  
2.2.17	  Flow	  cytometry	  
Purity	  of	  isolated	  T	  cell	  subsets	  from	  PBMC	  was	  assessed	  by	  staining	  of	  negative	  and	  positive	  
cell	  fractions	  for	  CD3,	  CD4,	  and	  CD8.	  Cells	  were	  blocked	  with	  autologous	  serum	  and	  stained	  
with	   FITC-­‐conjugated	   mouse	   anti-­‐human	   CD3	   (SK7),	   eFluor450®-­‐conjugated	   mouse	   anti-­‐
human	   CD4	   (RPA-­‐T4),	   and	   APC-­‐conjugated	   mouse	   anti-­‐human	   CD8	   (SK1;	   all	   1	   µl/well,	  
ebioscience).	  
Subsequent	  to	  IFN-­‐γ	  secretion	  assay,	  positively	  selected	  cell	  populations	  from	  patient	  PBMC	  
were	  blocked	  with	  autologous	  serum	  and	  stained	  with	  FITC-­‐conjugated	  mouse	  anti-­‐human	  
CD3	   (SK7,	   1	   µl/well),	   eFluor450®-­‐	   or	   PerCP-­‐conjugated	  mouse	   anti-­‐human	   CD4	   (RPA-­‐T4,	   1	  
µl/well,	  and	  SK3,	  5	  µl/well,	  respectively),	  and	  APC-­‐conjugated	  mouse	  anti-­‐human	  CD8	  (SK1,	  1	  
µl/well,	  all	  ebioscience).	  Selected	  mouse	  T	  cells	  were	  blocked	  with	  rat	  anti-­‐mouse	  CD16/32	  
(93,	  0.5	  µg/well,	  ebioscience)	  and	  stained	  with	  FITC-­‐conjugated	  rat	  anti-­‐mouse	  CD3	  (17A2),	  
Pacific	  Blue™-­‐conjugated	  rat	  anti-­‐mouse	  CD4	  (RM4-­‐5,	  both	  BioLegend),	  and	  APC-­‐conjugated	  
rat	   anti-­‐mouse	   CD8	   (53-­‐6.1,	   ebioscience;	   all	   0.5	   µl/well).	   Propidium	   iodide	   (PI,	   1	   µg/ml,	  
Sigma-­‐Aldrich)	  was	  used	  to	  exclude	  dead	  cells.	  Live	  single	  cells	  were	  gated	  on	  IFN-­‐γ+	  CD3+	  T	  
cells	  and	  analyzed	  for	  CD4	  and	  CD8	  expression.	  
For	   IDH1R132H-­‐specific	   T	   cell	   phenotype	   characterization,	   splenocytes	   from	   vaccinated	   or	  
sham-­‐treated	  mice	  were	  ex	  vivo	   stimulated	  with	  10	  µg/ml	   IDH1R132H	  (p123-­‐142)	  or	  equal	  
volume	  of	  DMSO	  as	  vehicle	  control	  for	  4	  days.	  For	  T	  cell	  line,	  DC	  were	  loaded	  with	  4	  µg/ml	  
IDH1R132H	   (p123-­‐142)	   or	   equal	   volume	   of	   DMSO	   as	   vehicle	   control.	   After	   stimulation	   of	  
splenocytes	  or	  T	  cells	  for	  4	  days,	  cells	  were	  restimulated	  as	  before	  and	  treated	  with	  5	  µg/ml	  
brefeldin	  A	  (Sigma-­‐Aldrich)	  for	  4.5	  h	  to	  inhibit	  secretion	  of	  cytokines.	  Alternatively,	  T	  cell	  line	  
was	  stimulated	  with	  20	  ng/ml	  PMA	  and	  1µg/ml	  ionomycin	  for	  4.5	  h	  in	  the	  presence	  5	  µg/ml	  
brefeldin	  A.	  Cells	  were	  blocked	  as	  above	  and	  stained	  with	  Pacific	  Blue™-­‐conjugated	  rat	  anti-­‐
mouse	   CD4,	   APC-­‐conjugated	   rat	   anti-­‐mouse	   CD8,	   and	   PE-­‐conjugated	   rat	   anti-­‐mouse	   CD25	  
(all	  0.5	  µl/well,	  BioLegend).	  For	  intracellular	  staining,	  cells	  were	  fixed	  and	  permeabilized	  with	  
cytofix/cytoperm	  solution	  (BD	  Bioscience)	  and	  stained	  in	  perm/wash	  buffer	  (BD	  Biosciences)	  
with	   PE-­‐conjugated	   rat	   anti-­‐mouse	   IFN-­‐γ	   (XMG1.2),	   APC-­‐conjugated	   rat	   anti-­‐mouse	   IL-­‐17	  
(17B7),	   FITC-­‐conjugated	   rat	   anti-­‐mouse	   IL-­‐4	   (BVD6-­‐24G2),	   and	   APC-­‐conjugated	   rat-­‐anti-­‐
mouse	  FoxP3	  (FJK-­‐16s,	  all	  1	  µl/well,	  ebioscience).	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For	   NY-­‐ESO-­‐1-­‐specific	   T	   cell	   phenotype	   characterization,	   splenocytes	   from	   vaccinated	   or	  
sham-­‐treated	  mice	   were	   ex	   vivo	   stimulated	   with	   10	   µg/ml	   NY-­‐ESO-­‐1	   (p119-­‐143)	   or	  MOG	  
(p35-­‐55)	  as	  negative	  control.	  After	  stimulation	  for	  4	  days,	  cells	  were	  restimulated	  as	  before	  
and	   treated	   with	   5	   µg/ml	   brefeldin	   A	   (Sigma-­‐Aldrich)	   for	   4.5	   h	   to	   inhibit	   secretion	   of	  
cytokines.	   Cells	   were	   blocked	   as	   above	   and	   stained	   with	   eFluor450®-­‐conjugated	   rat	   anti-­‐
mouse	  CD3	  (17A2),	  APC-­‐conjugated	  rat	  anti-­‐mouse	  CD4	  (RM4-­‐5),	  and	  PE-­‐conjugated	  rat	  anti-­‐
mouse	  CD8	   (53-­‐6.1,	   all	   0.5	  µl/well,	   ebioscience).	   For	   intracellular	   staining,	   cells	  were	   fixed	  
and	  permeabilized	  as	  above	  and	  stained	  with	  FITC-­‐conjugated	  rat	  anti-­‐mouse	  IFN-­‐γ	  (XMG1.2,	  
1	  µl/well,	  ebioscience).	  
Tumor-­‐infiltrating	   lymphocytes	  were	  stained	  for	   IDH1R132H-­‐specific	  T	  helper	  cells	  using	  an	  
HLA-­‐DRB1*01:01	  MHC	  class	   II	  tetramer	  bound	  to	  IDH1R132H	  p123-­‐142	  (kindly	  provided	  by	  
the	  National	  Institute	  of	  Health	  [NIH]	  tetramer	  core	  facility).	  Cells	  were	  blocked	  with	  rat	  anti-­‐
mouse	   CD16/32,	   stained	   with	   APC-­‐conjugated	   IDH1R132H-­‐	   or	   class	   II-­‐associated	   invariant	  
chain	   peptide	   (CLIP)-­‐bound	   control	   tetramer	   (15	   µg/ml,	   37°C,	   1h;	   NIH)	   in	   RPMI1640	  
containing	   10	   %	   FBS	   and	   100	   U/ml	   penicillin	   and	   100	   μg/ml	   streptomycin,	   washed	   and	  
stained	   with	   Pacific	   Orange™-­‐conjugated	   rat	   anti-­‐mouse	   CD45	   (30-­‐F11,	   1	   µl/well,	   Life	  
technologies,	   Invitrogen),	  PE-­‐Cy7-­‐conjugated	   rat	  anti-­‐mouse	  CD3,	  FITC-­‐conjugated	   rat	  anti-­‐
mouse	  CD4,	  and	  PE-­‐conjugated	  rat	  anti-­‐mouse	  CD8	  (all	  1	  µl/well,	  ebiosciences).	  PI	  (1	  µg/ml)	  
was	  used	  to	  exclude	  dead	  cells.	  Cells	  were	  subsequently	  gated	  on	  CD45+	  leukocytes,	  CD3+	  T	  
cells,	  and	  CD4+	  T	  cells	  to	  analyze	  tetramer+	  T	  helper	  cells.	  
For	   verification	   of	   T	   cell	   depletions,	   submandibular	   vein	   blood	   lymphocytes	  were	   blocked	  
with	   rat	   anti-­‐mouse	   CD16/32	   and	   stained	  with	   PE-­‐conjugated	   rat	   anti-­‐mouse	   CD3	   (17A2),	  
pacific	   blue™-­‐conjugated	   rat	   anti-­‐mouse	   CD4,	   and	   APC-­‐conjugated	   rat	   anti-­‐mouse	   CD8	  
(ebioscience;	  all	  0.5	  µl/well).	  Cells	  were	  gated	  on	  CD3+	  T	  cells	  and	  analyzed	  for	  CD4	  and	  CD8	  
expression.	  For	  verification	  of	  B	  cell	  depletions,	  submandibular	  vein	  blood	  lymphocytes	  were	  
blocked	   with	   rat	   anti-­‐mouse	   CD16/32	   and	   stained	   with	   eFluor450®-­‐conjugated	   rat	   anti-­‐
mouse	  CD3	  and	  APC-­‐conjugated	  rat	  anti-­‐mouse	  CD19	  (1D3;	  all	  0.5	  µl/well,	  ebioscience).	  
HLA-­‐expression	  in	  A2.DR1	  sarcoma	  cells	  was	  analyzed	  after	  stimulation	  with	  50	  or	  100	  ng/ml	  
recombinant	   mouse	   IFN-­‐γ	   (Peprotech	   GmbH)	   for	   48	   h.	   Cells	   were	   stained	   with	   FITC-­‐
conjugated	   mouse	   anti-­‐human	   HLA-­‐A2	   (BB7.2,	   1	   µl/well,	   BD	   Biosciences)	   and	   APC-­‐
conjugated	  mouse	  anti-­‐human	  HLA-­‐DR1	  (T36,	  2	  µl/well,	  Southern	  Biotechnology	  Assoc.	  Inc.)	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For	  activation	  and	  phenotype	  characterization	  of	  2-­‐HG-­‐treated	  T	  cells,	  CD4+	  or	  CD8+	  T	  cells	  
were	   treated	  with	  50	  or	  100	  µM	  2-­‐HG	  and	  stimulated	  via	   the	  TCR	  using	  anti-­‐human	  CD28	  
(CD28.6,	   2	   µg/ml),	   anti-­‐human	   CD3	   (OKT3,	   1.5	   µg/ml,	   both	   ebioscience)	   and	   recombinant	  
human	   IL-­‐2	   (100	  U/ml,	   Proleukin,	  Novartis	   AG,	   Basel,	   Switzerland)	   for	   10	   days.	   Cells	  were	  
blocked	   with	   autologous	   serum	   and	   stained	   for	   activation	   markers	   with	   PE-­‐conjugated	  
mouse	  anti-­‐human	  CD45RO	  (UCHL1,	  5	  µl/well,	  Biolegend)	  and	  APC-­‐conjugated	  mouse	  anti-­‐
human	   CD69	   (FN50,	   2	   µl/well,	   Biolegend).	   For	   phenotype	   characterization,	   cells	   were	  
restimulated	  with	  20	  ng/ml	  PMA	  and	  1	  µg/ml	  ionomycin	  and	  treated	  with	  GolgiStop	  (1:1500,	  
BD	  Biosciences,	  order	  no.	  554724)	  for	  4.5	  h	  to	  inhibit	  secretion	  of	  cytokines	  before	  blocking	  
with	  autologous	  serum.	  CD4+	  T	  cells	  were	  stained	  with	  PerCP-­‐conjugated	  mouse	  anti-­‐human	  
CD4	   (SK3,	   5µl/well,	   ebioscience)	   and	   APC-­‐conjugated	   mouse	   anti-­‐human	   CD25	   (4E3,	   5	  
µl/well,	  Miltenyi	  Biotec).	  CD8+	  T	  cells	  were	  stained	  with	  PE-­‐conjugated	  mouse	  anti-­‐human	  
CD8	   (SK1,	   0.5	   µl/well,	   ebioscience).	   T	   cells	   were	   fixed	   and	   permeabilized	   using	   the	  
Transcription	  Factor	  Buffer	  Set	  (BD	  PharmingenTM)	  according	  to	  manufacturer’s	  instructions	  
and	   stained	   in	   Perm/Wash	   buffer	   with	   eFluor450®-­‐conjugated	   mouse	   anti-­‐human	   IFN-­‐γ	  
(4S.B3,	   1	   µl/well).	   CD4+	   T	   cells	   were	   in	   addition	   stained	   with	   AlexaFluor488®-­‐conjugated	  
mouse	   anti-­‐human	   IL-­‐17	   (eBio64DEC17,	   5	   µl/well,	   both	   ebioscience),	   PE-­‐Cy7-­‐conjugated	  
mouse	  anti-­‐human	  IL-­‐4	  (8D4-­‐8,	  5	  µl/well,	  Novus	  Biologicals),	  and	  PE-­‐conjugated	  mouse	  anti-­‐
human	  FoxP3	  (236A/E7,	  2.5	  µl/well,	  ebioscience).	  
In	   all	   experiments,	   corresponding	   isotype	   controls	   were	   used.	   Cells	   were	   measured	   on	   a	  
FACS	  Canto	  II	  (BD	  Biosciences).	  For	  intracellular	  flow	  cytometry	  for	  detection	  of	  cytokines,	  a	  
minimum	  of	  105	  cells	  was	  recorded.	  Data	  analysis	  was	  done	  using	  FlowJo	  software.	  
2.2.18	  2-­‐HG	  measurement	  
2-­‐HG	  production	   in	   cells	   and	   tumors	  was	   analyzed	  by	   Jörg	  Balß	   [147].	   50%	  confluent	   cells	  
were	   collected,	   dissolved	   in	   220	  µl	   cell	   lysis	   buffer	   (Cell	   signaling,	  Danvers,	  MA,	  USA)	   and	  
freeze-­‐thawed	   three	   times.	   To	   remove	   cell	   debris	   samples	   were	   centrifuged	   for	   5	  min	   at	  
13000	  g.	   (R)-­‐2-­‐HG	  standard	  was	  prepared	  with	  concentrations	  of	  0.5,	  1,	  2.5,	  5,	  7.5,	  10,	  25	  
and	  50	  µM	  (R)-­‐2-­‐HG	  in	  ddH2O.	  10	  ml	  of	  assay	  solution	  containing	  100	  mM	  HEPES	  pH	  8.0,	  100	  
µM	  NAD+	  (Applichem,	  Darmstadt,	  Germany),	  0.1	  µg	  HGDH,	  5	  µM	  resazurin	  (Applichem)	  and	  
0.01	  U/ml	  diaphorase	  (0.01	  U/ml,	  MP	  Biomedical,	  Irvine,	  CA,	  USA)	  was	  prepared	  freshly	  for	  
each	  assay.	  Just	  before	  use	  75	  µl	  of	  assay	  solution	  were	  added	  to	  25	  µl	  sample	  volume	  and	  
incubated	   at	   RT	   in	   the	   dark	   for	   30	   min	   in	   black	   96-­‐well	   plates	   (Thermo	   Scientific).	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Fluorometric	   detection	   was	   carried	   out	   in	   triplicate	   with	   25	   µl	   deproteinized	   sample	  
analyzed	   in	   each	   reaction	   with	   excitation	   at	   540+/-­‐10	   nm	   and	   emission	   of	   610+/-­‐10	   nm	  
(FLUOstar	  Omega,	  BMG	  Labtech,	  Offenburg,	  Germany).	  
Measured	   2-­‐HG	   concentrations	   were	   compared	   to	   2-­‐HG	   concentrations	   found	   in	   patient	  
tumors,	  which	  range	  from	  1	  to	  30	  mM	  [92,	  147].	  
2.2.19	  Pathological	  organ	  analysis	  
Organs	  from	  A2.DR1	  mice	  preventively	  or	  therapeutically	  vaccinated	  with	  IDH1R132H	  (p123-­‐
142)	   or	   sham	   treated	  using	  Montanide®	  were	   excised,	   fixed	  with	  Roti®-­‐Histofix	   4,5%	   (Carl	  
Roth	  GmbH	  +	  Co.	  KG),	  paraffin-­‐embedded	  and	  cut	  to	  3	  µm	  sections	  which	  were	  stained	  using	  
hematoxylin	  and	  eosin	  and	  analyzed	  microscopically	  at	  the	  Freie	  Universität	  Berlin,	  Institute	  
of	  Veterinary	  Pathology.	  
2.2.20	  IDH	  enzymatic	  activity	  assay	  
IDH	  activity	  was	  measured	  based	  on	  NADPH	  production	  using	  the	  Isocitrate	  Dehydrogenase	  
Activity	  Colorimetric	  Assay	  Kit	  (BioVision).	  Liver	  and	  brain	  from	  A2.DR1	  mice	  therapeutically	  
vaccinated	   with	   IDH1R132H	   (p123-­‐142)	   or	   sham	   treated	   using	   Montanide®	   were	  
cryopreserved,	   homogenized	   in	   IDH	   assay	   buffer,	   and	   subjected	   to	   IDH1/2	   activity	  
measurement	   using	   NADP+	   as	   cofactor	   according	   to	   manufacturer’s	   instructions.	   NADPH	  
production	  was	  colorimetrically	  followed	  for	  30	  min	  after	  initial	  30	  min	  incubation	  at	  37	  °C.	  
IDH	   activity	   was	   analysed	   after	   subtraction	   of	   background	   without	   external	   substrate	   or	  
NADP+	   and	   calculated	   according	   to	   manufacturer’s	   instructions	   using	   an	   NADH	   standard	  
curve.	  
2.2.21	  Western	  Blot	  
Total	  protein	  was	  isolated	  by	  cell	  lysis	  with	  with	  ice	  cold	  tris	  (hydroxymethyl)	  aminomethane	  
hydrochloride	   (TRIS-­‐HCl,	   50	   mM,	   pH	   8,0;	   Carl	   Roth)	   containing	   150	  mM	   NaCl	   (J.T.	   Baker,	  
Deventer,	   Netherlands),	   1	  %	  Nondiet	   P-­‐40	   (Genaxxon	   Bioscience,	   Ulm,	   Germany),	   10	  mM	  
ethylenediaminetetraacetic	   acid	   (EDTA)	   (GerbuBiotechnik,	   Gaiberg,	   Germany),	   200	   mM	  
dithiothreitol	   (Carl	   Roth),	   100	   µM	   phenylmethylsulphonyl	   fluoride	   (PMSF)	   and	   complete	  
EDTA-­‐free	   (1:50,	  Roche,	  Mannheim,	  Germany)	   for	  20	  min	  and	  centrifuged	  to	  pellet	  debris.	  
Protein	  concentrations	  were	  measured	  via	  the	  Bio-­‐Rad	  protein	  assay	  (Bio-­‐Rad,	  Hercules,	  CA,	  
USA)	  at	  595	  nm	  and	  30	  µg	  of	  protein	  diluted	   in	  Laemmli	  sample	  buffer	  were	  denatured	  at	  
95	  °C	  for	  5	  min	  and	  electrophoretically	  separated	  on	  12	  %	  acrylamide-­‐polyacrylamide	  SDS-­‐
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containing	   gels.	   Proteins	   were	   blotted	   onto	   nitrocellulose	   membranes	   by	   wet	   blot	   at	   1.5	  
mA/cm2	  for	  1	  h.	  After	  blocking	  with	  5	  %	  milk	  powder	  in	  0.5	  M	  Tris-­‐based	  saline	  (TBS),	  pH	  7.4,	  
1.5	   M	   NaCl,	   0.05	   %	   Tween	   20,	   membranes	   were	   incubated	   consecutively	   with	   primary	  
monoclonal	   mouse	   anti-­‐IDH1R132H	   (1:500,	   H09,	   Dianova),	   monoclonal	   rat	   anti-­‐panIDH1	  
(1:500,	  W09,	  Dianova)	  for	  detection	  of	  wt	  and	  R132H	  IDH1,	  or	  monoclonal	  mouse	  anti-­‐NY-­‐
ESO-­‐1	   (1:500,	   E978,	   Sigma-­‐Aldrich)	   overnight	   at	   4	   °C,	   and	   mouse	   anti-­‐α-­‐tubulin	   (1:5000,	  
Sigma-­‐Aldrich)	  as	  loading	  control	  for	  1	  h	  at	  room	  temperature	  (RT).	  Staining	  with	  secondary	  
HRP-­‐conjugated	   anti-­‐rat	   (1:(1000xF),	   Dako)	   or	   anti-­‐mouse	   (1:5000,	   GE	   Healthcare,	  
Buckinghamshire,	   UK)	   antibodies	   was	   performed	   at	   RT	   for	   1	   h	   and	   was	   followed	   by	  
chemoluminescent	  development	  using	  ECL	  or	  ECL	  prime	  (both	  Amersham).	  
2.2.22	  Immunofluorescence	  
For	  immunoflourescent	  staining	  cells	  were	  seeded	  on	  glass	  coverslips,	  grown	  until	  70	  –	  90	  %	  
confluent	  and	  fixed	  and	  permeabilized	  with	  Cytofixx	  Pump	  Spray	  (Cell	  Path)	  and	  subsequent	  
4	  %	  PFA.	  For	  blocking	  and	  staining,	  5	  %	  FBS	  in	  PBS	  was	  used.	  Primary	  antibodies	  were	  mouse	  
anti-­‐IDH1R132H	  (1:50,	  H09,	  Dianova)	  and	  mouse	  anti-­‐NY-­‐ESO-­‐1	  (1:100,	  E978,	  Sigma-­‐Aldrich)	  
and	  secondary	  antibody	  was	  donkey	  anti-­‐mouse	  AlexaFluor®	  488	  (1:300,	  Molecular	  Probes,	  
Invitrogen).	   Vectashield	   HardSet	   Mounting	   Medium	   with	   DAPI	   (Vector	   laboratories)	   was	  
used	  for	  mounting	  and	  nuclear	  staining.	  Images	  were	  taken	  on	  LEICA	  DM	  IRB	  microscope.	  
IDH1R132H	  Immunofluorescent	  stainings	  were	  performed	  by	  Lukas	  Bunse.	  
2.2.23	  Immunohistochemistry	  
A2.DR1	  mouse	  tumor	  tissue	  was	  fixed	  with	  Roti®-­‐Histofix	  4.5	  %	  (Carl	  Roth	  GmbH	  +	  Co.	  KG),	  
paraffin-­‐embedded,	   cut	   to	   3	   µm	   sections	   and	   processed	   using	   a	   Ventana	   BenchMark	   XT®	  
immunostainer.	   Tissue	   was	   deparaffinized	   with	   HistoClearTMII	   and	   rehydrated.	   Antigen	  
retrieval	  was	  performed	  using	  Cell	  Conditioning	  Solution	  CC1	  (Ventana	  Medical	  Systems)	  for	  
30	  min.	  Endogenous	  peroxidase	  activity	  was	  blocked	  by	  3	  %	  hydrogen	  peroxide	  in	  PBS	  for	  10	  
min.	  Blocking	  was	  performed	  using	  5	  %	  FBS	  in	  PBS	  for	  30	  min.	  N-­‐Histofine®	  mousestain	  kit	  
(Nichirei	  Biosciences,	  Inc.)	  was	  used	  to	  reduce	  unspecific	  binding	  of	  monoclonal	  mouse	  anti-­‐
IDH1R132H	  (1:50,	  H09,	  Dianova)	  and	  rat	  anti-­‐CD3	  (1:300,	  Dako)	  in	  mouse	  tissue	  according	  to	  
manufacturer´s	   instructions.	   Briefly,	   before	   adding	   primary	   antibody,	   endogenous	   mouse	  
tissue	   IgG	   was	   blocked	   using	   reagent	   A	   and	   Fab´	   was	   blocked	   with	   reagent	   B	   prior	   to	  
incubation	  with	  Simple	  Stain	  Mouse	  MAX	  PO.	  Counterstaining	  was	  performed	  with	  hemalum	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(Carl	   Roth	   GmbH	   +	   Co.	   KG)	   for	   2	  min.	   Stained	   tissue	   was	   dehydrated	   and	  mounted	   with	  
Histomount™	   (National	   Diagnostics).	   H&E-­‐staining	   was	   performed	   using	   hematoxylin	   and	  
bluing	  reagent	  for	  4	  min.	  
Immunohistochemistry	  was	  performed	  by	  Lukas	  Bunse.	  
2.2.24	  Image	  analysis	  
20	  images	  per	  tumor	  were	  randomly	  taken	  of	  the	  tumor	  bulk	  with	  20x	  objective	  using	  LEICA	  
DM	   LB2	  microscope.	   IDH1R132H+	   A2.DR1	   tumor	   cells	   and	   CD3+	   T	   cells	   were	   counted	   by	  
ImageJ	  with	  an	  algorithm	  using	  background	  subtraction	  and	  color	  deconvolution	  plugin	  (see	  
6.4	   Fig.	   6.1).	   IDH1R132H+	   and	   CD3+	   cell	   counts	   of	   20	   images	   were	   set	   in	   relation	   to	  
calculated	  tumor	  volume	  in	  mm3.	  Image	  analysis	  was	  performed	  by	  Lukas	  Bunse.	  
2.2.25	  Statistics	  
The	  mean	  of	  variables	  was	  compared	  with	  Student‘s	  t	  test,	  assuming	  unequal	  variances,	  or	  
Welch‘s	  ANOVA,	  when	  more	  than	  two	  groups	  were	  compared.	  In	  that	  case,	  a	  pairwise	  t	  test	  
with	  Bonferroni	  correction	  was	  performed	  afterwards.	  Data	  shown	   in	  Fig.	  3.15d	  were	   log2	  
transformed	  prior	  to	  analysis.	  The	  area	  under	  the	  curve	  (AUC)	  of	  tumor	  area	  over	  time	  was	  
calculated	  through	  the	  MIfuns	  package,	  and	  median	  AUC	  was	  compared	  with	  the	  Wilcoxon	  
rank-­‐sum	   test.	  Odds	  were	   compared	  with	   Fisher‘s	   exact	   test.	   The	  Bonferroni	  method	  was	  
applied	   to	   adjust	   for	   type	   I	   error	   inflation	   due	   to	   multiple	   testing	   and	   p	   <	   0.05	   was	  
considered	   statistically	   significant	   (http://www.R-­‐project.org/).	   All	   tests	   were	   two-­‐sided.	  




3.1	  MHC	  binding	  studies	  reveal	  IDH1	  epitopes	  
	  
In	  order	  to	  generate	  an	  efficient	  antigen-­‐specific	  T	  cell	  response,	  peptides	  derived	  from	  the	  
antigen	   need	   to	   be	   presented	   on	  MHC	  molecules	   and	   are	   then	   called	   epitopes.	  Whereas	  
epitopes	   are	   presented	   to	   CD8+	   T	   cells	   on	   MHC	   class	   I,	   MHC	   class	   II	   molecules	   present	  
epitopes	  to	  CD4+	  T	  cells.	  
	  
Fig.	  3.1.	  Overlapping	  IDH1	  peptide	  libraries.	  a,	  Human	  IDH1wt	  (WT)	  and	  IDH1R132H	  (RH)	  amino	  acid	  
sequences	  covering	  the	  mutated	  residue	  indicate	  the	  amino	  acid	  exchange	  from	  arginine	  to	  histidine	  
at	  position	  132.	  Mouse	  and	  human	  sequences	  are	  identical	  in	  this	  region	  except	  for	  amino	  acid	  122	  
(serine	  in	  human,	  threonine	  in	  mouse).	  b	  and	  c,	  Peptide	  libraries	  of	  IDH1wt	  and	  IDH1R132H	  covering	  
the	  sequences	  shown	  in	  a	  and	  containing	  peptides	  of	  10	  (b),	  or	  15	  (c),	  amino	  acids	  were	  generated	  by	  
an	  overlap	  of	  9	  or	  13	  amino	  acids,	  respectively.	  
	  
Peptides	   presented	   on	   MHC	   class	   I	   can	   be	   8	   to	   11	   amino	   acids	   long,	   whereas	   those	  
presented	  on	  MHC	  class	  II	  contain	  15	  or	  more	  amino	  acids.	  Hence,	  IDH1R132H	  and	  IDH1wt	  
amino	  acid	  sequences	  (118-­‐146)	  were	  analyzed,	  which	  cover	  the	  amino	  acid	  exchange	  from	  
arginine	   to	   histidine	   at	   position	   132	   and	   include	   all	   possible	   putatively	   processed	   15-­‐mer	  
IDH1	  peptides	  containing	  position	  132	  (Fig.	  3.1a).	  Mouse	  and	  human	  sequences	  are	  identical	  
in	   this	   region	   except	   for	   amino	   acid	   122,	   which	   is	   a	   serine	   in	   human	   and	   a	   threonine	   in	  
mouse	   (see	   6.3.3).	   For	   in	   vitro	   binding	   studies,	   IDH1R132H	   and	   wt	   peptide	   libraries	  
containing	   10-­‐mer	   peptides	  with	   an	   overlap	   of	   9	   amino	   acids	   encompassing	   the	  mutated	  
IDH1R132H	  for	  MHC	  class	   I	  binding	  (Fig.	  3.1b)	  and	  containing	  15-­‐mer	  peptides	  overlapping	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by	  13	  amino	  acids	  for	  MHC	  class	  II	  binding	  (Fig.	  3.1c)	  were	  generated.	  
	  
3.1.1	  IDH1R132H	  peptides	  do	  not	  bind	  to	  HLA-­‐A2	  
To	   assess	   the	   immunogenic	   potential	   of	   the	   IDH1R132H	  mutation	   in	   situ,	   the	   amino	   acid	  
sequences	  encompassing	  the	  mutated	  (R132H)	  and	  corresponding	  wt	  residue	  of	  IDH1	  were	  
subjected	  to	  MHC	  binding	  prediction	  algorithms.	  
Because	   CD8+	   T	   cells	   are	   the	  main	   cytotoxic	   T	   cells	  with	   a	   high	   importance	   in	   anti-­‐tumor	  
immunity,	   first,	   IDH1R132H	   8-­‐,	   9-­‐,	   10-­‐,	   and	   11-­‐mers	   were	   subjected	   to	   MHC	   I	   binding	  
prediction	  to	  the	  most	  common	  HLA-­‐A	  type	  in	  Caucasians,	  HLA-­‐A*0201	  (HLA-­‐A2)	  [148],	  using	  
the	  NetMHC	  algorithm	  (Fig.	  3.2a)	  [144]	  or	  SYFPEITHI	  database	  (Fig.	  3.2b)	  [145].	  None	  of	  the	  
peptides	   were	   predicted	   to	   bind,	   although	   SYFPEITHI	   binding	   scores	   above	   10	   were	  
predicted	  for	  some	  peptides,	  which,	  compared	  to	  positive	  controls,	  might	  be	  considered	  as	  
positive	   binding	   to	   HLA-­‐A2.	   To	   verify	   the	   in	   silico	   results,	   the	   IDH1R132H	   10-­‐mer	   peptide	  
library	  (Fig.	  3.1b)	  was	  tested	  for	  binding	  to	  HLA-­‐A2	  in	  vitro	  by	  T2	  binding	  assay,	  which	  makes	  
use	  of	  the	  fact	  that	  T2	  cells	  are	  deficient	  of	  transporter	  associated	  with	  antigen-­‐processing	  
(TAP)	  and	  express	  HLA-­‐A2	  on	  their	  surface	  only	  when	  peptide	  is	  bound	  to	  HLA,	  and	  is	  based	  
on	  flow	  cytometric	  detection	  of	  surface	  HLA-­‐A2.	  In	  line	  with	  the	  prediction	  results,	  none	  of	  
the	  10-­‐mer	  IDH1R132H	  peptides	  was	  bound	  by	  and	  presented	  on	  HLA-­‐A2	  (Fig.	  3.2c).	  
	  
3.1.2	  IDH1	  peptides	  bind	  to	  HLA-­‐DR1	  
As	  CD4+	  T	  cells	  also	  have	  a	  great	  potential	   for	  anti-­‐tumor	   immunity	   [149-­‐151],	   IDH1R132H	  
peptides	  were	  in	  addition	  tested	  for	  binding	  to	  MHC	  class	  II.	  15-­‐mers	  were	  subjected	  to	  MHC	  
II	  binding	  prediction	  to	  one	  of	  the	  five	  most	  common	  HLA-­‐DR	  types	  in	  Caucasians	  [148],	  HLA-­‐
DRB1*0101	  (HLA-­‐DR1),	  using	  NetMHCII	  and	  SYFPEITHI.	  Some	  of	  the	  peptides	  were	  predicted	  
to	  bind	  by	  both	  algorithms;	  however,	  binding	  predictions	  for	  none	  of	  the	  peptides	  correlated	  
between	   both	   algorithms,	   which	   was	   also	   true	   for	   positive	   control	   peptides	   (Fig	   3.3a).	  
Considering	   the	   inefficient	   reliability	   and	   accordance	   of	   MHC	   class	   II	   peptide	   binding	  
prediction	  algorithms,	  IDH1	  peptides	  were	  tested	  for	  binding	  to	  HLA-­‐DR1	  in	  vitro.	  To	  this	  end,	  
the	   IDH1R132H	   and	   wt	   15-­‐mer	   peptide	   libraries	   (Fig.	   3.1c)	   were	   tested	   for	   immediate	  
binding	   to	   HLA-­‐DR1	   as	  well	   as	   stability	   in	   a	   class	   II	   REVEAL™	   peptide	   binding	   assay.	   IDH1	  
peptides	   bound	   to	   HLA-­‐DR1	   irrespective	   of	   the	   R132H	   mutation	   with	   various	   binding	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efficiency	  (p122-­‐136	  >	  p124-­‐138	  >	  p126-­‐140	  >	  128-­‐142),	  which	  was	  for	  the	  strongest	  binding	  
peptide	  comparable	  to	  the	  positive	  control	  concerning	  both	  immediate	  binding	  and	  stability	  
of	  the	  MHC:peptide	  complex	  after	  24	  h	  (Fig	  3.3b,	  c).	  
	  
	  
Fig.	  3.2. IDH1R132H	  peptides	  do	  not	  bind	  to	  HLA-­‐A2.	  a	  and	  b,	  MHC	  peptide	  binding	  predictions	  for	  
IDH1R132H	  peptides	   to	  HLA-­‐A*0201.	  NetMHC	  algorithm	  was	  used	   to	  predict	  binding	  of	  8-­‐,	  9-­‐,	  10-­‐,	  
and	   11-­‐mers	   (a).	   Peptides	  with	   IC50	   below	   500	   nM	   are	   defined	   as	  weak	   binders,	   those	  with	   IC50	  
below	  50	  nM	  are	  defined	  as	  strong	  binders,	  and	  those	  with	  IC50	  above	  500	  nM	  are	  defined	  as	  non-­‐
binders.	   9-­‐	   and	   10-­‐mers	   were	   also	   tested	   with	   SYFPEITHI	   (b).	   For	   comparison,	   positive	   control	  
peptides	   from	   Epstein-­‐Barr-­‐virus	   (EBV)	   and	   influenza	   are	   shown.	   c,	   IDH1R132H	   10-­‐mer	   peptide	  
binding	  to	  HLA-­‐A2	   in	  vitro	   in	  a	  T2	  binding	  assay.	  T2	  cells	  were	  loaded	  with	  individual	  peptides	  from	  
the	   IDH1R132H	   10-­‐mer	   peptide	   library	   (Fig.	   3.1b)	   and	   surface	   HLA-­‐A2	   was	   determined	   by	   flow	  
cytometry.	  Fluorescence	  intensities	  (black)	  are	  depicted	  after	  background	  subtraction	  and	  relative	  to	  






Fig.	  3.3.	  IDH1	  peptides	  bind	  to	  HLA-­‐DR1	  in	  silico	  and	  in	  vitro.	  a,	  MHC	  peptide	  binding	  predictions	  for	  
IDH1R132H	  peptides	   to	  HLA-­‐DRB1*0101.	  NetMHCII	  and	  SYFPEITHI	  algorithms	  were	  used	   to	  predict	  
binding	   of	   15-­‐mers.	   In	   NetMHCII,	   peptides	  with	   IC50	   below	   500	   nM	   are	   defined	   as	  weak	   binders,	  
those	  with	  IC50	  below	  50	  nM	  are	  defined	  as	  strong	  binders,	  and	  those	  with	  IC50	  above	  500	  nM	  are	  
defined	   as	   non-­‐binders.	   MPT63,	   control	   peptides;	   SYF,	   SYFPEITHI.	   b	   and	   c,	   HLA-­‐DR1-­‐binding	  
IDH1R132H	   (b),	   and	   IDH1wt	   (c),	   15-­‐mer	  epitopes	  were	   identified	  by	  Reveal	  Class	   II™	  binding	  assay	  
(ProImmune)	  using	  the	  peptide	  libraries	  from	  Fig	  3.1c.	  Immediate	  binding	  (0	  h,	  yellow)	  and	  stability	  
after	  24	  h	  (red)	  were	  tested.	  
	  
Collectively,	   the	   obtained	   in	   situ	   and	   in	   vitro	   data	   indicate	   that	   the	   IDH1R132H	   region	  
contains	  epitopes	  that	  bind	  to	  MHC	  class	  II	  HLA-­‐DR1,	  but	  not	  to	  MHC	  class	  I	  HLA-­‐A2	  and	  that	  
binding	  efficiency	  depends	  on	  amino	  acid	  residues	  125/126	  to	  135/136,	  but	  is	  not	  affected	  
by	  the	  mutation.	  
	  
3.2	  IDH1R132H	  is	  immunogenic	  in	  MHC-­‐humanized	  mice	  
	  
A	  suitable	  in	  vivo	  system	  to	  evaluate	  if	  epitope	  presentation	  on	  HLA	  molecules	  is	  associated	  












































































































15mers  NetMHCII  SYF 
sequence position IC50 (nM) score 
PRLVSGWVKPIIIGH 118-132 39,1 16 
RLVSGWVKPIIIGHH 119-133 60,4 20 
LVSGWVKPIIIGHHA 120-134 193,3 0 
VSGWVKPIIIGHHAY 121-135 490,1 15 
SGWVKPIIIGHHAYG 122-136 508,2 15 
GWVKPIIIGHHAYGD 123-137 518,9 25 
WVKPIIIGHHAYGDQ 124-138 566,6 10 
VKPIIIGHHAYGDQY 125-139 407,3 11 
KPIIIGHHAYGDQYR 126-140 308,7 18 
PIIIGHHAYGDQYRA 127-141 485,8 8 
IIIGHHAYGDQYRAT 128-142 564,9 8 
IIGHHAYGDQYRATD 129-143 920,1 1 
IGHHAYGDQYRATDF 130-144 2525,1 8 
GHHAYGDQYRATDFV 131-145 2693,5 1 
HHAYGDQYRATDFVV 132-146 3332,1 16 
VAMNNGMEDLLIWEP MPT63 561,7 16 
AVIPGYPVAGQVWEA MPT63 392,9 16 





for	   the	   analysis	   of	   adaptive	   immune	   functions	   in	   the	   context	   of	   human	   MHC	   in	  
immunocompetent	   mice.	   Human	   MHC	   expression	   is	   particularly	   important	   because,	   as	  
mentioned	   above,	   the	   ability	   of	   an	   epitope	   to	   be	   presented	   and	   therefore	   induce	   an	  
adaptive	   immune	   response	  heavily	   depends	  on	   the	  effective	  binding	   to	   an	  MHC,	  which	   in	  
turn	  can	  be	  restricted	  to	  a	  certain	  HLA-­‐type.	  A2.DR1	  mice	  are	  devoid	  of	  mouse	  MHC	  class	  I	  
(H-­‐2b)	  and	  class	  II	  (H-­‐IAb)	  and	  at	  the	  same	  time	  transgenic	  for	  the	  human	  MHCs	  HLA-­‐A2	  and	  
HLA-­‐DR1	   [142]	   and	  were	   used	   to	   study	   IDH1R132H-­‐specific	   cellular	   and	   humoral	   adaptive	  
immune	  responses	  after	  vaccination.	  This	  allowed	  for	  evaluation	  of	  both	  CD4+	  and	  CD8+	  T	  
cell	  functions	  in	  the	  context	  of	  epitope	  presentation	  on	  human	  MHC	  class	  I	  and	  II.	  
	  
3.2.1	  IDH1R132H	  peptide	  vaccination	  using	  complete	  Freund’s	  adjuvant	  induces	  mutation-­‐
specific	  T	  helper	  responses	  in	  A2.DR1	  mice	  
To	   induce	   antigen-­‐	   and	   potentially	  mutation-­‐specific	   adaptive	   immune	   responses	   in	  MHC-­‐
humanized	  mice,	  peptide	  vaccination	  was	  chosen	  as	  active	   immunization	  approach	  using	  a	  
20-­‐mer	  IDH1R132H	  peptide	  (p123-­‐142),	  which	  encompasses	  all	  R132H-­‐containing	  and	  HLA-­‐
DR1-­‐binding	  epitopes,	  but	  omits	   residue	  122,	  which	   is	  distinct	   in	  human	  and	  murine	   IDH1.	  
Peptide	  was	  emulsified	  in	  complete	  Freund’s	  adjuvant	  (CFA),	  which	  is	  a	  potent	  adjuvant,	  e.g.	  
used	  for	  in	  vivo	  models	  of	  T	  helper	  cell-­‐mediated	  autoimmune	  diseases	  such	  as	  experimental	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Fig.	  3.4.	  IDH1R132H	  peptide	  vaccination	  using	  CFA	  induces	  mutation-­‐specific	  T	  helper	  responses	  in	  
A2.DR1	  mice.	  a,	  ELISpot	  analysis	  of	  mutation-­‐specific	  IFN-­‐γ	  response	  to	  HLA-­‐DR1-­‐binding	  IDH1R132H	  
15-­‐mer	   epitopes	   (upper	   panel)	   and	   IDH1R132H	   peptides	   of	   the	   10-­‐mer	   library	   (lower	   panel)	   after	  
vaccination	   of	   A2.DR1	   mice	   with	   p123-­‐142	   (R132H)	   (vacc)	   or	   vehicle	   control	   (sham)	   in	   CFA	   and	  
restimulation	  of	  splenocytes	  with	  indicated	  peptides	  (white,	  negative	  controls;	  MOG,	  MOG	  (p35-­‐55);	  
red,	  p123-­‐142	  [R132H];	  blue,	  p123-­‐142	  [wt];	  black,	  R132H	  library	  peptides).	  (p123-­‐142	  [R132H	  vs.	  wt],	  
Welch	   t	   test;	  10-­‐,	  15-­‐mers,	  ANOVA;	  n	  =	  3).	  Error	  bars,	  mean	  +	  SEM.	  b,	   Splenocytes	   from	  p123-­‐142	  
(R132H)-­‐CFA	  vaccinated	  (red)	  or	  sham-­‐treated	  (black)	  A2.DR1	  mice	  were	  tested	  for	  production	  of	  T	  
helper	  cytokines	  IFN-­‐γ,	  TNFα,	  IL-­‐4,	  IL-­‐6,	  and	  IL-­‐17	  after	  ex	  vivo	  stimulation	  with	  p123-­‐142	  (R132H)	  or	  
vehicle	  in	  cytokine	  ELISA	  (Welch	  t	  test;	  n	  =	  3).	  Error	  bars,	  mean	  +	  SEM.	  c,	  Representative	  intracellular	  
flow	   cytometry	   of	   splenocytes	   from	   three	   vaccinated	   (upper	   panel)	   and	   three	   sham-­‐treated	  mice	  
(lower	  panel)	  after	  IDH1R132H	  (p123-­‐142)-­‐stimulation	  or	  vehicle	  treatment	  gated	  on	  CD4+	  cells.	  Red	  





Fig.	  3.4.	  IDH1R132H	  peptide	  vaccination	  using	  CFA	  induces	  mutation-­‐specific	  T	  helper	  responses	  in	  




In	   contrast	   to	   the	   control	   treatment	   without	   IDH1R132H	   peptide	   (sham),	   IDH1R132H	  
peptide	   vaccination	  with	   the	   20-­‐mer	   resulted	   in	   a	   robust	   IDH1-­‐specific	   T	   cell	   response	   as	  
measured	  by	  IFN-­‐γ	  enzyme-­‐linked	  immunoadsorbent	  spot	  assay	  (ELISpot)	  after	  restimulation	  
of	   splenocytes	  with	   IDH1	   20-­‐mer	   peptides.	   Importantly,	   the	   T	   cell	   response	   discriminated	  
between	   mutated	   and	   wildtype	   IDH1	   peptides	   (Fig	   3.4a),	   suggesting	   the	   induction	   of	   a	  
mutation-­‐specific	   T	   cell	   response	   after	   immunization	  with	   the	   p123-­‐142	   (R132H)	   peptide.	  
Moreover,	  ex	  vivo	  restimulation	  with	  individual	  peptides	  of	  the	  15-­‐mer	  IDH1	  peptide	  library	  
induced	   IFN-­‐γ	   responses,	  whose	  magnitude	   strongly	   correlated	  with	   the	   peptide	  HLA-­‐DR1	  
binding	  strength	  (p122-­‐136	  >	  p124-­‐138	  >	  p126-­‐140	  >	  128-­‐142)	  (Fig.	  3.4a;	  see	  Fig.	  3.3b,c).	  T	  
cell	   responses	   were	   restricted	   to	   15-­‐mer	   and	   20-­‐mer	   peptides	   and	   not	   induced	   by	  
IDH1R132H	   peptides	   of	   the	   10-­‐mer	   library	   (Fig.	   3.4a),	   suggesting	   predominant	   class	   II-­‐
restricted	  CD4+	  T	  cell	  responses.	  
Especially	  CD4+	  T	  cells	  are	  functionally	  diverse	  and	  even	  more	  importantly,	  regulatory	  T	  cells	  
(Treg)	  might	  be	  induced,	  which	  inhibit	  effector	  immune	  responses.	  The	  nature	  and	  phenotype	  
of	   the	   induced	   T	   cell	   response	   were	   analyzed	   in	   more	   detail	   by	   measuring	   signature	  
cytokines	  by	  enzyme-­‐linked	  immunoadsorbent	  assay	  (ELISA)	  and	  intracellular	  flow	  cytometry	  
including	   the	   signature	   transcription	   factor	   FoxP3,	   which	   is	   characteristic	   for	   Treg,	   after	  
restimulation	  with	  IDH1R132H	  p123-­‐142	  peptide	  ex	  vivo.	  In	  addition	  to	  confirmation	  of	  IFN-­‐γ	  
secretion,	  which	  is	  characteristic	  for	  T	  helper	  1	  (Th1)	  and	  CD8+	  cytotoxic	  T	  lymphocytes	  (CTL),	  
the	  Th2	  cytokine	  IL-­‐6,	  but	  not	  IL-­‐4,	  and	  the	  Th17	  cytokine	  IL-­‐17	  were	  induced	  by	  IDH1R132H	  
peptide	   stimulation	   in	   splenocytes	   from	   vaccinated	  mice,	   but	   not	   sham-­‐treated	  mice	   (Fig.	  
3.4b,c).	   However,	   no	   IDH1R132H-­‐specific	   TNF-­‐α,	   which	   is	   the	   second	   Th1	   cytokine,	   was	  
detected	  (Fig.	  3.4b).	  Of	  note,	  no	  Treg	  were	  induced	  after	  vaccination,	  as	  evidenced	  by	  FoxP3	  
positivity	  (Fig.	  3.4c).	  
	  
3.2.2	  Combined	  adjuvant	  Montanide®/imiquimod	  shifts	  the	  IDH1R132H	  T	  helper	  response	  
and	  induces	  CTL	  responses	  in	  A2.DR1	  mice	  
CFA	  is	  typically	  used	  to	  induce	  T	  helper	  responses	  and	  in	  this	  vaccination	  protocol,	  which	  has	  
been	   established	   for	   EAE	   induction,	   induces	   mainly	   Th1	   and	   Th17	   [152,	   153].	   For	   these	  
reasons,	  and	  to	  be	  able	  to	  transfer	  these	  findings	  to	  the	  clinic	  by	  vaccinating	  glioma	  patients,	  
the	  clinically	  approved	  cancer	  vaccine	  adjuvant	  Montanide-­‐ISA51®	  combined	  with	  the	  TLR-­‐7	  
agonist	   imiquimod	   (Aldara®),	   which	   is	   suitable	   also	   for	   poorly	   immunogenic	   tumors	   and	  
RESULTS	  
40	  
induction	   of	   CD4+	   T	   cell-­‐mediated	   antitumor	   immune	   responses	   and	   approved	   in	   a	  
commercial	   lung	   cancer	   vaccine	   [154,	   155],	   and	   recombinant	   GM-­‐CSF	   [47,	   156,	   157]	   was	  
applied	  for	  IDH1R132H	  peptide	  vaccination	  of	  A2.DR1	  mice.	  
	  
Fig.	  3.5.	  Combined	  adjuvant	  Montanide®/imiquimod	  shifts	  the	  IDH1R132H	  T	  helper	  response	  and	  
induces	   CTL	   responses	   in	   A2.DR1	  mice.	   a,	   ELISpot	   analysis	   of	  mutation-­‐specific	   IFN-­‐γ	   response	   to	  
IDH1	   peptides	   of	   HLA-­‐DR1-­‐binding	   IDH1R132H	   15-­‐mer	   epitopes	   after	   vaccination	   of	   A2.DR1	   mice	  
with	   p123-­‐142	   (R132H)	   and	   restimulation	   of	   splenocytes	   with	   indicated	   peptides	   (white,	   negative	  
controls;	   red,	   p123-­‐142	   [R132H];	   blue,	   p123-­‐142	   [wt];	   black,	   R132H	   library	   peptides).	   (p123-­‐142	  
[R132H	  vs.	  wt],	  Welch	  t	  test;	  15-­‐mers,	  ANOVA;	  n	  =	  3)	  Error	  bars,	  mean	  +	  SEM.	  b,	  Splenocytes	  from	  
p123-­‐142	   (R132H)-­‐Montanide®/imiquimod	   vaccinated	   (red)	   or	   sham-­‐treated	   (black)	   A2.DR1	   mice	  
were	  tested	  for	  production	  of	  T	  helper	  (Th)	  cytokines	  IFN-­‐γ,	  TNF-­‐α,	  IL-­‐4,	  IL-­‐6,	  and	  IL-­‐17	  after	  ex	  vivo	  
stimulation	  with	  p123-­‐142	  (R132H)	  or	  vehicle	  in	  cytokine	  ELISA	  (Welch	  t	  test;	  n	  =	  3).	  Error	  bars,	  mean	  
+	   SEM.	  c,	   Representative	   intracellular	   flow	   cytometry	  of	   splenocytes	   from	   three	   vaccinated	   (upper	  
panel)	   and	   three	   sham-­‐treated	   mice	   (lower	   panel)	   after	   p123-­‐142	   (IDH1R132H)-­‐stimulation	   or	  
vehicle-­‐treatment	  gated	  on	  CD4+	   (left	   and	   two	   right	  panels)	  or	  CD8+	   (second	   left	  panel)	   cells.	  Red	  
numbers,	  populations	  in	  percent.	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This	  clinically	  approved	  cancer	  vaccine	  adjuvant	  was	  equally	  capable	  of	  inducing	  a	  mutation-­‐
specific	   T	   cell	   IFN-­‐γ	   response	   in	   IDH1R132H	   peptide-­‐vaccinated	   mice	   with	   the	   same	  
congruence	   of	   the	   peptide	  MHC	   class	   II	   binding	   strength	   and	   the	  magnitude	   of	   the	   T	   cell	  
response	   after	   stimulation	  with	   15-­‐mer	   library	   peptides	   (Fig	   3.5a).	  With	   this	   regimen,	   the	  
Th1	  profile	  which	  was	  induced	  by	  CFA-­‐vaccination	  persisted	  with	  strong	  induction	  of	  IL-­‐6	  but	  
not	  tumor	  necrosis	  factor	  (TNF)-­‐α,	  but	  the	  Th17	  cytokine	  IL-­‐17	  was	  not	  induced	  (Fig.	  3.5b,c).	  
In	  addition	  to	   IFN-­‐γ	  and	  IL-­‐6-­‐producing	  CD4+	  T	  cells,	  also	   IFN-­‐γ-­‐producing	  cytotoxic	  CD8+	  T	  
cells	  were	  generated	  by	  vaccination	  (Fig.	  3.5c).	  
	  
	  
Fig.	   3.6.	   The	   strongest	   HLA-­‐DR-­‐binding	   IDH1R132H	   epitope	   is	   equally	   capable	   of	   inducing	  
IDH1R132H-­‐specific	   T	   cell	   responses	  with	   combined	   adjuvant	  Montanide®/imiquimod	   in	   A2.DR1	  
mice.	   ELISpot	   analysis	   of	   mutation-­‐specific	   IFN-­‐γ	   response	   to	   IDH1	   peptides	   after	   vaccination	   of	  
A2.DR1	  mice	  with	   IDH1R132H	   (vacc)	   (p123-­‐142),	   (p122-­‐136),	   (p124-­‐138),	   or	   vehicle	   control	   (sham)	  
using	   Montanide®/imiquimod	   and	   restimulation	   of	   splenocytes	   with	   indicated	   peptides	   (white,	  
negative	  controls;	  red,	  p123-­‐142	  [R132H];	  blue,	  p123-­‐142	  [wt];	  black,	  R132H	  library	  peptides).	  (p123-­‐




When	  A2.DR1	  mice	  were	   in	  addition	   to	   IDH1R132H	   (p123-­‐142)	  20-­‐mer	  peptide	  vaccinated	  
with	   HLA-­‐DR1-­‐binding	   IDH1R132H	   15-­‐mers	   (p122-­‐136)	   and	   (p124-­‐138)	   using	  
Montanide®/imiquimmod,	  IDH1R132H	  (p122-­‐136),	  but	  not	  (p124-­‐238),	  induced	  a	  mutation-­‐
specific	  IFN-­‐γ	  response	  to	  the	  20-­‐mer	  and	  HLA-­‐DR1	  15-­‐mer	  epitopes	  (p122-­‐136)	  and	  (p124-­‐
138)	  with	   an	   extent	   comparable	   to	   the	   vaccination	  with	   the	   20-­‐mer	   (p123-­‐142)	   (Fig.	   3.6).	  
These	  results	  indicate	  that	  for	  priming	  T	  cells	   in	  vivo,	   IDH1R132H	  amino	  acid	  residue	  123	  is	  
required	  to	  induce	  the	  response.	  
Nevertheless,	   for	   further	   vaccination	   experiments,	   IDH1R132H	   (p123-­‐142)	   was	   used,	  
because	   it	   induced	   the	   strongest	   and	   most	   mutation-­‐specific	   IFN-­‐γ	   response.	   Moreover,	  
amino	  acid	  122	  differs	  in	  mouse	  and	  human	  IDH1,	  thus	  immune	  responses	  after	  vaccination	  
with	   IDH1R132H	   (p122-­‐136)	   might	   be	   a	   result	   of	   foreign	   protein	   rather	   than	   mutation-­‐
specific	  (Fig.	  3.6,	  lower	  left	  panel).	  
	  
3.2.3	  Generation	  and	  characterization	  of	  IDH1R132H-­‐specific	  A2.DR1	  T	  cell	  line	  and	  clone	  
For	   a	  more	   detailed	   analysis	   of	   the	   nature	   of	   the	   IDH1R132H-­‐specific	   T	   cell	   response	   and	  
potential	  cloning	  of	  the	  IDH1R132H-­‐binding	  T	  cell	  receptor	  (TCR),	  an	  IDH1R132H	  (p123-­‐142)-­‐
specific	  CD4+	  T	  cell	  line	  was	  generated	  from	  IDH1R132H	  (p123-­‐142)-­‐stimulated	  splenocytes	  
of	  Montanide®/imiquimod-­‐vaccinated	  A2.DR1	  mice.	   T	   cells	  were	  expanded	  by	   four-­‐weekly	  
restimulation	   rounds	   with	   peptide-­‐loaded	   irradiated	   autologous	   splenocytes	   from	   naïve	  
A2.DR1	  mice	  as	  antigen-­‐presenting	  cells	  (APC).	  
Using	  the	  above	  described	  protocol,	  a	  highly	  antigen-­‐specific	  T	  cell	   line	  was	  established,	  as	  
shown	   by	   robust	  mutation-­‐specific	   responses	   to	   low	   concentrations	   of	   IDH1R132H	   (p123-­‐
142)	  peptide	   in	   IFN-­‐γ	  ELISpot	  analysis	  with	  peptide-­‐loaded	  autologous	  B	   cell	  blasts	   as	  APC	  
(Fig	  3.7a).	   IFN-­‐γ	  production	  was	  efficiently	   inhibited	  with	   an	  MHC	  class	   II	  HLA-­‐DR-­‐blocking	  
antibody,	  but	  not	  by	  an	  HLA-­‐A-­‐blocking	  antibody	  (Fig.	  3.7b),	  nor	  by	  MHC	  class	  II	  HLA-­‐DP-­‐	  nor	  
HLA-­‐DQ-­‐blocking	  antibodies	  (Fig.	  3.7c),	  proving	  the	  dependency	  of	  the	  T	  cell	  line	  on	  peptide	  
presentation	  on	  HLA-­‐DR1.	  Direct	  evidence	  for	  IFN-­‐γ	  secretion	  by	  CD4+	  T	  cells	  came	  from	  IFN-­‐
γ	   secretion	   assay	   after	   stimulation	   of	   the	   T	   cell	   line	   with	   IDH1R132H	   (p123-­‐142)-­‐loaded	  
autologous	  splenocytes	  (Fig.	  3.7d).	  In	  line	  with	  the	  characterization	  of	  the	  T	  cell	  response	  ex	  
vivo	  after	  vaccination	  (see	  Fig.	  3.5),	  the	  IDH1R132H-­‐specific	  T	  cell	  line	  had	  a	  Th1	  phenotype	  
and	  secreted	  IL-­‐17	  in	  addition	  after	  stimulation	  with	  the	  phorbol	  ester	  phorbol-­‐12-­‐myristate-­‐
13-­‐acetate	   (PMA)	   together	   with	   the	   ionophore	   ionomycin	   (Fig.	   3.7e).	   However,	   the	   Th17	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phenotype	  did	  not	  persist	  after	  antigen-­‐specific	  stimulation	  with	  peptide-­‐loaded	  autologous	  
dendritic	  cells	  (DCs)	  (Fig.	  3.7f).	  This	  discrepancy	  can	  be	  explained	  by	  the	  mode	  of	  action	  of	  
PMA	   and	   ionomycin,	   which	   bypass	   the	   TCR-­‐specific	   stimulation	   by	   activation	   of	   protein	  
kinase	  C	  and	  hence	  the	  MAPK	  and	  NF-­‐κB	  pathways	  and	  permeability	  increase	  and	  therefore	  
Ca2+	  influx,	  respectively	  [158].	  Therefore,	  PMA	  and	  ionomycin	  do	  not	  reflect	  antigen-­‐specific	  
stimulation.	  
During	  development,	  genetic	  rearrangement	  within	  the	  variable	  region	  leads	  to	  a	  variety	  of	  
25	  million	  TCRs	  [159],	  among	  which	  more	  than	  one	  might	  be	  able	  to	  bind	  a	  specific	  antigen	  
with	   varying	   affinity	   and	   avidity,	   hence	   a	   diverse	   ability	   to	   effectively	   stimulate	   the	   T	   cell	  
upon	  antigen	  encounter.	  Pursuing	  the	  aim	  to	   isolate	  and	  clone	  an	   IDH1R132H-­‐specific	  TCR	  
with	   a	  high	  activation	   capacity,	   CD4+	  T	   cell	   clones	  were	  established	   from	   the	   IDH1R132H-­‐
specific	  T	  cell	   line	  by	   limiting	  dilution.	   In	   line	  with	  the	  phenotype	  of	   the	  T	  cell	   line	   (see	  Fig	  
3.7),	  the	  one	  out	  of	  four	  T	  cell	  clones	  which	  was	  reactive	  against	  IDH1R132H	  was	  mutation-­‐
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Fig.	   3.7.	   IDH1R132H-­‐specific	   CD4+	   T	   cell	   line	   is	   mutation-­‐specific,	   dependent	   on	   HLA-­‐DR	  
presentation	   and	   has	   a	   Th1	   phenotype.	   a	   –	   c,	   ELISpot	   assays	   of	   T	   cells	   stimulated	  with	   peptide-­‐
loaded	  autologous	  APC	  (a,	  Welch	  t	  test;	  n	  =	  3;	  error	  bars,	  mean	  ±	  SEM)	  and	  treated	  with	  HLA-­‐blocking	  
antibodies	  (b,	  HLA-­‐A	  and	  HLA-­‐DR,	  n	  =	  2;	  c,	  HLA-­‐DP,	  HLA-­‐DQ,	  and	  HLA-­‐DR,	  n	  =	  3;	  pairwise	  Welch	  t	  test	  
with	   Bonferroni	   correction;	   error	   bars,	   mean	   +	   SEM)	   (white,	   MOG;	   black,	   vehicle;	   red,	   p123-­‐142	  
[R132H];	   blue,	   p123-­‐142	   [wt]).	   d,	   IFN-­‐γ	   secretion	   assay	   of	   T	   cells	   stimulated	   with	   peptide-­‐loaded	  
autologous	  APC	  followed	  by	  CD4	  and	  CD8	  surface	  staining	  and	  flow	  cytometry	  (flow	  through,	  IFN-­‐γ-­‐
negative	  fraction;	  SEB,	  staphylococcus	  enterotoxin	  B,	  positive	  control;	  IDH1R132H,	  p123-­‐142;	  upper	  
left	  panel,	  T	  cell	  line	  alone).	  e	  and	  f,	  Intracellular	  cytokine	  flow	  cytometry	  of	  T	  cells	  after	  stimulation	  
with	  PMA	  and	  Ionomycin	  (e)	  or	  with	  IDH1R132H	  (p123-­‐142)-­‐loaded	  or	  vehicle-­‐treated	  DC	  (f).	  Gated	  






Fig.	   3.7.	   IDH1R132H-­‐specific	   CD4+	   T	   cell	   line	   is	   mutation-­‐specific,	   dependent	   on	   HLA-­‐DR	  




Fig.	   3.8.	   IDH1R132H-­‐specific	   CD4+	   T	   cell	   clone	   is	   mutation-­‐specific	   and	   dependent	   on	   HLA-­‐DR	  
presentation.	  a,	  ELISpot	  analysis	  of	  IFN-­‐γ	  production	  by	  T	  cells	  after	  stimulation	  with	  peptide-­‐loaded	  
autologous	   B	   cell	   blasts	   (white,	  MOG;	   black,	   vehicle;	   blue,	   p123-­‐142	   [wt];	   red,	   p123-­‐142	   [R132H])	  
(Welch	   t	   test;	  n	   =	  3).	   Error	  bars,	  mean	  ±	  SEM.	  b,	   p123-­‐142	   (R132H)-­‐specific	   IFN-­‐γ	  production	  after	  
treatment	   with	   blocking	   antibodies	   against	   HLA-­‐DR-­‐	   and	   HLA-­‐A	   in	   ELISpot	   with	   peptide-­‐loaded	  
autologous	   B	   cell	   blasts	   (white,	   vehicle;	   black,	  MOG;	   blue,	   p123-­‐142	   [wt];	   red,	   p123-­‐142	   [R132H])	  
(Pairwise	  Welch	  t	  test	  with	  Bonferroni	  correction;	  n	  =	  3).	  Error	  bars,	  mean	  +	  SEM.	  
	  
3.2.4	  Cellular	  IDH1R132H	  responses	  are	  not	  restricted	  to	  HLA-­‐DR1	  in	  MHC-­‐humanized	  mice	  
The	  hitherto	  collected	  data	  on	  the	  immunogenicity	  of	  IDH1R132H	  were	  restricted	  to	  one	  of	  
the	  most	  common	  HLA-­‐DR	  types	  within	  the	  Caucasian	  population.	  However,	  only	  about	  10	  %	  
of	   this	  population	  are	  positive	   for	  serotype	  HLA-­‐DR1,	   including	  HLA-­‐DR1*0101,	  *0102,	  and	  
*0103	  [148].	  Consequently,	  in	  a	  potential	  clinical	  study,	  the	  possibility	  to	  enroll	  patients	  with	  
other	   HLA-­‐DR	   types	   would	   be	   of	   high	   value	   and	   advantage.	   Therefore,	   the	   potential	   of	  
IDH1R132H-­‐encompassing	  peptides	  to	  bind	  another	  HLA-­‐DR	  type	  and	  induce	  a	  specific	  T	  cell	  
response	  was	  evaluated.	  
The	   class	   II	   MHC	   serotype	   HLA-­‐DR4	   accounts	   for	   about	   11	   %	   of	   all	   HLA-­‐DR	   types	   in	   the	  
Caucasian	  population	  and	  is	  therefore	  more	  common	  than	  HLA-­‐DR1	  [148].	  DR4	  mice	  are	  like	  
A2.DR1	  mice	  deficient	  for	  mouse	  MHC	  class	  II	  (H-­‐IAb),	  but	  proficient	  for	  mouse	  MHC	  class	  I	  
(H-­‐2b)	  and	  transgenic	  for	  human	  HLA-­‐DRA*0101	  and	  HLA-­‐DRB1*0401	  (HLA-­‐DR4)	  [143].	  
Vaccination	  of	  DR4	  mice	  with	  IDH1R132H	  (p123-­‐142)	  with	  Montanide®/imiquimod	  resulted	  
in	   mutation-­‐specific	   IFN-­‐γ	   responses	   to	   IDH1R132H	   (p123-­‐142)	   (Fig	   3.9a).	   In	   concordance	  
with	   T	   cell	   responses	   in	  A2.DR1	  mice	   (see	   3.2.2),	   this	   vaccination	   regimen	   induced	  mainly	  
RESULTS	  
46	  
Th1	  responses,	  with	   IDH1R132H-­‐induced	  secretion	  of	   IFN-­‐γ	  and	  to	  a	   lesser	  extent	   IL-­‐6,	  but	  




Fig.	   3.9. IDH1R132H	  peptide	   vaccination	   using	  Montanide®/imiquimod	   induces	   Th1	   responses	   in	  
HLA-­‐DR4+	   humanized	  mice.	   a,	   ELISpot	  analysis	  of	  mutation-­‐specific	   IFN-­‐γ	   response	   to	   IDH1	   (p123-­‐
142)	   after	   vaccination	   of	   DR4	  mice	   with	   p123-­‐142	   (R132H)	   (vacc)	   or	   vehicle	   control	   (sham)	   using	  
Montanide®/imiquimod	   and	   restimulation	   of	   splenocytes	   with	   indicated	   peptides	   (white,	   negative	  
controls;	  red,	  p123-­‐142	  [R132H];	  blue,	  p123-­‐142	  [wt]).	  (Welch	  t	  test;	  n	  =	  3)	  Error	  bars,	  mean	  +	  SEM.	  b,	  
Splenocytes	   from	   p123-­‐142	   (R132H)-­‐Montanide®/imiquimod	   vaccinated	   (red)	   or	   sham-­‐treated	  
(black)	  DR4	  mice	  were	  tested	  for	  production	  of	  T	  helper	  (Th)	  cytokines	  IFN-­‐γ,	  TNF-­‐α,	  IL-­‐4,	  IL-­‐6,	  and	  IL-­‐
17	  after	  ex	  vivo	  stimulation	  with	  p123-­‐142	  (R132H)	  or	  vehicle	  in	  cytokine	  ELISA	  (Welch	  t	  test;	  n	  =	  3).	  
Error	   bars,	  mean	   +	   SEM.	   c,	   Representative	   intracellular	   flow	   cytometry	   of	   splenocytes	   from	   three	  
vaccinated	   (upper	  panel)	   and	   three	   sham-­‐treated	  mice	   (lower	  panel)	   after	  p123-­‐142	   (IDH1R132H)-­‐




3.2.5	  IDH1	  peptide-­‐coated	  serum	  ELISA	  allows	  detection	  of	  IDH1R132H-­‐binding	  antibodies	  
in	  IDH1R132H	  peptide-­‐vaccinated	  A2.DR1	  mice	  
Since	  one	  of	  the	  functions	  of	  antigen-­‐reactive	  T	  helper	  cells	  is	  to	  stimulate	  B	  cells	  to	  produce	  
and	  secrete	  antigen-­‐specific	  antibodies,	  T	  helper	  cell	   responses	  are	  usually	  associated	  with	  
the	   production	   of	   antigen-­‐binding	   antibodies,	   which	   can	   be	   detected	   in	   serum.	  With	   this	  
rationale,	  the	  consequent	  aim	  was	  the	  detection	  of	  IDH1R132H-­‐specific	  antibodies	  in	  A2.DR1	  
mouse	  serum	  after	  vaccination.	  To	  this	  end,	  a	  peptide	  ELISA	  using	  IDH1R132H	  peptides	  was	  
established	  to	  detect	  IDH1R132H-­‐binding	  immunoglobulin	  G	  (IgG)	  in	  mouse	  serum.	  
IDH1	  peptides	  of	  the	  15-­‐mer	  library	  as	  well	  as	  the	  20-­‐mer	  (p123-­‐142)	  were	  coated	  on	  ELISA	  
plates,	   serum	   was	   added	   and	   peptide-­‐bound	   IgG	   were	   detected	   with	   a	   horseradish	  
peroxidase	   (HRP)-­‐conjugated	   secondary	  antibody	  and	  TMB	  as	  a	   substrate	   (Fig.	   3.10a).	   The	  
ELISA	   system	   was	   established	   with	   the	   IDH1R132H-­‐specific	   antibody,	   which	   has	   been	  
developed	  and	  is	  routinely	  used	  at	  the	  University	  Hospital	  Heidelberg	  and	  internationally	  for	  
diagnosis	   of	   the	   IDH1	  mutation	   status	   in	   glioma	   patients	   [105,	   106].	   Using	   this	   antibody,	  
peptide	   concentration,	   buffer	   system,	   and	   surface	   of	   the	   ELISA	   plate	   were	   optimized.	   In	  
accordance	  with	   the	   immunogenic	  peptide	  used	   for	  production	  of	   the	   IDH1R132H-­‐specific	  
antibody	   (p125-­‐137),	   the	   antibody	   bound	   to	   IDH1R132H	   (p122-­‐136,	   p124-­‐138,	   and	   p126-­‐
140)	  (Fig.	  3.10b).	  A	  lower	  detection	  limit	  of	  about	  4	  µg/ml	  IgG	  was	  determined	  by	  titration	  of	  
the	  antibody	  using	  plate-­‐bound	   IDH1R132H	   (p122-­‐136)	   (Fig.	   3.10c).	   Importantly,	   the	  ELISA	  
system	  was	  suitable	  to	  discriminate	  between	  IDH1R132H	  and	  wt,	  i.	  e.	  antibody	  binding	  only	  
to	   the	   mutated	   IDH1,	   but	   not	   wt	   IDH1	   was	   detectable	   (Fig.	   3.10b,d).	   In	   addition	   to	   the	  
measurement	  of	   total	   IgG,	   detection	  of	  mouse	   IgG	   subtypes	   IgG1,	   IgG2a,	   IgG2b,	   and	   IgG3	  
was	   tested	   with	   subtype-­‐specific	   secondary	   antibodies.	   As	   expected	   from	   the	   antibody	  
subtype,	  only	  IgG2a	  binding	  to	  IDH1R12H	  was	  detected,	  verifying	  the	  specificity	  of	  secondary	  
antibodies	  in	  this	  system	  (Fig.3.10d).	  
With	   the	  established	   IDH1	  peptide	  ELISA	   system,	   IDH1R132H	   (p123-­‐142)-­‐binding	   IgG	  were	  
detected	   in	   serum	   of	   some,	   but	   not	   all	   A2.DR1	   mice	   which	   had	   been	   vaccinated	   with	  
IDH1R132H	   (p123-­‐142)	  with	  Montanide®/imiquimod.	  Of	   note,	   responding	  mice	   developed	  
antibodies	  which	  discriminated	  between	  wt	  and	  mutated	  IDH1	  (Fig.	  3.11a).	  These	  antibodies	  




Fig.	   3.10.	   IDH1	   peptide-­‐coated	   ELISA	   is	   established	   for	   detection	   of	   IDH1-­‐specific	   IgG	   in	   mouse	  
serum.	   a,	  ELISA	  plates	  are	   coated	  with	   IDH1R132H,	   IDH1wt,	  or	   control	  peptides,	  washed,	  blocked,	  
and	   incubated	  with	   human	   serum	   or	   serum	   from	   vaccinated	  mice.	   Bound	   IgG	   are	   detected	   using	  
horseradish	  peroxidase	  (HRP)-­‐conjugated	  anti-­‐mouse	  or	  anti-­‐human	  total	  IgG,	  IgG1,	  IgG2a,	  IgG2b,	  or	  
IgG3,	   respectively	   and	   subsequent	   addition	   of	   TMB.	   Colour	   reaction	   is	   stopped	   with	   H2SO4	   and	  
measured	  at	  450	  nm.	  b	  –	  d,	  ELISA	  IDH1R132H	  specificity	  and	  applicability	  were	  tested	  using	  mouse	  
anti-­‐IDH1R132H	  antibody	  as	  serum	  substitute.	  b,	  ELISA	  on	  indicated	  peptides	  of	  the	  10-­‐mer	  and	  15-­‐
mer	  libraries	  (blue,	  IDH1wt;	  red,	  IDH1R132H;	  10-­‐mer	  pool,	  all	  library	  peptides)	  and	  a	  negative	  control	  
peptide	  (white,	  HIV).	  c,	  p122-­‐136	  (IDH1R132H)	  was	  used	  to	  titrate	  the	  anti-­‐IDH1R132H	  antibody.	  d,	  
IgG	  subtype-­‐specific	  secondary	  antibodies	  were	  used	  with	  IDH1R132H-­‐specific	  antibody	  on	  p122-­‐136	  
(IDH1R132H).	  
	  
The	   results	   described	   here	   show	   that	   peptide	   vaccination	   with	   IDH1R132H	   induces	  
mutation-­‐specific	   T	   helper	   1-­‐mediated	   cellular	   responses	   and	   IgG	   production	   in	   MHC-­‐
humanized	  mice	  and	  that	  this	  immunogenicity	  is	  restricted	  to	  MHC	  class	  II,	  but	  not	  to	  HLA-­‐
DR1.	   Potent	   IFN-­‐γ	   T	   cell	   responses	   are	   induced	   not	   only	   by	   CFA,	   but	   also	  with	   a	   clinically	  
approved	   adjuvant.	   The	   established	   peptide	   ELISA	   allows	   mutation-­‐specific	   detection	   of	  




Fig.	   3.11.	   IDH1R132H	   peptide	   vaccination	   using	   Montanide®/imiquimod	   induces	   IDH1-­‐specific	  
antibodies	   in	   A2.DR1	   mice.	   a,	   Detection	   of	   IDH1R132H-­‐specific	   antibodies	   by	   MOG-­‐,	   p123-­‐142	  
(R132H,	  wt)	  peptide-­‐coated	  ELISA	  in	  serum	  of	  A2.DR1	  mice	  immunized	  with	  p123-­‐142	  (R132H)	  (red),	  
but	  not	  sham-­‐treated	  (black).	  OD	  values	  are	  depicted	  relative	  to	  negative	  control	  (MOG)	  OD	  (Welch	  t	  
test;	  n	   =	   3).	   Scatter	   plot	   showing	   individual	   values	   for	   each	  mouse	   and	   the	  mean.	  b,	   Detection	   of	  
IDH1R132H-­‐specific	   IgG	   subclasses	   IgG1,	   IgG2a,	   IgG2b,	   and	   IgG3	   with	   123-­‐142	   (R132H)-­‐peptide-­‐
coated	   ELISA	   in	   serum	   of	   vaccinated	   mice	   bearing	   IDH1R132H-­‐specific	   IgG.	   Values	   are	   depicted	  
relative	  to	  total	  IgG.	  
	  
3.3	  Spontaneous	  IDH1R132H	  cellular	  and	  humoral	  responses	  are	  detected	  in	  
glioma	  patients	  
	  
The	   ex	   vivo	   results	   obtained	   from	   the	   vaccination	   experiments	   in	   MHC-­‐humanized	   mice	  
indicate	   that	   the	   IDH1	  mutation	   is	   immunogenic	   in	   a	   way	   that	   an	   epitope	   harboring	   the	  
mutated	   residue	   is	   presented	   on	   MHC	   class	   II	   to	   induce	   an	   IDH1R132H-­‐specific	   T	   cell	  
response	   that	   is	   able	   to	   stimulate	   the	   production	   of	   IDH1R132H-­‐binding	   IgG	   antibodies.	  
Nevertheless,	  these	  results	  are	  not	  empowered	  to	  prove	  the	  processing	  of	  the	  immunogenic	  
epitope	  from	  the	  IDH1R132H	  protein.	  
To	   pursue	   the	   question	   of	   epitope	   processing,	   but	   even	   more	   to	   analyze	   the	   clinical	  
relevance	  of	  an	  IDH1R132H-­‐specific	   immune	  response,	  IDH1R132H-­‐positive	  glioma	  patients	  
were	   tested	   for	   spontaneous	   responses	   against	   the	  mutated	   IDH1.	   It	   has	   been	   shown	   for	  
other	   tumor	   entities	   and	   antigens	   that	   patients	   can	   harbor	   spontaneous	   tumor	   antigen-­‐
specific	  humoral	  and	  cellular	   immune	  responses,	  e.g.	  against	   the	  cancer	   testis	  antigen	  NY-­‐
ESO-­‐1	   [40,	   41].	   In	   high-­‐grade	   glioma,	   spontaneous	   immune	   reactions	   against	   the	   tumor-­‐
associated	   antigens	   IL13Rα2	   and	   EphA2,	   as	   indicated	   by	   specific	   T	   cells	   in	   the	   peripheral	  
blood,	   correlated	   with	   prolonged	   survival	   [160].	   Therefore,	   it	   was	   hypothesized	   that	   an	  
immunogenic	   IDH1R132H	  epitope	  might	  spontaneously	   induce	  specific	   immunity	   in	  glioma	  
patients	  with	  IDH1R132H-­‐mutated	  tumors.	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3.3.1	  IDH1R132H-­‐positive	  glioma	  patients	  harbor	  spontaneous	  IDH1R132H-­‐specific	  T	  
helper	  responses	  
IDH1R132H-­‐positive	   patients	   were	   screened	   for	   IDH1R132H-­‐induced	   IFN-­‐γ	   secretion	   in	  
peripheral	  blood	  mononuclear	  cells	   (PBMC)	  using	   library	  peptides	   in	  ELISpot	  analysis.	   Four	  
out	  of	  25	  patients	  (16	  %)	  with	  IDH1-­‐mutated	  tumors,	  but	  none	  of	  29	  glioma	  patients	  with	  an	  
IDH1	  wt	  status	  showed	  IDH1R132H-­‐specific	  IFN-­‐γ	  responses	  against	  the	  20-­‐mer	  IDH1R132H	  
peptide	  123-­‐142,	  which	  had	  been	  used	  for	  vaccination	  studies	   in	  MHC-­‐humanized	  mice,	   in	  
the	  periphery.	  These	  responses	  were	  mutation-­‐specific	  (Fig.	  3.12a-­‐c).	  Notably,	  no	  response	  
against	  IDH1R132H	  peptides	  of	  the	  10-­‐mer	  library	  (see	  Fig.	  3.1b)	  was	  detectable	  in	  any	  of	  23	  
IDH1R132H-­‐positive	   patients	   tested,	   including	   one	   patient	   with	   a	   response	   against	  
IDH1R132H	  (p123-­‐142)	  (Fig.	  3.12d),	  pointing	  towards	  the	  notion	  that	  immune	  responses	  are	  
not	  MHC	  class	  I-­‐mediated.	  
Supporting	   this	   idea	   and	   in	   line	   with	   the	   induced	   IDH1R132H-­‐specific	   T	   cell	   responses	   in	  
vaccinated	  MHC-­‐humanized	   mice,	   specific	   IFN-­‐γ	   secretion	   was	   abrogated	   by	   the	   HLA-­‐DR-­‐
blocking	   antibody	   in	   responsive	   patients	   (Fig.	   3.12e),	   indicating	   the	   presentation	   of	   the	  
IDH1R132H	   epitope	   on	   HLA-­‐DR	   and	   a	   CD4+	   T	   cell	   response.	   To	   further	   characterize	   the	  
phenotype	   of	   the	   T	   cell	   response,	   IFN-­‐γ	   secretion	   assays	   were	   performed	   enabling	   the	  
enrichment	   and	   flow	   cytometric	   analysis	   of	   IFN-­‐γ-­‐producing	   T	   cells	   from	   ELISpot	   positive	  
patients.	  In	  line	  with	  the	  results	  of	  the	  immunizations	  of	  MHC-­‐humanized	  mice,	  IDH1R132H-­‐
specific	  IFN-­‐γ-­‐producing	  T	  cells	  were	  predominantly	  CD4+	  in	  two	  patients	  tested	  positive	  for	  
IDH1R132H-­‐specific	  IFN-­‐γ	  responses	  (data	  shown	  for	  one	  patient,	  Fig.	  3.12f).	  
Notably,	   the	   spontaneous	   antigen-­‐specific	   T	   cell	   responses	   were	   of	   very	   low	   frequency	  
compared	   to	   those	   detected	   in	   vaccinated	   mice;	   however,	   this	   can	   be	   expected	   due	   to	  
immunosuppressive	  properties	  of	  the	  tumor	  [114]	  and	  an	  impaired	  antigen	  encounter	  as	  a	  
consequence	  of	  the	  blood	  brain	  barrier.	  In	  addition,	  no	  IDH1R132H-­‐induced	  IFN-­‐γ	  secretion	  
was	  detectable	  in	  patients	  with	  an	  IDH1	  wt	  status	  (Fig.	  3.12c),	  indicating	  that	  these	  cellular	  
responses	  are	  specific	  and	  of	  clinical	  relevance	  and	  that	  an	  IDH1R132H-­‐positive	  tumor	  might	  




Fig.	  3.12.	  Spontaneous	  IDH1R132H-­‐specific	  CD4+	  T	  cell	  responses	  are	  detected	  in	  some	  IDH1R132H-­‐
positive	  glioma	  patients.	  a	  and	  b,	  Representative	  IFN-­‐γ	  ELISpot	  analysis	  of	  PBMC	  from	  patients	  p001	  
(a)	   and	   p037	   (b),	   stimulated	   with	   IDH1R132H	   p123-­‐142	   (a,	   red),	   IDH1wt	   p123-­‐142	   (a,	   blue),	   and	  
negative	  controls	  (MOG	  p35-­‐55	  and	  vehicle;	  a,	  white).	  a,	  error	  bars,	  mean	  +	  SEM,	  n	  =	  2.	  c	  and	  d,	  IFN-­‐γ	  
ELISpot	  analyses	  of	  PBMC	  from	  patients	  with	  IDH1R132H-­‐mutated	  gliomas	  (c,	  red,	  n	  =	  25;	  d,	  n	  =	  23)	  
or	  IDH1wt	  gliomas	  (c,	  blue,	  n	  =	  29),	  stimulated	  with	  IDH1	  (p123-­‐142)	  R132H	  or	  wt	  (c)	  or	  indicated	  10-­‐
mer	   peptides	   (d;	   black;	   green,	   positive	   control	   PMA+I,	   phorbol	  myristate	   acetate	   +	   ionomycin.	   (c,	  
Wilcoxon	  rank-­‐sum	  test;	  Fisher’s	  exact	  test	  of	  odds,	  p	  =	  0.043;	  d,	  Welch	  ANOVA)	  Data	  are	  depicted	  as	  
specific	  spots	  after	  subtraction	  of	  background	  spots	  (MOG,	  negative	  values	  set	  to	  zero)	   in	  a	  scatter	  
plot	   showing	   values	   for	   each	   patient.	   Dashed	   line,	   cut-­‐off	   for	   positivity	   set	   to	   50	   in	   c.	   e,	   IFN-­‐γ	  
production	  by	  PBMC	  of	  patient	  p037	  in	  response	  to	  p123-­‐142	  (R132H)	  as	   in	  a	   including	  an	  HLA-­‐DR-­‐
specific	  blocking	  antibody	   (Welch	  t	   test;	  n	  =	  3).	  Error	  bars,	  mean	  +	  SEM.	   f,	   IFN-­‐γ	  secretion	  assay	  of	  
(p123-­‐142)-­‐stimulated	   PBMC	   from	   patient	   p037	   (flow	   through,	   IFN-­‐γ-­‐negative	   fraction;	   MOG,	  
negative	  control;	  SEB,	  positive	  control;	  IDH1R132H,	  p123-­‐142).	  Red	  numbers,	  populations	  in	  percent.	  
Data	  in	  b,	  c,	  e,	  and	  f	  collected	  and	  analyzed	  by	  L.	  Bunse.	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3.3.2	  IDH1R132H-­‐specific	  antibodies	  can	  be	  detected	  in	  the	  serum	  of	  IDH1R132H-­‐positive	  
glioma	  patients	  
The	  results	  obtained	  from	  glioma	  patient	  peripheral	  blood	  described	  above	  (see	  3.3.1)	  show	  
that	  an	   immunogenic	   IDH1R132H	  epitope	   induces	  an	   IDH1R132H-­‐specific	  cellular	   response	  
only	  in	  those	  patients	  harboring	  IDH1-­‐mutated	  tumors.	  Moreover,	  the	  cellular	  response	  was	  
restricted	   to	   CD4+	   T	   helper	   cells.	   Consequently,	   as	   in	   vaccinated	   mice,	   spontaneous	  
IDH1R132H-­‐specific	  T	  cell	   responses	  might	  be	  accompanied	  by	  humoral	  responses	   in	  these	  
patients	  as	  well.	  
Before	  glioma	  patients	  were	  screened,	  IDH1	  peptides	  of	  the	  15-­‐mer	  library	  and	  the	  20-­‐mer	  
peptides	  were	   tested	   for	  binding	   to	   serum	   IgG	   from	   IDH1R132H	  glioma	  patients	  using	   the	  
established	  ELISA	   system	   (see	  3.2.5).	   IDH1R132H-­‐specific	   IgG	  bound	  exclusively	   to	  one	  15-­‐
mer	  peptide	  (p122-­‐136)	  (Fig	  3.13a),	  which	  was	  subsequently	  used	  for	  screening.	  
IDH1R132H-­‐positive	  glioma	  patients	  who	  were	  tested	  with	  the	  ELISA	  had	  significantly	  higher	  
IgG	   IDH1R132H-­‐peptide	   binding	   values	   than	   patients	   with	   IDH1wt	   gliomas.	   The	   obtained	  
data	  from	  89	  patients	  in	  total	  was	  used	  to	  define	  a	  binding	  capacity	  threshold	  for	  positivity,	  
which	  was	  defined	  as	  a	   five-­‐fold	   IDH1R132H-­‐binding	  value	   relative	   to	   the	  negative	  control	  
peptide	   (Fig.	  3.13b).	  According	   to	   this	   threshold,	   compliant	  with	   the	  vaccination	  studies	   in	  
MHC-­‐humanized	  mice,	  IDH1R132H-­‐specific	  antibodies	  were	  detected	  in	  4	  of	  42	  patients	  with	  
IDH1R132H-­‐mutated	  but	  not	  in	  47	  patients	  with	  IDH1wt	  tumors	  and	  not	  in	  healthy	  donors,	  
indicating	   the	   presence	   of	   IDH1R132H-­‐specific	   antibodies	   in	   a	   fraction	   (9.5	   %)	   of	   glioma	  
patients	   with	   IDH1R132H-­‐mutated	   tumors.	   Of	   note,	   as	   opposed	   to	   IDH1R132H	   T	   cell	   and	  
antibody	  reactivity,	  there	  was	  no	  difference	  between	  patients	  with	  IDH1wt	  and	  IDH1R132H-­‐
mutated	  tumors	  nor	   IDH1R132H-­‐responders	  and	  non-­‐responders	   in	  their	  ability	  to	  react	  to	  
the	   foreign	   positive	   control	   antigen	   tetanus	   toxoid	   with	   specific	   antibody	   production	  
(Fig.3.13c),	   indicating	   that	   the	   difference	   is	   not	   due	   to	   a	   different	   ability	   to	   react	   to	   a	  
neoantigen	  in	  general	  between	  the	  groups.	  Serum	  of	  10	  patients	  with	  IDH1R132H+	  tumors,	  
who	   had	   been	   shown	   to	   have	   elevated	   IDH1R132H-­‐specific	   IgG	   levels,	   was	   tested	   for	  
IDH1R132H-­‐binding	   IgG	   subtypes.	   In	   correlation	   with	   vaccination-­‐induced	   specific	   IgG	  
production	  in	  mice,	  patient	  IDH1R132H-­‐binding	  IgG	  were	  of	  IgG1	  subtype	  (Fig.	  3.13d).	  
Collectively,	  screening	  of	  glioma	  patients	  harboring	  IDH1wt	  or	  IDH1R132H	  tumors	  revealed	  
that	   spontaneous	  mutation-­‐specific	   IDH1R132H-­‐directed	  T	   cell	   and	  humoral	   responses	   are	  
rare,	  but	  detectable	   in	   IDH1R132H-­‐positive	  patients,	  but	  not	   in	   IDH1wt	  patients,	   indicating	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that	   R132H-­‐mutated	   IDH1	   is	   naturally	   processed	   in	   glioma	   patients	   to	   present	   an	  
immunodominant	  epitope	  in	  the	  p123-­‐142	  region	  on	  MHC	  class	  II	  molecules	  to	  CD4+	  T	  cells	  
to	   induce	   a	   spontaneous	  mutation-­‐specific	   Th1-­‐polarized	   response	   and	   the	   production	   of	  
mutation-­‐specific	  antibodies	  detectable	   in	  patients	  with	   IDH1R132H-­‐mutated	  but	  not	   IDH1	  
wt	  gliomas.	  
	  
Fig.	   3.13	   IDH1R132H-­‐specific	   antibodies	   can	   be	   detected	   in	   some	   IDH1R132H-­‐positive	   glioma	  
patients.	   a,	   Peptide-­‐coated	   ELISA	   analyzing	   IDH1-­‐specific	   IgG	   in	   serum	   of	   2	   IDH1R132H-­‐positive	  
patients	   using	   indicated	   IDH1	  15-­‐mer	   library	   and	  20-­‐mer	   peptides	   (blue,	   IDH1wt;	   red,	   IDH1R132H;	  
white,	   MOG	   negative	   control).	   Data	   are	   presented	   relative	   to	   MOG.	   b,	   Peptide-­‐coated	   ELISA	  
analyzing	   IDH1R132H-­‐specific	   IgG	   in	  serum	  of	  42	   IDH1R132H-­‐positive	  patients,	  47	   IDH1wt	  patients,	  
and	   4	   healthy	   donors.	   (Wilcoxon	   rank-­‐sum	   test;	   Fisher’s	   exact	   test	   of	   odds,	   p	   =	   0.043)	   Data	   are	  
depicted	  relative	  to	  MOG.	  Dashed	  line,	  cut	  off	  for	  positivity	  set	  to	  5.	  c,	  Detection	  of	  tetanus	  toxoid-­‐
specific	  IgG	  in	  serum	  of	  IDH1wt	  patients	  (blue,	  n	  =	  44)	  and	  IDH1R132H-­‐positive	  patients	  (red,	  n	  =	  40).	  
IDH1R132H-­‐positive	   patients	   are	   grouped	   into	   IDH1R132H-­‐IgG	   positive	   (responder,	   n	   =	   4)	   and	  
negative	  (non-­‐responder,	  n	  =	  36)	  according	  to	  b	  (Wilcoxon	  rank-­‐sum	  test).	  Data	  are	  depicted	  relative	  
to	  MOG.	  d,	   IDH1R132H-­‐specific	   IgG	  and	   IgG	   subtypes	   IgG1,	   IgG2,	   IgG3,	   and	   IgG4	  were	  detected	   in	  
serum	  of	  IDH1R132H-­‐positive	  glioma	  patients	  (Pairwise	  Welch	  t	  test	  with	  Bonferroni	  correction;	  n	  =	  
10).	  Data	  are	  depicted	   relative	   to	   total	   IgG.	   Scatter	  plots	   showing	  values	   for	  each	  patient	   (and	   the	  
mean	  in	  a,	  c,	  d).	  Data	  in	  b	  –	  d	  collected	  and	  analyzed	  by	  L.	  Bunse.	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3.4	  IDH1R132H	  vaccination	  specifically	  reduces	  IDH1R132H	  tumor	  growth	  in	  
A2.DR1	  mice	  
	  
3.4.1	  Establishment	  of	  a	  syngeneic	  MHC-­‐humanized	  tumor	  model	  for	  vaccination	  
An	  essential	  but	  hitherto	  open	  question	  was	  the	  therapeutic	  relevance	  and	  functionality	  of	  
the	   IDH1R132H-­‐specific	   immune	   response,	   which	   is	   spontaneously	   detectable	   in	  
IDH1R132H-­‐positive	   glioma	   patients	   and	   inducible	   by	   peptide	   vaccination	   in	   MHC-­‐
humanized	   mice.	   To	   address	   this	   question,	   which	   is,	   in	   other	   words,	   the	   question	   if	   the	  
specific	  anti-­‐IDH1R132H	  CD4+	  T	  helper	  cell	  response	  after	  vaccination	  is	  capable	  of	  inducing	  
an	  effective	  anti-­‐tumor	   immune	  response,	  a	  syngeneic	   tumor	  mouse	  model	   for	  preventive	  
and	  therapeutic	  vaccination	  studies	  was	  required.	  Since	  vaccination	  studies	  were	  performed	  
with	  MHC-­‐humanized	  mice	   and	   the	   human	  MHC	   context	  was	   to	   be	   retained,	   a	   syngeneic	  
model	   in	  A2.DR1	  mice	  was	  established.	   To	   this	   end,	   sarcomas	  were	   chemically	   induced	   in	  
A2.DR1	  mice,	   excised	   and	   passaged	   through	   immunodeficient	   NOD/SCID	  mice	   to	   increase	  
the	  HLA	  expression	  for	  establishment	  of	  a	  sarcoma	  cell	  line	  suitable	  for	  vaccination	  studies	  (J.	  
Quandt,	  Fig.	  3.14a,b).	  Notably,	  sarcoma	  cells	  upregulated	  the	  surface	  expression	  of	  HLA-­‐A2,	  
but	  not	  HLA-­‐DR1	  after	  passage	   through	  NOD/SCID	  mice	   (Fig.	  3.14c).	  Cells	  were	   retrovirally	  
transduced	  with	  human	  IDH1R132H	  or	  IDH1wt	  as	  control	  for	  stable	  antigen	  expression	  (Fig.	  
3.14a,d)	   to	   generate	   2-­‐HG	   levels	   comparable	   to	   human	   gliomas endogenously	   expressing	  
IDH1R132H,	   which	   lie	   between	   1	   and	   30	   mM	   [69],	   as	   an	   indicator	   for	   clinically	   relevant	  
antigen	  expression	  levels	  (Fig.3.14e).	  These	  levels	  were	  maintained	  in	  clone	  IVC1,	  which	  was	  
generated	   by	   limiting	   dilution	   and	   selected	   for	   homogenous	   IDH1R132H	   expression	   (Fig.	  
3.14d,e).	  Interestingly,	  when	  cells	  (R132H	  line)	  were	  implanted	  s.c.	  into	  the	  flank	  of	  A2.DR1	  
mice,	  IDH1R132H-­‐overexpressing	  tumors	  grew	  slower	  than	  tumors	  lacking	  the	  mutation	  (Fig.	  
3.14f).	   Principally,	   this	   is	   in	   line	   with	   the	   clinical	   situation,	   in	   which	   glioma	   patients	   with	  
IDH1R132H-­‐expressing	   tumors	   show	   a	   longer	   overall	   and	   progression-­‐free	   survival	   than	  




Fig.	   3.14.	   Establishment	   of	   a	   syngeneic	   MHC-­‐humanized	   tumor	   model	   for	   vaccination.	   a,	   3-­‐
methylcholantrene	  (MCA)	  was	  injected	  s.	  c.	  into	  flanks	  of	  A2.DR1	  mice	  and	  spontaneously	  developing	  
tumors	  were	  excised,	  passaged	  once	  through	  NOD/SCID	  mice	  by	  s.	  c.	  injection	  and	  excised	  to	  expand	  
a	  cell	  line.	  Cells	  were	  retrovirally	  transduced	  with	  human	  IDH1R132H	  or	  IDH1wt	  for	  implantation	  into	  
A2.DR1	  mice.	  b,	  H&E	  staining	  of	  MCA-­‐induced	  and	  NOD/SCID-­‐passaged	  established	  A2.DR1	  sarcoma	  
cell	   line.	   A2.DR1	   sarcoma	   cells	   were	   implanted	   into	   A2.DR1	  mice,	   tumors	   were	   excised	   and	   H&E-­‐
stained.	   c,	   HLA-­‐expression	   of	   A2.DR1	   sarcoma	   cell	   line.	   Cells	   were	   stimulated	   with	   different	  
concentrations	   of	   IFN-­‐γ	   for	   48h,	   stained	   for	   HLA-­‐A	   and	   HLA-­‐DR1	   and	   analyzed	   by	   flow	   cytometry.	  
dark	  grey,	  unstained;	   light	  grey,	   isotype	  control;	   red,	  100	  ng/ml	   IFN-­‐γ;	  blue,	  50	  ng/ml	   IFN-­‐γ;	  green,	  
untreated.	   d,	   IDH1R132H-­‐expression	   in	   transduced	   A2.DR1	   sarcoma	   cells.	   Cells	   were	   retrovirally	  
transduced	   with	   IDH1wt	   (wt)	   or	   IDH1R132H	   (RH)	   and	   selected	   for	   stable	   expression.	   IDH1R132H	  
protein	  detection	   in	   IDH1R132H-­‐expressing	   and	   IDH1wt-­‐expressing	   cell	   lines	   and	   IDH1R132H	  clone	  
IVC1	  by	  immunofluorescent	  staining	  (left;	  green,	  IDH1R132H;	  blue,	  nuclei)	  and	  by	  western	  blot	  in	  cell	  
lines	  (right).	  e,	  2-­‐HG	  concentrations	  in	  A2.DR1	  syngeneic	  sarcoma	  cells	  in	  vitro	  and	  IVC1	  tumor	  in	  vivo	  
measured	   by	   enzymatic	   assay.	   Red	   dashed	   lines	  mark	   the	   range	   of	   2-­‐HG	   concentrations	   found	   in	  
patient	  tumors.	   f,	   IDH1R132H-­‐	  (red)	  and	  wt-­‐expressing	  (blue)	  A2.DR1	  sarcoma	  cells	  were	  implanted	  
into	  A2.DR1	  mice	  and	  tumor	  growth	  was	  measured	  (Wilcoxon	  rank-­‐sum	  [WRS]	  test	  for	  median	  area	  
under	  the	  curve	  [AUC];	  n	  =	  5	  mice	  per	  group).	  Error	  bars,	  mean	  ±	  SEM.	  A2.DR1	  sarcoma	  cell	  line	  and	  
data	  in	  b	  provided	  by	  J.	  Quandt.	  Scheme	  in	  a	  by	  J.	  Jung.	  Establishment	  and	  analysis	  of	  clone	  IVC1	  by	  L.	  





3.4.2	  Preventive	  IDH1R132H	  peptide	  vaccination	  reduces	  IDH1R132H,	  but	  not	  IDH1wt	  
tumor	  growth	  
To	  evaluate	  whether	  IDH1R132H	  is	  endogenously	  processed	  and	  presented	  in	  a	  human	  HLA-­‐
DR1	   context,	   which	   is	   a	   prerequisite	   for	   exerting	   antigen-­‐specific	   anti-­‐tumor	   immune	  
responses,	   A2.DR1	  mice	   were	   vaccinated	   by	   injection	   of	   irradiated	   syngeneic	   tumor	   cells	  
overexpressing	   IDH1wt	   or	   IDH1R132H	   (clone	   IVC1)	   as	   a	   whole	   tumor	   cell	   vaccine. 
Vaccination	   with	   IDH1R132H	   but	   not	   IDH1wt	   A2.DR1	   sarcomas	   induced	   a	   robust	   T	   cell	  
response	   to	   IDH1R132H,	   but	   not	   wt	   IDH1	   p123-­‐142	   epitope	   suggesting	   that	   IDH1	   is	  
endogenously	  processed	  to	  present	  the	  R132H-­‐containing	  epitope	  on	  HLA-­‐DR1	  (Fig.	  3.15a).	  
For	  assessment	  of	  a	  functional	  anti-­‐tumor	  immune	  response	  in	  the	  HLA-­‐DR1	  context	  in	  vivo,	  
A2.DR1	  mice	  were	  vaccinated	  with	  IDH1R132H	  (p123-­‐142)	  using	  Montanide®/imiquimod	  as	  
an	  adjuvant	  or	  adjuvant	  only	   (sham)	  and	  subsequently,	   IDH1R132H-­‐	  or	   IDH1wt-­‐transduced	  
sarcoma	  cell	   lines	  were	  s.	  c.	   transplanted	   into	  the	  flank	  (Fig.	  3.15g).	  Peptide	  vaccination	  of	  
A2.DR1	  mice	  with	   IDH1R132H	   (p123-­‐142)	   resulted	   in	   a	   growth	   suppression	   of	   IDH1R132H	  
but	   not	   IDH1wt	   tumors	   (Fig.	   3.15b)	   although	   vaccination	   efficacy	   was	   comparable	   if	   not	  
higher	   in	   mice	   with	   IDH1wt	   tumors	   evidenced	   by	   IDH1R132H-­‐specific	   IFN-­‐γ	   secretion	  
measured	   by	   ELISA	   (Fig	   3.15e)	   and	   ELISpot	   (Fig.	   3.15f).	   Importantly,	   IDH1R132H	   tumors	  
which	   resisted	   IDH1R132H-­‐specific	   peptide	   vaccination,	   displayed	   greatly	   and	   significantly	  
reduced	   IDH1R132H	   expression	   while	   sarcomas	   in	   the	   control	   group	   retained	   their	  
IDH1R132H	  expression	  (Fig.	  3.15c,d).	  The	  loss	  of	  antigen	  expression	  after	  specific	  vaccination	  
indicates	  the	  biological	  activity	  and	  effectiveness	  of	  vaccination	  and	  can	  explain	  the	  limited	  
success	  of	  vaccination	  with	  an	  outgrowth	  of	  mostly	  IDH1R132H-­‐negative	  tumor	  cells,	  which	  
were	  enclosed	  among	  the	  IDH1R132H-­‐transduced	  sarcoma	  cells	  (Fig.	  3.14d,	  upper	  left),	  and	  
display	   a	   growth	   advantage	   over	   IDH1R132H-­‐expressing	   cells	  per	   se	   (Fig.	   3.14f)	   after	   two	  




Fig.	  3.15.	  Preventive	  IDH1R132H	  peptide	  vaccination	  reduces	  IDH1R132H+,	  but	  not	  IDH1wt	  tumors.	  
a,	  IFN-­‐γ	  ELISpot	  of	  splenocytes	  from	  A2.DR1	  mice	  vaccinated	  with	  IDH1R132H	  (red)	  or	  IDH1wt	  (black)	  
sarcoma	  cells	  after	  stimulation	  with	  IDH1	  p123-­‐142	  (R132H,	  RH)	  or	  wt.	  (Welch	  t	  test;	  n	  =	  4	  mice)	  Data	  
are	   depicted	   as	   specific	   spots	   after	   subtraction	   of	   background	   spots	   (MOG,	   negative	   values	   set	   to	  
zero)	  in	  a	  scatter	  plot	  showing	  values	  for	  each	  mouse	  and	  the	  mean.	  b,	  Growth	  of	  IDH1R132H	  and	  wt	  
tumors	  after	  vaccination	  with	  IDH1R132H	  p123-­‐142	  (vacc,	  red)	  or	  vehicle	  (sham,	  black)	  (WRS	  test	  for	  
median	  AUC).	  Error	  bars,	  mean	  ±	  SEM.	   c	  and	  d,	   IDH1R132H	  IHC	  of	   IDH1R132H	  (RH)	  and	  wt	  tumors	  
after	  vaccination	  (vacc,	  red)	  or	  sham	  (black).	  c,	  representative	  images;	  d,	  scatter	  plot	  showing	  values	  
for	   each	   tumor	   and	   the	   mean	   (Welch	   one-­‐way	   ANOVA,	   pairwise	   Welch	   t	   tests	   with	   Bonferroni	  
correction	  after	  log2	  transformation).	  e	  and	  f,	  IDH1R132H	  p123-­‐142	  immune	  responses	  of	  vaccinated	  
(vacc)	  or	  sham-­‐treated	  mice	  by	  ELISA	  (e)	  and	  ELISpot	  (f,	  spot	  counts	  are	  depicted	  after	  subtraction	  of	  
background	  spots	   [MOG])	   (Welch	   t	   test).	   Error	  bars,	  mean	  +	  SEM.	  b	  –	   f;	  n	   =	  8	   IDH1R123H	   tumors,	  
vacc;	  n	  =	  6	  IDH1R132H	  tumors,	  sham;	  n	  =	  5	  IDH1wt	  tumors	  g,	  Schedule	  for	  tumor	  cell	  inoculation	  into	  
vaccinated	  mice.	  dpi,	  days	  post	  inoculation.	  Data	  in	  c	  and	  d	  collected	  and	  analyzed	  by	  L.	  Bunse.	  
RESULTS	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3.4.3	  Therapeutic	  IDH1R132H	  peptide	  vaccination	  reduces	  IDH1R132H	  tumor	  growth	  
	  
Taken	   together,	   the	   hitherto	   obtained	   data	   indicate	   that	   the	   immunogenic	   epitope	   is	  
processed	   and	   presented	   in	   an	   IDH1R132H-­‐positive	   tumor	   and	   that	   a	   peptide	   vaccine	  
targeting	   IDH1R132H	   induces	   a	   mutation-­‐specific	   immune	   response	   restricted	   to	   human	  
MHC,	  which	  is	  able	  to	  trigger	  an	  effective	  anti-­‐tumor	  immune	  response	  in	  a	  syngeneic	  mouse	  
model	  in	  vivo.	  However,	  the	  preventive	  vaccination	  study	  is	  limited	  in	  that	  it	  does	  not	  reflect	  
the	  patient	  situation	  –	  apart	  from	  the	  fact	  that	  a	  sarcoma	  model	  is	  used	  –	  in	  two	  ways.	  First,	  
the	  vaccination	  was	  preventive,	  which	  is	  the	  reason	  why	  a	  therapeutic	  vaccination	  at	  a	  time	  
point	  when	  tumors	  were	  established	  was	  conducted	  (see	  Fig.	  3.16e).	  Second,	  sarcoma	  cells	  
were	  heterogeneous	  in	  terms	  of	  IDH1R132H	  expression,	  leading	  to	  antigen	  loss	  in	  vaccinated	  
tumors	  (Fig.	  3.15c,d).	  Although	  this	  finding	  is	  important	  as	  it	  clearly	  demonstrates	  biological	  
functionality	   of	   the	   vaccine,	   this	   setting	   does	   not	   reflect	   the	   homogenous	   expression	   of	  
IDH1R132H	   within	   the	   tumor	   that	   is	   found	   in	   patients	   with	   IDH1-­‐mutated	   gliomas	   [107].	  
Therefore,	   a	   more	   homogenous	   sarcoma	   cell	   line	   was	   required	   for	   the	   therapeutic	  
vaccination	   study,	   which	   is	   why	   clone	   IVC1	   was	   selected	   for	   in	   vivo	   experiments	   by	  
immunofluorescent	   staining	   according	   to	   homogenous	   IDH1R132H	   expression	   (see	   Fig.	  
3.14d,e	   and	   3.4.1)	   and	   used	   to	   test	   whether	   the	   peptide	   vaccine	   would	   also	   be	   able	   to	  
control	  pre-­‐established	  tumors	  in	  a	  clinically	  relevant	  treatment	  setting.	  
For	   this	   purpose,	   vaccination	  was	   initiated	   6	   days	   after	   the	   inoculation	   of	   an	   IDH1R132H-­‐
positive	   sarcoma	  cell	   clone	   (IVC1)	  after	  measurable	   tumors	  had	   formed	   (Fig.3.16e).	   In	   line	  
with	  the	  preventive	  vaccination	  results,	  therapeutic	  IDH1R132H	  peptide	  vaccination	  of	  mice	  
bearing	  established	  IDH1R132H-­‐positive	  sarcomas	  efficiently	  suppressed	  the	  growth	  of	  these	  
tumors	   (Fig.	   3.16a).	   Vaccination	   went	   along	   with	   high	   vaccination	   efficiencies	   shown	   by	  
systemic	   specific	   T	   cell-­‐mediated	   IFN-­‐γ	   responses	   in	   all	   vaccinated	   mice	   (Fig.3.16b)	   and	  
antibody	  production	  by	  5	  out	  of	  7	  vaccinated	  mice	  (Fig.3.16c).	  
Of	  note,	   the	   IDH1R132H	  peptide	  vaccine	  did	  not	  cause	  any	  overt	   toxicity	  compared	  to	   the	  
sham-­‐treated	  animals	  as	  evidenced	  by	  histopathological	  organ	  analysis	  (Table	  3.1),	  nor	  did	  it	  
impair	   IDH1wt	   enzymatic	   function,	   verified	   by	   biochemical	   assay	   for	   enzymatic	   activity	   in	  




Fig.	   3.16.	   Therapeutic	   IDH1R132H	   peptide	   vaccination	   suppresses	   IDH1R132H+	   tumor	   growth.	   a,	  
Growth	   of	   subcutaneous	   tumor	   clone	   IVC1	   in	   A2.DR1	  mice	   immunized	   on	   day	   6	   with	   IDH1R132H	  
p123-­‐142	   (vacc,	   red)	   or	   vehicle	   (sham,	   black)	   using	  Montanide®/imiquimod	   (WRS	   test	   for	  median	  
AUC,	   n	   =	   7	   for	   each	   group.	   Error	   bars,	   mean	   ±	   SEM.	   b	   and	   c,	   Systemic	   immune	   responses	   in	  
therapeutically	   vaccinated	   A2.DR1	   mice.	   Splenocytes	   (spleen)	   and	   lymph	   node	   cells	   (LN)	   were	  
analyzed	  for	  IFN-­‐γ	  production	  after	  ex	  vivo	  stimulation	  with	  p123-­‐142	  (R132H	  [RH]	  and	  wt)	  by	  ELISpot	  
(b,	   spot	   counts	   are	   depicted	   after	   subtraction	   of	   MOG	   negative	   control-­‐induced	   spots)	   and	  
IDH1R132H-­‐specific	  serum	  IgG	  were	  detected	  by	  ELISA	  (c,	  OD	  values	  are	  depicted	  relative	  to	  negative	  
control	   [MOG])	   (Welch	   t	   test;	  n	  =	  7	  vacc	  mice,	  n	  =	  6	  sham	  mice).	  d,	   IDH1/2	  enzymatic	  activity	  was	  
measured	   in	   liver	   and	   brain	   homogenates	   of	   A2.DR1	  mice	   vaccinated	  with	   IDH1R132H	   (p123-­‐142)	  
(vacc,	  red)	  or	  sham-­‐treated	  (sham,	  black)	  using	  Montanide®/imiquimod	  (Welch	  t	  test;	  n	  =	  6,	  vacc;	  n	  =	  
5,	  sham).	  b	  –	  d,	  scatter	  plots	  showing	  values	  for	  each	  mouse	  and	  the	  mean.	  e,	  Schedule	  for	  tumor	  cell	  
inoculation	  and	  vaccination.	  
	  
Aiming	   at	   benchmarking	   the	  quality	   of	   the	   IDH1R132H	  neoantigen	   in	   order	   to	   classify	   the	  
relevance	   of	   vaccination	   efficacy,	   A2.DR1	   sarcomas	   were	   transduced	   with	   the	   well-­‐
established	  and	  clinically	   relevant	   tumor-­‐associated	  antigen	  human	  NY-­‐ESO-­‐1	   [37,	  43,	  161]	  
(see	  1.1),	  which	  contains	  a	  41	  %	  sequence	  homology	  to	  mouse	  CTAG2,	  which	  has	  the	  highest	  
similarity	  with	  the	  epitope	  used	  for	  therapeutic	  vaccination	  (59	  %	  for	  the	  DR1	  epitope)	  (Fig.	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3.17a,b).	  NY-­‐ESO-­‐1	  is	  an	  antigen	  that	  not	  only	  elicits	  CTL	  responses,	  but	  also	  CD4+	  T	  helper	  
cell	   activity	   [40,	   41].	   Six	  days	   after	   implantation	  of	  NY-­‐ESO-­‐1+	   sarcomas,	   after	  measurable
	  
ID treatment heart lung liver kidney stomach intestine brain 
384 sham - - minimal multifocal single-cell necrosis n.d. - - - 
386 sham - - - n.d. - - - 
394 vacc - - - - - - - 
395 vacc - - minimal extramedullary hematopoiesis - - - - 
399 vacc - - - - - - - 
400 vacc - - - - - - - 
413 sham - - - - - - - 
419 sham - - - - - - - 
421 sham - - - - - - - 
431 vacc - - - n.d. - - - 
432 vacc - - minimal extramedullary hematopoiesis - - - - 
434 vacc - - - - - - - 
435 vacc - - - - - - - 
Table	   3.1.	   Pathological	   analysis	   of	   organs	   from	   IDH1R132H	   (p123-­‐142)	   vaccinated	   and	   sham-­‐
treated	  A2.DR1	  mice.	  n.d.,	  not	  determined.	  
	  
tumors	  had	   formed,	  A2.DR1	  mice	  were	   vaccinated	  with	   the	  NY-­‐ESO-­‐1	  peptide	   (p119-­‐143),	  
which	   represents	   an	   HLA-­‐DR1-­‐restricted	   immunodominant	   epitope	   [162],	   with	  
Montanide®/imiquimod	   as	   an	   adjuvant	   or	   adjuvant	   only	   (sham).	   The	   vaccine	   efficiently	  
induced	   an	   NY-­‐ESO-­‐1-­‐specific	   T	   helper	   cell	   response	   in	   A2.DR1	   mice	   (Fig.	   3.17d,e)	   and	  
resulted	   in	   the	   control	  of	  NY-­‐ESO-­‐1+	   sarcomas	   (Fig.	   3.17c).	   Thus,	   the	   therapeutic	  effect	  of	  
the	   IDH1R132H	  peptide	   vaccine	   compared	  well	  with	   another	  HLA-­‐DR1-­‐restricted,	   clinically	  
relevant	  peptide	  vaccine	  (growth	  suppression	  by	  58.8	  %	  for	  p123-­‐142	  [R132H]	  vs.	  65.4	  %	  for	  
p119-­‐143	   [NY-­‐ESO-­‐1])	   (Fig.	   3.16a	   and	   3.17c).	   This	   underlines	   both	   the	   suitability	   of	   the	  
A2.DR1	   syngeneic	   tumor	   model	   for	   MHC	   class	   II	   and	   CD4+	   T	   cell-­‐mediated	   therapeutic	  
vaccination	  and	  the	  relevance	  of	  IDH1R132H	  as	  an	  immunogenic	  neoantigen.	  
Collectively,	   these	   data	   suggest	   that	   a	   peptide	   vaccine	   targeting	   IDH1R132H	   induces	   a	  
mutation-­‐specific	   immune	  response	   restricted	   to	  human	  MHC	  class	   II	   capable	  of	   triggering	  
an	  effective	  anti-­‐tumor	   immune	   response	   in	   vivo	   in	   a	   therapeutic	   setting	   comparable	   to	  a	  





Fig.	  3.17.	  NY-­‐ESO-­‐1	  is	  a	  suitable	  antigen	  for	  HLA-­‐DR1-­‐dependent,	  CD4+	  T	  cell-­‐mediated	  therapeutic	  
peptide	   vaccination	   in	   A2.DR1	   mice.	   a,	   Protein	   alignment	   of	   hNY-­‐ESO-­‐1	   with	   mCTAG2.	   HLA-­‐DR1	  
epitope	   NY-­‐ESO-­‐1	   p119-­‐143	   (red	   box)	   was	   blasted	   against	   murine	   proteome	   for	   maximal	   score,	  
CTAG2	  was	  identified,	  proteins	  were	  aligned.	  Sbjct,	  subject.	  b,	  NY-­‐ESO-­‐1	  protein	  detection	  by	  IF	  and	  
western	  blot	  in	  NY-­‐ESO-­‐1	  (NY)	  and	  wt	  sarcoma	  cells.	  c,	  Growth	  of	  NY-­‐ESO-­‐1	  tumors	  after	  vaccination	  
with	  NY-­‐ESO-­‐1	  p119-­‐143	  (vacc,	  red)	  or	  sham	  (black)	  (WRS	  test	  for	  median	  AUC).	  Error	  bars,	  mean	  ±	  
SEM.	  d	  and	  e,	  Splenocytes	  (spleen,	  d	  and	  e)	  and	  LN	  cells	  (d)	  from	  NY-­‐ESO-­‐1	  (p119-­‐143)-­‐vacc	  or	  sham	  
mice	  were	  ex	  vivo	  stimulated	  with	  NY-­‐ESO-­‐1	  (p119-­‐143)	  and	  MOG	  and	  subjected	  to	  IFN-­‐γ	  ELISpot	  (d,	  
spot	  counts	  depicted	  after	  subtraction	  of	  MOG-­‐induced	  spots	  in	  scatter	  plot	  showing	  values	  for	  each	  
mouse	  and	  the	  mean)	  (WRS	  test)	  and	  flow	  cytometry	  gated	  on	  CD4+	  T	  cells	  (upper	  panel)	  or	  CD8+	  T	  
cells	  (lower	  panel)	  (e).	  Representative	  plots	  are	  shown.	  Red	  numbers,	  populations	  in	  percent.	  n	  =	  7.	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3.4.4	  IDH1R132H	  peptide	  vaccination-­‐induced	  tumor	  growth	  suppression	  depends	  on	  
IDH1R132H-­‐specific	  CD4+	  T	  cells	  and	  B	  cells	  
Although	   there	   is	   increasing	   evidence	   that	   antigen-­‐specific	   cytotoxic	   CD4+	   T	   cells	   are	   in	  
principle	  capable	  and	  sufficient	  to	  exert	  antitumor	  immunity	  [151],	  the	  relevance	  of	  a	  CD4+	  T	  
cell-­‐mediated	  antitumor	  immune	  response	  in	  the	  absence	  of	  an	  MHC	  class	  I-­‐restricted	  CD8+	  
T	   cell	   response	   is	   still	   controversial.	   Consequently,	   the	   functional	   contribution	   of	  
IDH1R132H-­‐specific	   CD4+	   T	   cells	   to	   control	   tumor	   growth	   was	   delineated.	   Analyses	   of	  
splenocytic	  T	  cells	  recovered	  from	  IFN-­‐γ	  secretion	  assays	  after	  immunization	  of	  A2.DR1	  mice	  
with	   IDH1R132H	   (p123-­‐142)	   and	  Montanide®/imiquimod	   confirmed	   that	   antigen-­‐specific	   T	  
cells,	  responding	  to	   IDH1R132H	  (p123-­‐142)	  with	  high	   IFN-­‐γ	  production,	  were	  CD4+	  but	  not	  
CD8+	  T	  cells	  (Fig.	  3.18a).	  This	  finding	  was	  verified	  by	  the	  separation	  of	  CD4+	  and	  CD8+	  T	  cells	  
from	   spleens	   of	   IDH1R132H	   (p123-­‐142)-­‐vaccinated	   A2.DR1	   mice	   and	   stimulation	   with	  
IDH1R132H	   (p123-­‐142)-­‐loaded	   autologous	   dendritic	   cells.	   CD4+,	   but	   not	   CD8+	   T	   cells	  
produced	  IFN-­‐γ	  specifically	  in	  response	  to	  IDH1R132H	  (p123-­‐142)	  (Fig.	  3.18b).	  	  
Tumors	   from	   vaccinated	   mice	   were	   highly	   infiltrated	   by	   pan	   T	   cells	   compared	   to	   sham-­‐
treated	  mice	  (Fig.	  3.18	  c,d).	  In	  order	  to	  assess	  if	  these	  T	  cells	  included	  T	  helper	  cells	  specific	  
for	   IDH1R132H,	   IDH1R132H	   (p123-­‐142)	   HLA-­‐DR1	   tetramers	   were	   used	   to	   stain	   tumor-­‐
infiltrating	   lymphocytes	   (TILs),	   which	   allowed	   confirmation	   that	   IDH1R132H-­‐expressing	  
A2.DR1	  sarcomas	  were	  indeed	  infiltrated	  by	  IDH1R132H	  HLA-­‐DR1	  tetramer-­‐positive	  T	  helper	  
cells	  only	  after	  vaccination	  with	  IDH1R132H	  (p123-­‐142)	  (Fig.	  3.18e).	  
This	  result	  proved	  the	  induction	  of	  –	  and	  infiltration	  of	  tumors	  with	  –	  IDH1R132H-­‐specific	  T	  
helper	  cells	  after	  vaccination,	  but	  not	   the	   requirement	   for	   this	  T	  cell	  population	   for	   tumor	  
growth	  suppression	  in	  the	  therapeutic	  vaccination.	  
To	   address	   this	   question,	   CD4+	   T	   cells	   and	  B	   cells	  were	  depleted	   from	  A2.DR1	  mice	  using	  
antibodies	   and	   therapeutic	   vaccination	   of	   pre-­‐established	   syngeneic	   IDH1R132H-­‐positive	  
A2.DR1	   sarcomas	   was	   performed	   (Fig.	   3.19f).	   Depletion	   of	   CD4+	   T	   cells	   abrogated	   the	  
therapeutic	  effects	  of	  the	  IDH1R132H	  (p123-­‐142)	  Montanide®/imiquimod	  vaccine,	  signifying	  
that	   the	   therapeutic	  efficacy	   is	  dependent	  on	  CD4+	  T	  cells	   (Fig.	  3.19a,b).	   Interestingly,	   the	  
vaccine-­‐mediated	   control	   of	   tumor	   growth	   was	   also	   abrogated	   when	   CD19+	   B	   cells	   were	  
depleted	  (Fig.	  3.19c,d),	  although	  T	  cell	  responses	  were	  strongly	  induced	  by	  vaccination	  (Fig.	  






Fig.	   3.18.	   Therapeutic	   IDH1R132H	   peptide	   vaccination	   induces	   specific	   T	   helper	   cells,	   but	   not	  
cytotoxic	  T	  cells,	  which	  are	  recruited	  into	  the	  tumor.	  a,	  IFN-­‐γ	  secretion	  assay	  followed	  by	  CD3,	  CD4,	  
and	   CD8	   surface	   staining	   and	   flow	   cytometry	   (DMSO,	   negative	   control;	   SEB,	   positive	   control;	  
IDH1R132H,	  p123-­‐142)	  of	  ex	  vivo	  stimulated	  splenocytes	  from	  5	  A2.DR1	  mice	  immunized	  with	  p123-­‐
142	   (R132H)	   (vacc,	   lower	   panel)	   or	   sham-­‐treated	   (sham,	   upper	   panel).	   b,	   ELISpot	   analysis	   of	  
mutation-­‐specific	   IFN-­‐γ	   response	   to	   IDH1	   p123-­‐142	   of	   isolated	   CD4+	   or	   CD8+	   T	   cells	   from	  A2.DR1	  
mice	  vaccinated	  with	   IDH1R132H	  p123-­‐142	  using	  Montanide®/imiquimod	  or	  established	  T	  cell	   line,	  
stimulated	  by	  autologous	  dendritic	  cells	   loaded	  with	  IDH1	  p123-­‐142	  (R132H,	  red;	  wt,	  blue)	  or	  MOG	  
(white),	  or	  with	  PMA	  and	   ionomycin	  (black)	  (Welch	  t	  test;	  n	  =	  3).	  Error	  bars,	  mean	  +	  SEM.	  c	  and	  d,	  
Immunohistochemistry	   for	   CD3	   expression	   in	   tumors	   expressing	   IDH1R132H	   after	   therapeutic	  
vaccination	   with	   IDH1R132H	   p123-­‐142	   (vacc,	   red)	   or	   sham	   treatment	   (sham,	   black)	   shown	   as	  
representative	   images	   (c)	   and	   scatter	   plot	   showing	   individual	   values	   of	   CD3	   expression	   for	   each	  
tumor	  and	  the	  mean	  (d,	  Welch	  one-­‐way	  ANOVA	  and	  pairwise	  Welch	  t	  tests;	  n	  =	  5	  per	  group).	  e,	  Flow	  
cytometric	   analysis	   of	   IDH1R132H-­‐specific	   CD4+	   T	   cells	   in	   IDH1R132H+	   tumors	   (tumor-­‐infiltrating	  
lymphocytes,	   TIL)	   after	   vaccination	  with	   IDH1R132H	  p123-­‐142	   (vacc)	   or	   sham	   treatment	   (sham)	   in	  
comparison	  to	  IDH1R132H-­‐specific	  T	  cell	  line	  stained	  with	  IDH1R132H	  (p123-­‐142)-­‐	  and	  control	  (CLIP)-­‐






Fig.	  3.19.	  IDH1R132H+	  tumor	  growth	  suppression	  by	  therapeutic	  IDH1R132H	  peptide	  vaccination	  is	  
dependent	  on	  T	  helper	  and	  B	  cells.	  a	  and	  c,	  Growth	  of	  IDH1R132H+	  tumors	  in	  A2.DR1	  mice	  depleted	  
of	  CD4+	  T	  cells	  (a)	  or	  CD19+	  B	  cells	  (c)	  (blue)	  and	  vaccinated	  with	  IDH1R132H	  p123-­‐142	  in	  comparison	  
to	   non-­‐depleted,	   vaccinated	   (red)	   and	   sham-­‐treated	   (black)	  mice	   (WRS	   test	   for	  median	   AUC	   with	  
Bonferroni	  correction;	  n	  =	  6	  per	  group;	  n	  =	  7,	  vacc	  without	  depletion).	  Error	  bars,	  mean	  ±	  SEM.	  b	  and	  
d,	  CD4	  /	  CD8	  staining	  gated	  on	  CD3+	  T	  cells	  (b)	  and	  CD3	  /	  CD19	  staining	  (d)	  of	  blood	  lymphocytes	  (b;	  
GK1.5,	  anti-­‐CD4;	  LTF-­‐2,	  isotype	  control;	  d;	  1D3,	  anti-­‐CD19;	  2A3,	  isotype	  control)	  from	  mice	  in	  a	  and	  c.	  
Samples	  were	  taken	  from	  two	  mice	  per	  group	  on	  day	  7	  and	  day	  17.	  Representative	  plots	  are	  shown	  
for	   day	   17.	   Red	  numbers,	   populations	   in	   percent.	  e,	   IFN-­‐	   γ	   ELISpot	   of	   splenocytes	   (spleen)	   and	   LN	  
cells	   from	  mice	  depleted	  of	  B	  cells	  and	  vacc	   (blue),	   control-­‐treated	  and	  vacc	   (red)	  or	   sham-­‐treated	  
(black),	  after	  ex	  vivo	  stimulation	  with	  IDH1	  p123-­‐142	  (R132H	  [RH]	  and	  wt).	  Spot	  counts	  are	  depicted	  
after	   subtraction	   of	   background	   spots	   (MOG)	   (Welch	   one-­‐way	   ANOVA	   and	   pairwise	  Welch	   t	   tests	  
with	   Bonferroni	   correction;	  n	   =	   6).	   Scatter	   plots	   showing	   values	   for	   each	  mouse	   and	   the	  mean.	   f,	  
Schedule	  for	  tumor	  cell	  inoculation,	  lymphocyte	  depletion,	  and	  vaccination.	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The	  inhibition	  of	  IDH1R132H-­‐expressing	  tumor	  growth	  in	  MHC-­‐humanized	  mice	  by	  antigen-­‐
specific	   peptide	   vaccination	   demonstrates	   the	   functional	   relevance	   and	   therapeutic	  
efficiency	  of	   active	   immunotherapy	   targeting	   IDH1R132H	  as	  a	  novel	   antigen.	   The	   systemic	  
cellular	  and	  humoral	  IDH1R132H-­‐specific	  responses	  that	  are	  induced	  by	  vaccination	  are	  not	  
only	  accompanied	  by	  an	   increased	  overall	  T	  cell	   infiltration,	  but	  also	  by	  the	  recruitment	  of	  
IDH1R132H-­‐specific	  T	  helper	  cells	   into	   the	   tumor.	  This	  observation	  and	  the	   loss	  of	  efficacy	  
after	  depletion	  of	  CD4+	  T	  cells	   suggests	   that	  antigen-­‐specific	  T	  helper	  cells	  are	   responsible	  
for	   combatting	   the	   tumor	   leading	   to	   growth	   reduction.	   However,	   the	   roles	   of	   cytotoxic	   T	  
cells	  that	  might	  be	   locally	  but	  unspecifically	  activated	  by	  bystander	  effect	  after	  vaccination	  
and	  of	  antibody	  responses	  –	  and	  other	  B	  cell	  functions	  –	  require	  further	  clarification.	  
	  
To	   recapitulate	   the	   previous	   results	   obtained	   by	   peptide	   vaccination	   of	   MHC-­‐humanized	  
mice	  and	  patient	  screening,	   IDH1R132H	  represents	  a	  tumor-­‐specific	  neoantigen	  recognized	  
by	   CD4+	   IFN-­‐γ-­‐producing	   T	   cells	   in	   patients	   with	   IDH1R132H-­‐positive	   tumors	   and	   in	  
vaccinated	  mice.	  An	  IDH1R132H	  vaccine	  induces	  both	  specific	  cellular	  and	  humoral	  immune	  
responses	   that	   in	   addition	   are	   effective	   against	   IDH1R132H-­‐mutated	   tumors	   in	   an	   MHC-­‐
humanized	  animal	  model.	  These	  data	  underline	  that	  mutant	  IDH1	  may	  serve	  as	  a	  therapeutic	  
target	  not	  only	  through	  drug-­‐mediated	  inhibition	  of	  the	  neomorphic	  enzymatic	  function	  [108,	  
109]	  but	  also	  through	  T	  cell-­‐based	  targeting	  of	  the	  mutant	  epitope.	  
	  
3.5	  The	  IDH1R132H-­‐derived	  cancer	  metabolite	  2-­‐hydroxyglutarate	  does	  not	  
influence	  T	  cells	  
	  
IDH1	   and	   IDH2	   point	   mutations	   that	   have	   been	   described	   mainly	   in	   gliomas	   and	   acute	  
myeloid	   leukemia	   (AML)	   uniformly	   occur	   in	   the	   catalytic	   pocket,	   impairing	   enzymatic	  
function	  and	  leading	  to	  a	  neomorphic	  enzymatic	  function	  in	  terms	  of	  the	  conversion	  of	  the	  
natural	  product	  α-­‐ketoglutarate	  (α-­‐KG)	  to	  the	  oncometabolite	  R-­‐2-­‐hydroxyglutarate	  (2-­‐HG).	  
The	   molecular	   consequences	   of	   this	   metabolic	   shift	   have	   been	   extensively	   studied.	   The	  
accumulation	  of	  2-­‐HG	  has	  been	  shown	  to	  be	   sufficient	   to	  alter	   the	  epigenome	  of	  glial	  and	  
hematopoietic	   cells	   [95,	   96]	   resulting	   in	   a	   hypermethylation	   phenotype	   [97,	   98],	   genetic	  
instability,	   the	   subsequent	   acquisition	   of	   additional	   mutations	   and	   ultimately	   malignant	  
transformation	  [100].	  However,	  these	  analyses	  have	  mostly	  focused	  on	  autocrine	  effects	  on	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tumor	  and	  tumor-­‐initiating	  cells.	  One	  study	  on	  differentiation	  analyzed	  2-­‐HG	  effects	  with	  a	  
model	  of	  adipocyte	  differentiation	  [95].	  Until	  now,	  no	  evidence	  has	  been	  published	  on	  the	  
paracrine	  effects	  of	  the	  accumulation	  of	  2-­‐HG	  in	  the	  tumor	  stroma	  on	  cells	  of	  the	  innate	  and	  
adaptive	  immune	  system.	  Although	  AML	  studies	  on	  the	  effects	  of	  the	  IDH2	  mutation	  R172K	  
revealed	   changes	   in	   cells	   of	   the	   haematopoietic	   system,	   these	   studies	   focus	   on	   the	  
respective	  tumor	  entity	  [96].	  	  
Nevertheless,	   the	   effects	   of	   the	   IDH	   mutation	   and	   2-­‐HG	   accumulation	   described	   for	  
haematopoietic	   cells	   led	   to	   the	   assumption	   that	   2-­‐HG	   produced	   by	   IDH1R132H-­‐positive	  
glioma	   cells	   might	   have	   consequences	   for	   functionality	   or	   phenotype	   of	   infiltrating	   or	  
peripheral	  T	  cells.	  This	  potential	   influence	  can	  be	  of	  particular	   importance	  when	  aiming	  at	  
the	   application	   of	   an	   IDH1R132H-­‐targeted	   vaccination	   for	   stimulation	   of	   directed	   T	   cell	  
function.	  
	  
3.5.1	  Peripheral	  T	  cell	  proliferation	  is	  not	  altered	  by	  exogenous	  2-­‐hydroxyglutarate	  
First,	  2-­‐HG	  effects	  on	  human	  T	  cell	  proliferation	  were	  analyzed	  by	  mixed	  leukocyte	  reactions	  
(MLRs),	  which	  reflect	  mainly	  CD8+	  T	  cell	  proliferation.	  To	  this	  end,	  MLRs	  were	  performed	  on	  
top	  of	  IDH1wt	  or	  2-­‐HG-­‐producing,	  R132H-­‐overexpressing	  human	  glioma	  cells	  (Fig.	  3.20a,d)	  or	  
in	  supernatant	  of	  these	  cells	  (Fig	  3.20b),	  but	  T	  cell	  proliferation	  was	  not	  affected.	  To	  exclude	  
other	  factors	  potentially	  overriding	  the	  2-­‐HG	  effects,	  MLRs	  were	  exogenously	  treated	  with	  2-­‐
HG,	  but	  one-­‐week	  treatment	  did	  not	  affect	  proliferation	  in	  this	  setting	  either	  (Fig.	  3.20c).	  
	  
3.5.2	  Peripheral	  T	  cell	  activation	  is	  not	  altered	  by	  exogenously	  administered	  2-­‐
hydroxyglutarate	  
To	  gain	  deeper	  insights	  into	  2-­‐HG	  effects	  on	  T	  cell	  functionality,	  isolated	  human	  CD8+	  T	  cells	  
were	   treated	  with	  2-­‐HG.	  Several	   surface	  T	   cell	   activation	  markers	   serve	  as	   indicators	   for	  T	  
cell	   functionality,	   since	   they	   are	   differentially	   expressed	   after	   stimulation.	   Regulation	   of	  
these	  activation	  markers	  by	  CD8+	  T	  cells	  after	  TCR-­‐mediated	  stimulation	  was	  not	  affected	  by	  
treatment	   of	   T	   cells	  with	   2-­‐HG	   (Fig.	   3.21a),	   indicating	   that	   2-­‐HG	   does	   not	   influence	   T	   cell	  
activation.	  Extending	  these	  findings	  to	  IDH1R132H-­‐responsive	  T	  cells,	  CD4+	  T	  cell	  activation	  
as	   defined	  by	   stimulation-­‐mediated	   regulation	  of	   surface	   expression	  of	   activation	  markers	  




Fig.	   3.20.	   Exogenous	   2-­‐hydroxyglutarate	   does	   not	   affect	   T	   cell	   proliferation	   in	   an	  MLR.	   a,	  Mixed	  
leukocyte	  reactions	  were	  performed	  with	  PBMCs	  from	  two	  unrelated	  donors	  on	  LN229	  glioma	  cells	  
overexpressing	  IDH1.	  black,	  empty	  vector	  control;	  blue,	  IDH1wt;	  red,	  IDH1R13H,	  clone	  H3,	  and	  clone	  
H114.	   b,	   Mixed	   leukocyte	   reactions	   were	   performed	   with	   PBMCs	   from	   two	   unrelated	   donors	   in	  
supernatant	  of	  LN229	  glioma	  cells	  overexpressing	  IDH1.	  White,	  medium;	  black,	  empty	  vector	  control;	  
blue,	   IDH1wt;	   red,	   IDH1R13H,	   clone	   H3,	   and	   clone	   H114.	   c,	   Mixed	   leukocyte	   reactions	   were	  
performed	   with	   PBMCs	   from	   two	   unrelated	   donors.	   Cells	   were	   stimulated	   with	   indicated	  
concentrations	  of	  2-­‐HG.	  Proliferation	  was	  measured	  after	  7	  days	  by	   3H-­‐thymidine	   incorporation.	  d,	  
Western	   Blot	   of	   LN229	   transfected	   with	   IDH1.	   LN229	   clone	   H3	   expresses	   half	   the	   amount	   of	  
endogenous	  IDH1	  protein,	  clone	  H114	  expresses	  the	  same	  protein	  amount.	  	  
	  
For	  an	  effective	   tumor	   immunotherapy	  by	  vaccination,	   the	  phenotype	  of	   the	  responding	  T	  
cells	   is	  of	  particular	   importance,	   especially	   in	   the	   case	  of	   T	  helper	   cell	   responses,	  because	  
CD4+	  T	  helper	  cells	  are	  the	  most	  diverse	  and	  plastic	  cells	  in	  the	  haematopoietic	  system.	  For	  
this	  reason,	  the	  phenotype	  of	  activated	  T	  cells	  must	  be	  taken	  into	  account	  when	  studying	  2-­‐
HG	  effects	  on	  this	  cell	  population.	  Thus,	   in	  addition	  to	  surface	  activation	  markers,	  cytokine	  
profiles	  as	  indicator	  for	  T	  cell	  phenotypes	  were	  analyzed	  to	  rule	  out	  that	  these	  are	  altered	  by	  
2-­‐HG.	   Indeed,	  no	  2-­‐HG-­‐mediated	  effect	  was	  detectable	  after	  10-­‐day	   treatment	  of	  CD8+	  or	  
CD4+	   T	   cells.	   Activated	   T	   cells	   showed	   identical	   IFN-­‐γ,	   IL-­‐4,	   and	   IL17	   production.	   Hence,	  
neither	   the	   frequency	   of	   cytotoxic	   T	   cells	   (CTL)	   (Fig.	   3.22a),	   nor	   Th1	   (Fig.	   3.22b),	   Th2,	   nor	  
Th17	  (Fig.	  3.22c)	  was	  altered	  by	  2-­‐HG	  treatment.	  Moreover,	  no	  change	  in	  the	  frequency	  of	  




Fig.	   3.21.	   Peripheral	   T	   cell	   activation	   is	   not	   altered	   by	   exogenously	   administered	   2-­‐
hydroxyglutarate.	  a	  and	  b,	  Activation	  of	  CD8+	  (a),	  or	  CD4+	  (b)	  human	  T	  cells	  after	  6	  day-­‐treatment	  
with	  2-­‐HG	  and	  TCR-­‐mediated	  stimulation	  with	  anti-­‐CD3	  and	  anti-­‐CD28	  antibodies	  and	  recombinant	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Fig.	   3.22.	   Peripheral	   T	   cell	   phenotypes	   are	   not	   altered	   by	   exogenously	   administered	   2-­‐
hydroxyglutarate.	   a,	  Human	   cytotoxic	   T	   cells	   (CTL)	   were	   analyzed	   by	   flow	   cytometry	   after	   6	   day-­‐
treatment	   of	   CD8+	   T	   cells	   with	   2-­‐HG	   and	   TCR-­‐mediated	   stimulation	   with	   anti-­‐CD3	   and	   anti-­‐CD28	  
antibodies	  and	  recombinant	  IL-­‐2	  and	  TCR-­‐independent	  stimulation	  with	  PMA	  and	  ionomycin.	  b	  and	  c,	  
Cytokine	  analysis	  by	  flow	  cytometry	  of	  human	  CD4+	  T	  cells	  after	  6	  day-­‐treatment	  with	  2-­‐HG	  and	  TCR-­‐
mediated	   stimulation	   with	   anti-­‐CD3	   and	   anti-­‐CD28	   antibodies	   and	   recombinant	   IL-­‐2	   and	   TCR-­‐
independent	   stimulation	   with	   PMA	   and	   ionomycin.	   Th1	   (b),	   Th2	   and	   Th17	   (c)	   phenotypes	   were	  




Fig.	   3.22.	   Peripheral	   T	   cell	   phenotypes	   are	   not	   altered	   by	   exogenously	   administered	   2-­‐
hydroxyglutarate.	  See	  page	  68	  for	  details.	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Taken	   together,	   exogenously	   administered	   2-­‐HG	   does	   not	   seem	   to	   influence	   human	  
peripheral	  T	  cell	  proliferation,	  activation,	  nor	  phenotype	  of	  activated	  T	  cells	  in	  this	  system.	  In	  
this	  context,	   it	   is	  noteworthy	  that	  the	  metabolite	  2-­‐HG	   is	  not	  tumor	  cell	  permeable,	  which	  
might	  be	  the	  reason	  why	  T	  cells	  in	  the	  periphery	  or	  within	  the	  tumor	  microenvironment	  are	  




4.1	  Targeting	  IDH1R132H	  as	  a	  novel	  immunotherapeutic	  approach	  for	  glioma	  
	  
Despite	  50	  years	  of	  extensive	  research	  in	  the	  field	  of	  neurooncology	  and	  glioma	  therapy	  to	  
improve	   standard	   of	   care	   and	   to	   prolong	   survival	   also	   for	   patients	   with	   low-­‐grade	   and	  
anaplastic	  gliomas,	  overall	   survival	   in	   these	  patients	   is	   still	   limited	  with	  a	   five-­‐year	  survival	  
rate	  of	  45	  to	  60	  %	  for	  grade	  II	  gliomas	  and	  only	  25	  %	  for	  anaplastic	  astrocytoma	  (grade	  III)	  
[55,	  60].	  
The	  standard	  of	   care	   for	   low-­‐grade	  and	  anaplastic	  gliomas	   is	  defined	  as	  maximal	   tolerable	  
resection	  followed	  by	  postoperative	  radiotherapy	  or	  alkylating	  chemotherapy	  [66,	  104].	  As	  
opposed	  to	  glioblastoma,	   the	  beneficial	  effect	  of	  concomitant	  chemotherapy	  has	  not	  been	  
demonstrated	   in	   controlled	   clinical	   trials.	   Only	   in	   anaplastic	   oligodendroglioma	   with	   a	  
combined	   deletion	   of	   chromosomes	   1p/19q,	   the	   combined	   therapy	   with	   procarbazine,	  
lomustine,	   and	   vincristine	   (PCV)	   in	   addition	   to	   radiotherapy	   improves	   overall	   survival	  
compared	   to	   radiotherapy	   alone	   [163,	   164].	   A	   major	   characteristic	   of	   low-­‐grade	   and	  
anaplastic	   gliomas	   is	   inevitable	   recurrence,	   and	   there	   is	   currently	   no	   standard	   treatment	  
during	   remission	  or	  at	   recurrence.	  Participation	   in	  clinical	   trials	  using	  anti-­‐angiogenic,	  anti-­‐
invasive,	   differentiating	   or	   immune-­‐modulatory	   compounds	   are	   the	   best	   option	   for	   these	  
patients	  [66].	  
Conceptually,	  patients	  with	  low-­‐grade	  and	  anaplastic	  gliomas	  represent	  a	  patient	  population,	  
which	  may	  particularly	  benefit	  from	  a	  tumor	  vaccine,	  as	  these	  tumors	  may	  remain	  stable	  or	  
minimally	  growing	   for	   several	   years	  but	  will	   inevitably	   recur,	   often	  with	  a	  more	  malignant	  
phenotype,	   and	   as	   there	   is	   currently	   no	   maintenance	   therapy	   available	   preventing	  
recurrence	  in	  this	  relatively	  young	  and	  immunologically	  competent	  patient	  population	  [165].	  
As	  these	  tumors	  have	  a	  high	  prevalence	  of	  the	  IDH1R132H	  mutation,	  IDH1R132H	  represents	  
an	  ideal	  target	  for	  active	  immunotherapy.	  
Active	   immunotherapy	   trials	   using	   autologous	   tumor	   lysates	   [137]	   and	   also	   targeting	  
mutated	  antigens	  such	  as	  EGRRvIII	   [35]	  for	  glioma	  patients	  have	  been	  conducted.	  Mutated	  
antigens	  are	  attractive	  and	  clinically	  relevant	  targets	  in	  gliomas	  and	  other	  types	  of	  tumors	  in
general,	  because	  they	  have	  the	  advantage	  of	  being	  highly	  specific	  for	  the	  target	  cells	  as	  they
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do	  not	  occur	  in	  healthy	  cells	  and	  hence,	  minimize	  autoimmunity.	  In	  fact,	  IDH1R132H-­‐positive
cells	   are	   used	   histopathologically	   to	   define	   tumor	   cells	   and	   identify	   distant	   brain	  
manifestations	  of	  macroscopically	   circumscript	   tumors	   [107].	   Specificity	  of	   a	   vaccination	   is	  
not	   guaranteed	   by	   the	   exclusive	   expression	   of	   the	   target	   antigen	   alone,	   but	   requires	  
specificity	  of	  reactive	  T	  cells.	  This	  is	  particularly	  important	  when	  targeting	  mutation	  antigens,	  
because	  T	  cells	  must	  not	  react	  against	  the	  wt	  protein.	  In	  the	  case	  of	  EGFRvIII,	  T	  cell	  specificity,	  
which	   is	   the	   specific	   binding	   of	   the	   TCR	   to	   a	   given	   epitope	  presented	  on	  MHC	  molecules,	  
arises	   from	   the	  generation	  of	   a	   completely	  novel	  epitope.	  An	   in-­‐frame	  deletion	   leads	   to	  a	  
truncated	   extracellular	   domain	   with	   creation	   of	   an	   antigenic	   junction	   harboring	   a	   novel	  
glycine	  residue	  [141].	  The	  point	  mutation	  in	  IDH1	  is	  more	  critical	  as	  only	  one	  amino	  acid	  is	  
exchanged.	  
Although	  wt	   IDH1	  epitopes	  bound	  to	  MHC	  class	   II	  with	  the	  same	  efficiency	  and	  stability	  as	  
IDH1R132H	   epitopes	   in	   vitro	   (see	   3.1.2,	   Fig.	   3.3),	   T	   cells	   that	   were	   stimulated	   by	   specific	  
peptide	  vaccination	  in	  vivo	  were	  significantly	  more	  responsive	  to	  mutated	  epitopes	  (e.g.	  Fig.	  
3.4).	   This	   specificity	  was	  also	   verified	  when	  mice	  were	   immunized	  with	   IDH1R132H	  or	  wt-­‐
expressing	   tumor	   cells	   (Fig.	   3.15),	   indicating	   that	   non-­‐mutated	   protein	   regions	   were	  
recognized	  as	  self	  and	  subjected	  to	  central	  tolerance.	  As	  opposed	  to	  overexpressed	  antigens,	  
where	  an	  efficient	   immune	  response	  might	  be	   limited	  due	   to	  central	   tolerance	   [166,	  167],	  
this	   is	   not	   a	   problem	  when	   targeting	   IDH1R132H,	  which	   is	  why	   strong	   immune	   responses	  
could	  be	  observed.	  Although	  reactivity	  against	  IDH1wt	  epitopes	  could	  be	  detected	  in	  some	  
mice	   (Fig.	   3.4,	   3.6),	   no	   tumor	   growth	   suppression	   of	   IDH1wt	   tumors	   was	   observed	   after	  
IDH1R132H-­‐specific	  vaccination	  (Fig.	  3.15),	  strengthening	  the	  observation	  that	   IDH1R132H-­‐
primed	  T	  cells	  remain	  mutation-­‐specific	  in	  vivo.	  With	  respect	  to	  reactivity	  against	  IDH1wt	  in	  
non-­‐transformed	   cells,	   cross-­‐reactivity	   is	   a	  major	   concern	   due	   to	   the	   important	  metabolic	  
function	  of	   IDH	   [108,	  109].	  No	   significant	   reduction	  of	   IDH1	  and	   IDH2	  enzymatic	  activity	  –	  
neither	   in	   liver	  nor	   in	  brain	  –	  was	  observed	   in	   IDH1R132H-­‐vaccinated	  mice	   (Fig.	  3.16),	  nor	  
could	  pathological	  evidence	  for	  toxic	  side	  effects	  be	  found	  (Table	  3.1).	  Thus,	  T	  cells	  that	  are	  
induced	   by	   IDH1R132H-­‐targeted	   vaccination	   are	   specific	   for	   the	   mutation,	   as	   are	  
spontaneously	   occurring	   IDH1R132H-­‐specific	   T	   cells	   in	   the	   peripheral	   blood	   of	   glioma	  
patients	  with	  IDH1R132H-­‐positive	  tumors	  (Fig.	  3.12).	  
This	   specificity	   against	   histidine-­‐containing	   and	   not	   arginine-­‐containing	   epitopes	  might	   be	  
explained	  by	  structural	  properties	  of	  these	  amino	  acids	  [85],	  with	  an	  aromatic	   imidazole	   in	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the	  histidine	  residue,	  which	  might	  be	  critical	  for	  TCR	  binding.	  Moreover,	  the	  neoepitope	  that	  
is	  generated	  by	  the	  mutation	  seems	  to	  be	  unique	  as	  to	  no	  cross-­‐reactivity	  to	  other	  epitopes	  
occurs.	   The	   same	   consideration	   holds	   true	   for	   B	   cell	   receptor	   specificity	   and	   antibody	  
responses,	   which	   are	   also	   observed	   after	   vaccination	   and	   spontaneously	   in	   patients	   with	  
IDH1R132H-­‐mutated	  tumors	  and	  which	  explicitly	  bind	  to	  IDH1R132H,	  but	  not	  wt	  IDH1	  (Fig.	  
3.11,	  3.13).	  
For	   many	   antigen-­‐specific	   immunotherapies	   especially	   in	   glioma,	   which	   are	   in	   general	  
characterized	  by	  intra-­‐tumoral	  heterogeneity	  [168-­‐171],	  immunological	  escape	  constitutes	  a	  
conceptual	   pitfall,	   which	   arises	   when	   not	   all	   tumor	   cells	   carry	   the	  mutation	   [35].	   Indeed,	  
with	   the	   preclinical	   vaccination	   approach	   using	   tumors	   in	  which	   not	   100	  %	  of	   tumor	   cells	  
expressed	  IDH1R132H	  (Fig.	  3.14,	  3.15),	  evidence	  of	  immunological	  escape	  was	  found,	  which	  
is	  a	  robust	  sign	  of	  biological	  activity	  in	  an	  experimental	  setting	  where	  not	  all	  tumor	  cells	  are	  
transduced	   with	   the	   therapeutic	   target	   (Fig.	   3.15).	   However,	   fortunately,	   this	   does	   not	  
reflect	  the	  clinical	  situation,	  in	  which	  all	  tumor	  cells	  are	  IDH1R132H	  mutated	  [105,	  107,	  172]	  
and	  therefore	  immunological	  escape	  by	  outgrowth	  of	  target-­‐negative	  tumor	  cells	  is	  unlikely	  
to	  occur.	  In	  a	  therapeutic	  vaccination	  setting	  in	  vivo,	  IDH1R132H	  mutated	  tumors	  were	  even	  
more	   efficiently	   controlled,	   most	   probably	   due	   to	   homogeneous	   target	   expression	   in	   all	  
tumor	  cells	   (Fig.	  3.14,	  3.16).	  Therefore,	   the	  ubiquitous	  expression	  of	   IDH1R132H	   in	  glioma	  
cells	   without	   respective	   heterogeneity	   within	   one	   tumor	   as	   it	   is	   observed	   for	  most	   other	  
potential	   immunotherapeutic	   targets	   in	  glioma	  [35,	  171]	  make	   IDH1R132H	  a	  very	  effective	  
glioma-­‐specific	  antigen.	  
The	   fact	   that	   a	   fraction	   of	   patients	   with	   IDH1R132H-­‐mutated	   tumors	   harbor	   detectable	  
amounts	   of	   IDH1R132H-­‐specific	   T	   cells	   and	   antibodies	   in	   their	   peripheral	   blood	   (Fig.	   3.12,	  
3.13)	   supports	   the	   observation	   that	   the	   immunogenic	   epitope	   is	   presented	   on	   MHC	  
molecules	   to	  T	   cells,	  be	   it	  by	   tumor	  cells	   themselves	  or	  antigen-­‐presenting	  cells	  which	  are	  
found	   in	   the	   tumor	   stroma	   (see	   4.3).	   This	   essential	   prerequisite	   for	   an	   effective	   immune	  
response	  is	  also	  proven	  by	  MHC	  binding	  studies	  (Fig.	  3.3)	  and	  whole	  tumor	  cell	  vaccination	  in	  
mice	   (Fig.	   3.15).	   Spontaneous	   immune	   responses	   to	   relevant	   tumor	   antigens	   have	   been	  
observed,	  e.g.	  against	  NY-­‐ESO-­‐1	  in	  melanoma	  patients	  [40,	  41],	  and	  support	  the	  suitability	  of	  
IDH1R132H	  as	  an	  immunologically	  targetable	  molecule.	  
In	   conclusion,	   the	   IDH1R132H	   mutation	   fulfills	   important	   requirements	   for	   an	  
immunotherapeutically	  relevant	  target	  neoantigen:	  (i)	  It	  is	  tumor-­‐specifically	  expressed	  and	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hence	  autoimmunity	  is	  unlikely	  to	  occur.	  Indeed,	  no	  hints	  for	  autoimmune	  reactions	  or	  side	  
effects	   could	   be	   observed	   in	   mice	   (Fig.	   3.16,	   Table	   3.1).	   (ii)	   It	   has	   a	   high	   uniformity	   and	  
penetrance,	  being	  present	  in	  more	  than	  70	  %	  of	  grade	  II	  and	  grade	  III	  gliomas	  and	  in	  other	  
tumor	  entities,	  but	  more	   importantly	  being	  uniformly	  expressed	  within	  one	  tumor,	  making	  
immunological	   escape	   that	   can	   occur	   due	   to	   selection	   for	   IDH1R132H-­‐negative	   cells	   by	  
targeting	   IDH1R132H-­‐expressing	   cells	   unlikely.	   In	   the	   mouse	   model,	   IDH1R132H-­‐positive	  
tumor	  cells	  were	  lost	  in	  a	  slow-­‐growing	  tumor	  after	  vaccination	  only	  when	  not	  all	  implanted	  
tumor	   cells	   expressed	   the	   antigen	   (Fig.	   3.14,	   3.15),	   but	   no	   immunological	   escape	   in	   the	  
clinically	   relevant	   situation	  was	   observed	   (Fig.	   3.16).	   A	   prerequisite	   for	   an	   effective	   T	   cell	  
activation	  is	  (iii)	  the	  presentation	  of	  epitopes	  on	  MHC	  and	  (iv)	  stability	  of	  the	  MHC:peptide	  
complex.	  IDH1	  epitopes	  containing	  the	  mutation	  were	  processed	  and	  presented	  in	  vivo	  (Fig.	  
3.15)	  and	  bound	  to	  MHC	  class	   II	   in	  vitro	  with	  a	  stability	   that	  was	  comparable	   to	  a	  positive	  
control	  (Fig.	  3.3).	  (v)	  Presentation	  of	  the	  epitope	  leads	  to	  highly	  mutation-­‐specific	  T	  cells	  (Fig.	  
3.4-­‐9,	  3.12)	  that	  are	  (vi)	  tumor-­‐reactive	  and	  capable	  of	  controlling	  the	  growth	  of	  IDH1R132H-­‐
expressing	   but	   not	   IDH1wt	   tumors	   (Fig.	   3.15,	   3.16).	   (vii)	   Furthermore,	   vaccination	   and	  
induction	  of	   IDH1R132H-­‐specific	  T	  helper	  cells	   lead	   to	  production	  of	  antibodies	  specifically	  
binding	  mutated	  IDH1	  (Fig.	  3.11,	  3.13),	  which	  are	  in	  principle	  also	  able	  to	  exhibit	  anti-­‐tumor	  
activity	  [173,	  174].	  Beyond	  IDH1R132H	  being	  a	  suitable	  target	  for	  immunotherapy	  in	  itself,	  it	  
is	   principally	   appropriate	   for	   a	   patient	   population	   among	   glioma	   patients	   that	   can	  
particularly	  benefit	  from	  immunotherapy.	  
	  
4.2	  IDH1R132H	  –	  a	  versatile	  target?	  
	  
The	  delineated	  data	  underline	  that	  mutant	  IDH1	  may	  serve	  as	  a	  therapeutic	  target	  not	  only	  
through	  drug-­‐mediated	  inhibition	  of	  the	  neomorphic	  enzymatic	  function	  [108,	  109],	  but	  also	  
through	  T	  cell-­‐based	  targeting	  of	  the	  mutant	  epitope.	  
Inhibition	   of	   mutant	   IDH1	   and	   IDH2	   using	   small	   molecules	   relies	   on	   its	   neomorphic	  
enzymatic	   production	   of	   2-­‐HG,	   and	   inhibitors	   of	   enzymatic	   function	  with	   respect	   to	   2-­‐HG	  
production	   have	   been	   developed	   [108,	   109].	   In	   erythroleukemia	   cells,	   where	   mutant	  
IDH2R140Q	   led	   to	   growth	   factor-­‐independency	   and	   de-­‐differentiation	   towards	  
hematopoietic	  stem	  cells,	  and	  in	  primary	  AML	  cells	  with	  endogenous	  IDH2R140Q,	  inhibition	  
of	   mutant	   IDH2	   resulted	   in	   restoration	   of	   differentiation	   capacity	   and	   induction	   of	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maturation	  to	  monocytes	  and	  granulocytes	  shown	  by	  specific	  marker	  expression,	  which	  was	  
accompanied	   by	   decreased	   blast	   numbers,	   respectively	   [109].	   Likewise,	   inhibiting	  
IDH1R132H	  in	  primary	  oligodendroglioma	  cells	  endogenously	  and	  heterozygously	  expressing	  
IDH1R132H	   induced	   differentiation	   into	   astrocytic	   cells	   evidenced	   by	   RNA	   expression	  
profiling	   and	   the	   increase	   in	   glial	   fibrillary	   acidic	   protein	   (GFAP)-­‐expressing	   astrocytes	   and	  
concomitant	   loss	   of	   Nestin,	   a	   neuroprogenitor	   marker,	   expression	   [108].	   In	   the	   glioma	  
model,	   re-­‐differentiation	   was	   most	   probably	   due	   to	   a	   decrease	   in	   repressive	   histone	  
methylation	  of	  respective	  promoters,	  as	  would	  be	  expected	  by	  inhibition	  of	  2-­‐HG	  production	  
[97];	   however,	   no	   decrease	   in	   DNA	   methylation	   was	   observed.	   The	   effectiveness	   of	   the	  
inhibitor	  was	  evident	   in	  vivo	   through	  specific	   reduction	  of	  growth	  of	  established	  tumors	   in	  
the	   flank	   of	   immunodeficient	   mice,	   which	   was	   due	   to	   reduced	   proliferation,	   but	   not	  
apoptosis	  induction.	  Nevertheless,	  most	  strikingly,	  no	  alteration	  of	  histone	  methylation	  was	  
achieved	  by	   low	  doses	  of	   the	   inhibitor,	  whereas	   the	   same	   tumor	   growth	   suppression	  was	  
observed,	   suggesting	   non-­‐transcriptional	   mechanisms	   of	   IDH1R132H	   independent	   of	  
epigenetic	  effects	  [108].	  These	  might	  be	  associated	  with	  the	  cardiovascular	  system,	  which	  is	  
altered	  in	  IDH1R132H-­‐expressing	  mouse	  brain	  in	  vivo	  [175].	  
Of	   note	   and	   in	   contrast	   to	   IDH1R132H-­‐targeted	   immunotherapy,	   enzymatic	   inhibition	   of	  
mutant	   IDH	   did	   not	   lead	   to	   loss	   of	   target	   gene	   expression	   nor	   apoptosis-­‐mediated	   tumor	  
reduction	   [108,	   109].	   Although	   apoptosis	   in	   IDH1R132H-­‐expressing	   tumor	   cells	   after	  
vaccination	  was	   not	   addressed	  within	   this	   thesis,	   it	   can	  be	   assumed	   that	   these	   cells	  were	  
lysed	  by	  cytotoxic	  activity	  of	  T	   lymphocytes	  or	  other	  effector	   cells	  which	  might	  have	  been	  
induced	  by	  vaccination	  and	  recruited	  into	  the	  tumor	  (see	  4.3).	  In	  view	  of	  this	  background,	  it	  
is	   interesting	   to	   speculate	   about	   the	   fate	   of	   still	  mutant	   IDH-­‐expressing	   cells,	   which	   have	  
been	   subjected	   to	   2-­‐HG-­‐decreasing	   inhibition	   and	   underwent	   re-­‐differentiation,	   when	  
treatment	  with	  the	  inhibitor	  is	  discontinued.	  It	  is	  believed	  –	  and	  evidence	  has	  accumulated	  
recently	  by	  analysis	  of	  multiple	  biopsies	  of	  same	  patients	  at	  recurrence	  [172]	  –	  that	  the	  IDH1	  
mutation	   in	   glioma	   [67]	   and	   other	   tumor	   entities	   [92,	   100]	   is	   an	   early	   and	  maybe	   even	   a	  
driving	   event	   in	   tumorigenesis	   [82,	   84,	   172].	   Ohgaki	   and	   Kleihues	   speculate	   that	   the	  
mutation	  of	  IDH1	  or	  IDH2	  in	  a	  common	  glial	  precursor	  cell	  is	  the	  first	  step	  towards	  low-­‐grade	  
glioma	   and	   precedes	   TP53	   mutation	   or	   1p/19q	   co-­‐deletion	   as	   driving	   forces	   towards	  
astrocytomas	   and	   oligodendrogliomas,	   respectively	   [67].	   They	   further	   conjecture	   that	   the	  
acquirement	  of	  an	  IDH	  mutation	  confers	  a	  growth	  advantage	  in	  early	  stages	  of	  development	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and	   differentiation	   [67],	   which	   is	   in	   contrast	   to	   later	   stages	   and	   the	   better	   prognosis	   of	  
IDH1R132H-­‐mutated	   gliomas	   compared	   to	   IDH1wt	   gliomas,	   probably	   representing	   a	  
distinctive	  tumor	  entity.	  However,	  in	  vivo	  studies	  indicate	  that	  the	  cell	  of	  glioma	  origin	  is	  not	  
necessarily	  a	  neural	   stem	  cell	  or	  a	  common	  precursor	  cell,	  but	  might	  also	  be	  a	  committed	  
glial	  cell,	  i.e.	  an	  astrocyte	  or	  oligodendrocyte	  [59].	  For	  these	  reasons,	  it	  cannot	  be	  excluded	  
that	   re-­‐differentiated	   IDH1R132H-­‐expressing	  glial	   cells	   that	   are	  no	   longer	   treated	  with	   the	  
inhibitor	   might	   again	   malignantly	   transform	   to	   form	   a	   low-­‐grade	   glioma.	   Although	   GFAP-­‐
specific	  heterozygous	  knock	  in	  of	  IDH1R132H	  in	  mice	  does	  not	  lead	  to	  glioma	  development	  
in	  these	  mice,	  this	  is	  most	  probably	  due	  to	  the	  early	  death	  of	  these	  mice	  [175].	  
As	  opposed	  to	   inhibitor	  treatment,	   IDH1R132H-­‐expressing	  cells	  are	  not	  expected	  to	  persist	  
with	   targeted	  vaccination,	  but	   to	  be	   specifically	   lysed.	  Hence,	  malignant	   transformation	  of	  
these	   cells	   should	   not	   occur.	   Moreover,	   immunotherapy	   has	   the	   advantage	   of	  
immunological	  memory,	   defined	  by	   antigen-­‐specific	  memory	   T	   cells	   remaining	   and	   readily	  
being	   expanded	   and	   activated	   at	   antigen	   encounter,	   and	   therefore	   can	   exhibit	   long-­‐term	  
therapeutic	   beneficial	   effects	   maybe	   even	   at	   recurrence	   without	   continuous	   treatment	  
throughout	   life	   even	   years	   after	   final	   boost	   vaccination	   [176-­‐178].	   In	   this	   context,	  
administration	  might	   also	   be	   an	   advantage	   of	   immunotherapy,	   because	   it	   is	   not	   required	  
daily,	   as	   the	   inhibitor	   might	   need	   to	   be	   administered	   [108].	   For	   glioma	   treatment,	   the	  
administration	   of	   an	   inhibitor	   might	   need	   to	   take	   other	   routes	   than	   the	   described	   oral	  
application	  [108].	  Vaccination	  therapy	  on	  the	  other	  hand	  might	  require	  adjuvant	  therapies	  to	  
reduce	   immunosuppression	   and	   to	   enhance	   recruitment	  of	   effector	   cells	   to	   the	   tumor,	   or	  
immune	  checkpoint	  blockade	  (see	  4.5).	  These	  strategies	  might	  reduce	  the	  frequency	  of	  non-­‐
responders,	  who	  do	  not	  benefit	  from	  a	  vaccine.	  
In	   any	   case,	   the	   biological	   activity	   and	   effectiveness	   of	  mutant	   IDH	   inhibitors	   in	   terms	   of	  
tumor	  growth	  suppression	  [108,	  109]	  demonstrate	  the	  suitability	  of	  the	  IDH1	  mutation	  as	  a	  
therapeutic	  target,	  supporting	  the	  strategy	  of	  IDH1R132H-­‐targeted	  immunotherapy.	  
	  
4.3	  Cellular	  and	  molecular	  mechanisms	  of	  IDH1-­‐targeted	  anti-­‐tumor	  
immunity	  
	  
T	   cell-­‐mediated	   immunotherapies	   have	  mainly	   focused	   on	   CD8+	   T	   cells	   due	   to	   their	   high	  
cytolytic	   activity	   against	   target	   antigen-­‐expressing	   tumors	   [179,	   180].	  However,	   it	   has	   also	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been	  shown	  that	  the	  cytotoxic	  anti-­‐tumor	  effect	  of	  CD8+	  T	  cells	  depends	  on	  CD4+	  T	  cells	  in	  
their	   role	   of	   T	   helper	   cells,	   augmenting	   and	   supporting	   CD8+	   T	   cell	   activity	   [181,	   182]	   by	  
providing	  growth	  factors	  and	  cytokines	  such	  as	  IL-­‐2	  for	  CD8+	  T	  cells,	  enabling	  CD8+	  memory	  
T	   cells	   to	   acquire	   effector	   phenotype	   and	   function	   [183,	   184].	  Without	   CD4+	   T	   cell	   help,	  
CD8+	  T	  cells	  might	   fail	   to	  elicit	   sufficient	   responses	   [185].	  Even	  more,	   it	  has	  more	  recently	  
been	  appreciated	  that	  CD4+	  T	  cells	  can	  in	  addition	  directly	  mediate	  specific	  tumor	  cell	  killing	  
and	  are	  suitable	  for	  use	  in	  adoptive	  T	  cell	  transfer	  for	  cancer	  immunotherapy	  [186-­‐189].	  
It	  has	  been	  shown	  that	  tumor	  cells	  can	  endogenously	  process	  MHC	  class	  II-­‐binding	  epitopes	  
by	  autophagy	  and	  present	  them	  on	  their	  surface	  [190].	  Although	  most	  tumors	  are	  MHC	  class	  
II	   deficient,	   IFN-­‐γ	   exposure	   can	   lead	   to	   upregulation	   of	  MHC	   class	   II	   also	   in	   gliomas	   [191,	  
192].	  The	  human	  glioma	  cell	  line	  LN229	  even	  ubiquitously	  expresses	  MHC	  class	  II	  in	  vitro	  and	  
expression	   can	   be	   enhanced	   by	   IFN-­‐β,	   as	   has	   been	   found	   in	   the	   course	   of	   this	  work.	   The	  
mechanisms	   of	   CD4+	   T	   cell-­‐mediated	   immune	   responses	   and	   tumor	   eradication	   in	   the	  
context	  of	  specific	  tumor-­‐associated	  antigens	  (TAA;	  NY-­‐ESO-­‐1,	  TYRP1)	  have	  been	  extensively	  
studied	  using	  adoptive	  transfer	  (AT)	  of	  antigen-­‐specific	  CD4+	  T	  cells	  in	  preclinical	  models	  of	  
melanoma	  [149,	  151]	  and	  demonstrated	  in	  melanoma	  patients	  [30].	  Using	  CD4+	  TRYP1	  TCR-­‐
transgenic	  mice	  as	  a	  source	  for	  CD4+	  T	  cells	  for	  AT,	  Quezada	  and	  co-­‐workers	  [151]	  showed	  
that	   these	   T	   cells	   were	   sufficient	   to	   completely	   eliminate	   exclusively	   antigen-­‐expressing	  
melanoma	  and	  revealed	  a	  dependency	  on	   IFN-­‐γ	  production	  by	   these	  cells	  when	  combined	  
with	   CTLA-­‐4	   blockade	   and	   radiotherapy	   (RT).	   As	   evidenced	   by	   depletion	   experiments	   and	  
knock	  out	  (KO)	  mice,	  this	  effect	  was	  independent	  of	  host	  T	  cells,	  B	  cells,	  or	  natural	  killer	  (NK)	  
cells,	  and	  TNF-­‐α	  secretion.	  The	  authors	  propose	  a	  model	  in	  which	  RT-­‐induced	  lymphopenia	  
allows	   in	  vivo	  differentiation	  and	  expansion	  of	  transferred	  CD4+	  T	  cells	  and	  due	  to	  reduced	  
Treg	  functions	  by	  CTLA-­‐4	  blockade,	  these	  CD4+	  T	  cells	  are	  able	  to	  produce	  sufficient	  amounts	  
of	   IFN-­‐γ,	  which	   in	  turn	  together	  with	  RT	   leads	  to	  enhanced	  MHC-­‐class	   II	  expression	  on	  the	  
tumor,	  making	   it	   susceptible	   to	  CD4+	  T	   cell-­‐mediated	  killing	   [151].	  Comparable	  anti-­‐tumor	  
effects	  were	  achieved	  when	  substituting	  CTLA-­‐4	  blockade	  with	  engagement	  of	  OX40,	  a	  co-­‐
stimulatory	  molecule	  expressed	  on	  activated	  CD4+	  T	  cells	  [149].	  
Based	  on	  and	  in	  line	  with	  these	  findings,	  it	  is	  reasonable	  to	  speculate	  that	  with	  IDH1R132H-­‐
specific	   vaccination	   using	   the	   HLA-­‐DR1-­‐binding	   p123-­‐142	   epitope,	   induced	   IFN-­‐γ-­‐secreting	  
CD4+	   T	   cells	   specific	   for	   IDH1R132H	   are	   capable	   of	   and	   sufficient	   in	   directly	   killing	   and	  
controlling	   established	   IDH1R132H-­‐mutated	   tumors	   in	   MHC-­‐humanized	   mice.	   This	   is	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supported	   by	   the	   notion	   that	   IDH1R132H-­‐specific	   CD8+	   T	   cells	   cannot	   be	   induced	   by	  
vaccination	  (Fig.	  3.18).	  
However,	   the	  classical	  mechanism	  of	  an	  MHC	  class	   II-­‐restricted	  CD4+	  T	  cell-­‐mediated	  anti-­‐
tumor	   immune	   response	   is	   the	   release	  of	   antigen	  –	   in	   this	   case	   IDH1R132H	  epitopes	  –	  by	  
apoptotic	  tumor	  cells,	  which	  is	  phagocytosed,	  processed	  in	  phagosomes,	  and	  presented	  on	  
MHC	  class	  II	  by	  professional	  antigen-­‐presenting	  cells	  (APC)	  that	  are	  recruited	  into	  the	  tumor.	  
Antigen	  encounter	  and	  recognition	  of	  APC	  by	  T	  helper	  cells	  stimulates	  cytokine	  secretion	  by	  
T	   helper	   cells,	   which	   in	   turn	   activate	   APC	   and	   induce	   an	   inflammatory	   tumor	  
microenvironment,	  providing	  co-­‐stimulation	  for	  innate	  and	  adaptive	  immune	  cells	  [150].	  This	  
recruits	  additional	  CD4+	  and	  CD8+	  T	  cells	  as	  well	  as	  NK	  or	  NKT	  cells,	  which	  infiltrate	  into	  the	  
tumor,	   results	   in	   the	  upregulation	  of	  MHC	   class	   I	   expression	  by	   tumor	   cells	   and	  enhances	  
tumor	  immunogenicity.	  These	  mechanisms	  are	  essential	  in	  tumors	  deficient	  in	  MHC	  class	  II,	  
but	  which	  are	  recognized	  and	  eliminated	  by	  CD4+	  T	  cells	  via	  indirect	  recognition	  of	  TAA	  on	  
APC	   which	   recruit	   innate	   and	   adaptive	   immune	   cells	   [188],	   e.g.	   macrophages	   which	   are	  
stimulated	   to	   secrete	   IFN-­‐γ	   [186,	   193],	   or	   activated	  NK	   cells	   [189].	  Of	   note,	   Th1-­‐polarized	  
CD4+	  T	  cells	  are	  probably	  the	  most	  effective	  T	  helper	  cells	  because	  of	  their	  IFN-­‐γ	  secretion;	  
however,	  Th17	  cells	  might	  play	  an	  important	  role	  via	  the	  recruitment	  of	  innate	  immune	  cells	  
[150,	   194].	   The	   consideration	   that	   this	   classical	   mechanism	   applies	   for	   the	   effect	   of	  
IDH1R132H	   vaccination	   is	   reinforced	   by	   the	   fact	   that	   the	   sarcoma	   cells	   used	   in	   the	  
therapeutic	  model	  do	  not	  express	  MHC	  class	  II	  per	  se	  nor	  after	  IFN-­‐γ	  stimulation	  in	  vitro	  (Fig.	  
3.14),	  speaking	  against	  direct	  recognition	  and	  killing	  of	  tumor	  cells	  by	  CD4+	  T	  cells.	  Whether	  
MHC	   II	  expression	   in	   the	   tumor	   that	  was	  observed	   in	  vivo	   can	  be	  assigned	  to	   the	  sarcoma	  
cells	   or	   infiltrating	   cells	   in	   the	   tumor	  microenvironment	   needs	   to	   be	   elucidated.	   Another	  
point	   is	   the	   finding	   of	   antigen	   loss	   in	   previously	   IDH1R132H-­‐expressing	   tumors	   after	  
vaccination	   (Fig.	   3.15),	   because	   immunologic	   escape	   is	   rather	   unlikely	   to	   be	   induced	   by	  
exclusively	  CD4+	  T	  cell-­‐mediated	  immunity	  but	  has	  been	  described	  for	  CD8+	  T	  cell	  responses	  
[195].	  
With	  this	  rationale,	  it	  can	  be	  expected	  that	  tumor-­‐infiltrating	  T	  cells	  (Fig.	  3.18)	  in	  addition	  to	  
IDH1R132H-­‐specific	  CD4+	  T	  cells	  contain	  CD8+	  T	  cells,	  and	  NK	  or	  NKT	  cells,	  which	  might	  as	  
well	  exhibit	  anti-­‐tumor	  activity	  by	  antigen-­‐spreading,	  which	  is	  the	  immune	  response	  to	  other	  
TAA	  apart	  from	  IDH1R132H	  p123-­‐142,	  in	  this	  case,	  arising	  from	  antigen	  release	  by	  apoptotic	  
tumor	   cells	   and	  encounter	  of	   these	  antigens	  by	  T	   cells	  of	  appropriate	   specificity,	   so-­‐called	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cross-­‐presentation	  and	  cross-­‐priming	  [196].	  Antigen	  spreading	  has	  been	  observed	  in	  CD4+	  T	  
cell	  AT	  for	  melanoma	  expressing	  several	  relevant	  TAA	  [30].	  Antigens	  that	  are	  recognized	  by	  
locally	  activated	  CD8+	  T	  cells	   in	  the	  therapeutic	  vaccination	  model	  using	   IDH1R132H	  p123-­‐
142	  might	  include	  other	  IDH1R132H	  epitopes	  or	  other	  antigens	  expressed	  by	  the	  tumor	  cells.	  
APC,	  which	  might	  present	  the	  IDH1R132H	  epitope	  on	  MHC	  II	  to	  specific	  CD4+	  T	  cells	   in	  the	  
tumor,	   instead	  of	   tumor	   cells	   themselves,	   can	   include	   infiltrating	  macrophages	   or	  DC,	   but	  
also	  B	  cells,	  which	  can	  infiltrate	  into	  and	  represent	  a	  considerable	  amount	  within	  the	  tumor	  
[197].	  Of	  note,	  B	  cells	  are	  capable	  to	  enrich	  small	  amounts	  of	  antigen	  and	  present	  on	  MHC	  
class	   II	   [198].	   This	   B	   cell	   function	   might	   play	   a	   role	   in	   IDH1R132H-­‐specific	   anti-­‐tumor	  
immunity,	  because	  anti-­‐tumor	  effectiveness	  was	   lost	  when	  CD19+	  B	  cells	  were	  depleted	   in	  
vaccinated	   mice	   (Fig.	   3.19)	   and	   this	   effect	   was	   probably	   not	   completely	   dependent	   on	  
IDH1R132H-­‐specific	  antibody	  production	  evidenced	  by	   the	   fact	   that	  not	  all	   vaccinated	  and	  
responding	   mice	   developed	   specific	   antibodies.	   Yet,	   clinical	   responses	   correlated	   with	  
IDH1R132H-­‐binding	  antibodies	   in	  vaccinated	  mice	   (data	  not	  shown),	  supporting	  the	  notion	  
that	  antibody	  production	  is	  another	  B	  cell	  function	  that	  contributes	  to	  B	  cell-­‐dependent	  anti-­‐
tumor	   immunity.	   Nevertheless,	   it	   might	   also	   be	   possible	   that	  MHC	   class	   II	   expression	   on	  
tumor	  cells	  is	  upregulated	  by	  IFN-­‐γ-­‐secreting	  IDH1R132H-­‐specific	  CD4+	  T	  cells	  that	  infiltrate	  
into	  the	  tumor	  (Fig.	  3.18)	  as	  observed	  in	  the	  experimental	  AT	  of	  antigen-­‐specific	  CD4+	  T	  cells	  
for	   melanoma	   [151].	   The	   finding	   of	   HLA-­‐DR	   expression	   in	   tumors	   from	   vaccinated	   mice	  
supports	  all	  these	  hypotheses.	  
Further	   clarification	   will	   be	   achieved	   by	   analyzing	   tumor-­‐infiltrating	   lymphocytes	   in	   more	  
detail	  by	  staining	  for	  specific	  markers	  such	  as	  CD8,	  CD19,	  and	  NK-­‐1.1	  for	  cytotoxic	  T	  cells,	  B	  
cells,	  and	  NK	  cells,	  respectively,	  and	  co-­‐stainings	  with	  HLA-­‐DR	  to	  delineate	  if	  tumor	  cells	  or	  
recruited	  TILs	  present	  IDH1R132H	  epitopes	  to	  specific	  CD4+	  T	  cells	  inside	  the	  tumor.	  Insights	  
into	  the	  contribution	  of	  the	  different	  lymphocytic	  subpopulations	  to	  therapeutic	  efficacy	  can	  
be	  gained	  by	  depletion	  of	  these	  cells	   in	  vivo.	   Interestingly,	  depletion	  of	  CD8+	  T	  cells	   in	  the	  
therapeutic	   setting	   dramatically	   diminished	   the	   vaccination	   effect	   similar	   to	   CD4+	   T	   cell	  
depletion	  (data	  not	  shown).	  Finally,	  IDH1R132H-­‐specific	  CD4+	  T	  cells	  –	  which	  are	  available	  –	  
can	  be	  adoptively	  transferred	  into	  lymphopenic	  or	  immunodeficient	  mice	  to	  reveal	  if	  CD4+	  T	  
cells	  alone	  are	  sufficient	  for	  the	  anti-­‐tumor	  response.	  This	  approach	  could	  be	  facilitated	  by	  
cloning	  of	  the	  IDH1R132H-­‐binding	  TCR	  and	  the	  generation	  of	  a	  CD4+	  TCR-­‐transgenic	  mouse	  
as	  a	  source	  for	  IDH1R132H-­‐specific	  CD4+	  T	  cells.	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The	  mechanism	   behind	   the	   observed	   vaccination-­‐induced	   loss	   of	   antigen	   expression	   (Fig.	  
3.15)	   also	   remains	   unclear.	   As	   stated	   above,	   it	   is	   usually	   not	   induced	  by	   sole	   CD4+	   T	   cell-­‐
mediated	   responses.	  Related	   to	   the	  considerations	  outlined	  above,	   the	  effects	   responsible	  
for	   this	   phenomenon	  might	   be	   locally	   activated	   IDH1R132H-­‐specific	   or	   bystander	   CD8+	   T	  
cells,	  or	  IFN-­‐γ	  secretion	  by	  CD4+	  T	  cells	  in	  the	  tumor,	  which	  lead	  to	  antigen	  loss	  [199,	  200].	  
However,	  no	  reduced	   IDH1R132H	  expression	  within	  the	  tumor	  was	  observed	   in	  vaccinated	  
mice	  compared	  to	  sham	  treated	  mice	  when	  a	  completely	  homogenous	  tumor	  with	  respect	  
to	   IDH1R132H	   expression	   was	   implanted	   and	   established	   tumors	   were	   therapeutically	  
treated	   (data	   not	   shown).	   This	   points	   towards	   a	   limited	   vaccination-­‐driven	   loss	   of	   antigen	  
expression	   in	   that	   the	   clonal	   tumor	   cells	   are	   limited	   in	   proliferation	   but	   are	   not	   able	   to	  
escape	  the	  immune	  system	  by	  antigen	  loss	  in	  vivo	  after	  vaccination.	  Rather,	  it	  is	  likely	  that	  in	  
the	  preventive	  vaccination	  with	  heterogeneous	  tumor	  cells,	  IDH1R132H-­‐positive	  tumor	  cells	  
were	  eliminated,	  be	   it	  due	  to	  CD4+	  or	  CD8+	  T	  cell	  activity,	  and	  IDH1R132H-­‐negative	  tumor	  
cells	   grew	  out	   in	   response	   to	   selective	  pressure	  by	  vaccination	   in	  addition	   to	   their	   growth	  
advantage	  per	  se	  (Fig.	  3.14).	  This	  scenario	  would	  be	  in	  contrast	  to	  downregulation	  and	  gene	  
silencing	   of	   IDH1R132H	   in	   previously	   IDH1R132H-­‐expressing	   cells,	   but	   in	   line	   with	  
observations	   made	   in	   clinical	   studies	   targeting	   the	   tumor	   antigen	   EGFRvIII	   by	   peptide	  
vaccination	  in	  glioma	  patients	  [35].	  Here,	  the	  primary	  tumor	  was	  heterogeneous	  for	  EGFRvIII	  
expression	  and	  vaccination	   led	  to	   loss	  of	  antigen	  expression	   in	  recurrent	  tumors.	  Although	  
this	  can	  be	  interpreted	  as	  a	  sign	  of	  biological	  activity,	  this	  would	  be	  unwanted	  in	  the	  clinical	  
situation.	  As	  this	  is	  after	  IDH1R132H	  vaccination	  only	  observed	  with	  a	  heterogeneous	  tumor,	  
it	   is	   unlikely	   to	   occur	   in	   glioma	   patients	  with	   IDH1R132H-­‐mutated	   tumors,	  where	   all	   cells	  
express	  the	  antigen	  [105,	  107,	  172].	  
Conceptually,	  CD4+	  T	  cells	  might	   indeed	  be	  more	  efficient	   in	  anti-­‐tumor	  activity	  than	  CD8+	  
CTL	  [150,	  189].	  Since	  CD8+	  T	  cells	  recognize	  endogenous	  antigens	  presented	  on	  MHC	  class	  I,	  
expressed	  by	  normal	  and	  tumor	  cells,	  CD8+	  T	  cell-­‐mediated	  TAA-­‐specific	  immune	  responses	  
rely	  on	  the	  MHC	  class	  I	  expression	  and	  antigen	  presentation	  on	  tumor	  cells.	  But	  because	  of	  
genomic	   instability,	   tumor	  cells	  are	  mostly	  defective	   in	  antigen	  presentation	  due	  to	   loss	  of	  
molecules	  required	  for	  antigen	  processing	  and	  presentation,	  such	  as	  β2-­‐microglobulin,	  TAP	  
or	  MHC	  I	  chains	  [15,	  201].	  Conversely,	  CD4+	  T	  cell	  functions	  are	  independent	  of	  autophagy-­‐
mediated	   antigen	   presentation	   on	   tumor	   cells.	   Instead,	   CD4+	   T	   cells	   recognize	   antigens	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commonly	  presented	  on	  APC.	  Moreover,	  CD4+	  T	  cells	  exhibit	  versatile	  effector	  functions	  and	  
represent	  a	  plastic	  cell	  population	  capable	  to	  “evolve,	  adapt,	  and	  self-­‐regulate”	  [150].	  
	  
4.4	  IDH1R132H-­‐derived	  2-­‐HG	  and	  the	  immune	  system	  
	  
The	   IDH	  mutations	   are	   unique	   tumor-­‐specific	  mutations	   inasmuch	   as	   they	   produce	   2-­‐HG,	  
which	  in	  turn	  reduces	  histone	  and	  DNA	  methylation,	  thereby	  altering	  the	  entire	  epigenome	  
of	  the	  tumor.	  The	  mode	  of	  autocrine	  action	  of	  2-­‐HG	  has	  been	  a	  matter	  of	  extensive	  research	  
and	   is	   now	   largely	   understood	   [92].	   2-­‐HG	   is	   a	   competitive	   antagonist	   of	   the	   natural	   IDH	  
product	  α-­‐KG,	  because	  it	  binds	  to	  α-­‐KG-­‐dependent	  dioxygenases.	  Among	  these	  are	  histone-­‐
and	  DNA-­‐demethylating	  enzymes,	  which	  are	  inhibited	  by	  2-­‐HG	  [97].	  The	  broad	  and	  constant	  
autocrine	  effects	  of	  endogenous	  2-­‐HG	  on	  all	  solid	  tumors	  expressing	  mutant	  IDH	  [73,	  95,	  99],	  
but	   also	   cells	   of	   the	   hematopoietic	   system	   in	   the	   context	   of	   leukemia	   [97]	   as	  well	   as	   the	  
possibility	  to	  mimic	  these	  effects	  by	  applying	  exogenous	  2-­‐HG	  to	  cells	  not	  expressing	  the	  IDH	  
mutation	  [95],	  gave	  rise	  to	  the	  hypothesis	  that	  T	  cells	  –	  and	  possibly	  other	  lymphocytes	  and	  
innate	  immune	  cells	  –	  might	  as	  well	  be	  altered	  in	  function	  by	  exposure	  to	  2-­‐HG.	  Particularly,	  
T	   cell	   functions	   are	   important	   in	   the	   context	   of	   T	   cell-­‐mediated	   IDH1R132H-­‐targeted	  
immunotherapy.	  
Treatment	   of	   human	  peripheral	   blood	  mononuclear	   cells	   (PBMC)	   did	   not	   reveal	   any	   2-­‐HG	  
effects	   on	  T	   cell	   proliferation,	   activation,	   nor	  differentiation	   into	  effector	  phenotypes	   (see	  
3.6,	   Fig.	   3.20-­‐22).	  Many	   explanations	  why	   2-­‐HG	  did	   not	   affect	   T	   cells	   in	   this	   experimental	  
model	  are	  possible.	  
One	   reason	   might	   be	   the	   2-­‐HG	   concentrations	   used,	   which	   with	   100	   µM	   lie	   below	   the	  
concentrations	  of	  up	  to	  30	  mM	  now	  found	  in	  IDH1R132H+	  tumor	  tissue	  [92,	  147].	  Another	  
reason	   could	   be	   the	   exposure	   time,	   which	   is	   not	   long	   enough	   to	   induce	   2-­‐HG-­‐mediated	  
changes.	   In	  tumor	  cells,	  all	  2-­‐HG-­‐mediated	  alterations	  are	  induced	  via	  methylation-­‐induced	  
epigenetic	   rearrangements,	   which	   generally	   require	   time	   to	   lock	   in,	   hence	   occur	   over	  
extended	  periods	  of	  time	  [98,	  202,	  203].	  In	  fact,	  epigenetic	  changes	  and	  establishment	  of	  the	  
hypermethylation	   phenotype	   via	   introduction	   of	   IDH1R132H	   are	   detectable	   only	   after	  
prolonged	  culture	  periods	  and	  numerous	  passages	   in	  vitro,	  not	  only	   in	  primary	  astrocytes,	  
but	  also	  in	  fibroblasts	  differentiating	  into	  adipocytes	  [95,	  98].	  Thus,	  the	  time	  factor	  seems	  to	  
be	  independent	  of	  cell	  type.	  Reasoning	  that	  any	  2-­‐HG-­‐mediated	  influence	  on	  T	  cells	  should	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be	  mediated	  via	  epigenetic	  changes,	  the	  treatment	  over	  10	  days	  is	  most	  likely	  not	  sufficient	  
for	   this	   analysis.	   Longer	   exposure	   times	   in	   primary	   T	   cells	   are	   difficult	   to	   achieve	   due	   to	  
limited	  survival	  of	  these	  cells	  in	  vitro.	  Thus,	  it	  might	  be	  feasible	  to	  use	  T	  cell	  lines,	  e.g.	  human	  
immortalized	   Jurkat	   T	   cells	   [204],	   or	   antigen-­‐specific	   murine	   T	   cells	   such	   as	   CD8+	   gp100-­‐
specific	  T	  cells	  from	  pmel	  mice	  [205],	  CD4+	  ovalbumin	  (OVA)-­‐specific	  T	  cells	  from	  OT-­‐II	  mice	  
[206],	   or	  CD4+	   IDH1R132H-­‐specific	   T	   cells	   described	  here	   (see	  3.2.3).	   These	   cells	   have	   the	  
advantage	   of	   not	   only	   prolonged	   culture,	   but	   also	   of	   the	   possibility	   to	   study	   effects	   on	  
antigen-­‐specific	  activation.	  Yet,	  the	  question	  remains	  if	  2-­‐HG	  is	  able	  to	  enter	  T	  cells	  or	  other	  
cell	  types	  and	  thus	  to	  exhibit	  paracrine	  effects.	  It	  has	  been	  assumed	  that	  2-­‐HG	  is	  in	  general	  
not	   cell-­‐permeable,	  which	   is	   the	   reason	  why	   cell-­‐permeable	   derivatives	   of	   the	  metabolite	  
have	  been	  developed	  and	  used	  to	  study	  if	  mutant	  IDH	  exerts	  its	  effects	  via	  2-­‐HG	  production	  
in	   an	   autocrine	   manner	   [100].	   Nevertheless,	   cell-­‐permeable	   2-­‐HG	   did	   not	   have	   any	  
detectable	  impact	  for	  T	  cell	  functions	  in	  preliminary	  experiments	  (data	  not	  shown).	  
Still,	  due	  to	  the	  non-­‐permeability	  of	  2-­‐HG,	  another	  possibility	  that	  appears	  more	  likely	  than	  
direct	  effects	   is	   that	  2-­‐HG	  affects	  T	  cells	   indirectly	  via	  epigenetic	  changes	   in	  and	   therefore	  
altered	   expression	  profile	   of	   tumor	   cells.	   Since	   IDH-­‐mutated	   cells	   secrete	   2-­‐HG	   [147],	   it	   is	  
reasonable	   to	   hypothesize	   that	   2-­‐HG	   might	   alter	   the	   tumor	   microenvironment.	   In	   vivo	  
studies	  using	  a	  unique	  heterozygous	  conditional	  IDH1R132H	  knock	  in	  (KI)	  mouse	  model	  [96,	  
175]	   show	  that	  expression	  of	   IDH1R132H	  specifically	   in	  nestin+	  neural	   stem	  cells	  or	  GFAP-­‐
expressing	  astrocytes	   induces	  brain	  hemorrhage	  and	  alters	  collagen	  maturation,	   leading	  to	  
perturbed	  basement	  membrane	  (BM)	  formation	  [175].	  These	  effects	  are	  attributed	  to	  2-­‐HG-­‐
mediated	  competitive	  inhibition	  of	  the	  prolyl	  hydroxylase	  domain-­‐containing	  proteins	  (PHD)	  
and	  collagen	  prolyl-­‐hydroxylases,	  which	  both	  belong	  to	  α-­‐KG-­‐dependent	  prolyl	  hydroxylases.	  
PHD	   mark	   hypoxia-­‐inducible	   factors	   1/2	   α	   (HIF1/2α)	   for	   ubiquitination	   and	   subsequent	  
proteasomal	  degradation	   [207];	   thus,	   PHD	   inhibition	   leads	   to	  HIF1/2α	  protein	   stabilization	  
and	  target	  gene	  expression.	  One	   important	  target	  gene	   in	  the	  context	  of	  glioma	  and	  other	  
solid	   tumors	   that	   was	   upregulated	   in	   nestin-­‐IDH1R132H	   KI	   mouse	   embryos	   is	   vascular	  
endothelial	   growth	   factor	   (VEGF),	   which	   is	   an	   important	   growth	   factor	   regulating	  
vasculogenesis	   and	   angiogenesis	   during	   development	   [208]	   and	   which	   is	   upregulated	   in	  
glioma	   [209-­‐211].	   Consequently,	   the	   IDH1R132H-­‐driven	   enhancement	   of	   VEGF	   levels	   does	  
not	   only	   contribute	   to	   embryonic	   hemorrhage	   in	   this	   mouse	   model	   [175],	   but	   bears	  
considerable	   implications	   for	  glioma	  pathology.	   In	  this	  regard,	   it	  might	  be	  noteworthy	  that	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preliminary	   results	  obtained	  during	   this	   thesis	   showed	   that	  2-­‐HG	   increased	   the	  angiogenic	  
potential	   of	   human	   umbilical	   vein	   endothelial	   cells	   (HUVEC)	   in	   a	   sprouting	   assay	   in	   vitro.	  
Impaired	   collagen	   maturation	   in	   nestin-­‐IDH1R132H	   KI	   mice	   appeared	   to	   be	   caused	   by	  
diminished	   hydroxylation	   of	   collagen	   IV,	   which	   is	   a	   central	   BM	   component	   and	   which	  
mediates	   interactions	   between	   astrocytes	   and	   endothelial	   cells	   [212].	   Thus,	   collagen	   IV	  
disruption	  led	  to	  BM	  breakdown	  in	  these	  mice	  [175].	  Strikingly,	  in	  relation	  to	  IDH1R132H	  and	  
2-­‐HG-­‐mediated	   effects	   on	   the	   immune	   system,	   some	   viable	   GFAP-­‐IDH1R132H	   KI	   mice	  
demonstrated	  splenomegaly	  and	  an	  elevated	  white	  blood	  cell	  count	  as	  well	  as	  inflammatory	  
symptoms.	  Although	  the	  authors	  report	  on	  leaky	  gene	  expression	  in	  other	  tissues	  [175],	  it	  is	  
tempting	   to	   speculate	   that	   astrocytic	   IDH1R132H	   expression	   might	   affect	   the	   immune	  
system	  in	  vivo.	  
Despite	   these	   findings	   and	   observed	   changes	   that	   are	   connected	   to	   tumorigenesis,	   GFAP-­‐
IDH1R132H	  KI	  mice	  did	  not	  develop	  brain	   tumors,	  most	  probably	  due	  to	  reduced	   life	  span	  
[175].	   While	   reduced	   hydroxymethylation,	   which	   precedes	   hypermethylation,	   was	  
detectable,	  no	  changes	  in	  histone	  methylation	  were	  observed,	  leading	  to	  the	  hypothesis	  that	  
epigenetic	   modifications	   are	   the	   key	   factor	   required	   for	   malignant	   transformation	   and	  
tumorigenesis	   [175]	   and	   therefore	   also	   for	   microenvironmental	   alterations.	   Indeed,	  
hypermethylation-­‐mediated	  alterations	  within	  tumor	  cells	  that	  might	  presumably	  affect	  the	  
microenvironment	  have	  been	  described	  in	  human	  astrocytes	  and	  primary	  low-­‐grade	  gliomas	  
in	   vitro	   [98].	   These	   are	   transcriptional	   programs	   related	   to	   several	   cellular	   pathways,	  
including	   TGF-­‐β	   signaling,	   PDGF	   and	   EGFR	   signaling,	   wnt	   signaling,	   and	   angiogenesis,	   to	  
name	  just	  a	  few.	  Given	  the	  versatile	  roles	  and	  paracrine	  impact	  of	  these	  pathways	  on	  cells	  in	  
the	   tumor	   stroma,	   e.g.	   the	   suppression	   of	   T	   cell	   proliferation	   and	   NK	   cell	   activity	   and	  
induction	  of	  T	  cell	  apoptosis	  by	  TGF-­‐β	  [111],	  the	  connection	  between	  IDH1R132H-­‐derived	  2-­‐
HG,	  hypermethylation,	  and	  tumor-­‐infiltrating	   lymphocytes	  or	  resident	  microglia	   is	  certainly	  
worth	   investigating.	   In	   fact,	   IDH1R132H-­‐mutated	   anaplastic	   astrocytomas	   (A°III)	   are	   less	  
infiltrated	  by	  T	  cells	  than	  IDH1wt	  A°III	  (TCGA	  data	  analysis).	  
To	   verify	   this	   finding	   in	   an	   in	   vivo	   model,	   to	   examine	   the	   underlying	  mechanisms	   of	   this	  
correlation,	  and	  to	  identify	  the	  compartments	  of	  the	  immune	  system	  involved,	  will	  be	  main	  
aims	  of	  prospective	  studies.	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4.5	  Translating	  the	  IDH1R132H	  vaccine	  to	  the	  clinic	  –	  implications	  and	  
considerations	  
	  
Among	  gliomas,	  GBM	  are	  the	  most	  aggressive	  tumors	  with	  dramatically	  decreased	  survival	  
times	  (14-­‐17	  months)	  compared	  to	  low-­‐grade	  and	  anaplastic	  gliomas	  [63,	  64].	  Consequently,	  
most	   clinical	   studies	   that	   have	   been	   conducted	   in	   the	   last	   years	   have	   focused	   on	   GBM	  
patients.	  Yet,	  although	  patients	  with	  low-­‐grade	  and	  anaplastic	  gliomas	  have	  a	  median	  overall	  
survival	  of	  7-­‐10	  or	  2-­‐5	  years,	   respectively,	   these	  patients	   inevitably	   suffer	   from	  recurrence	  
and	  ultimately	  malignant	  progression	  and	  eventually	  die	  of	   the	  disease	   [60-­‐62].	  Therefore,	  
novel	  therapeutic	  strategies	  are	  required	  not	  only	  for	  GBM	  patients,	  but	  also	  for	  low-­‐grade	  
glioma	  patients	  in	  order	  to	  prevent	  progression.	  For	  many	  of	  these	  patients,	  no	  appropriate	  
follow-­‐up	   therapy	   is	  available	  after	   resection,	  while	  grade	   III	   glioma	  patients	  often	   receive	  
radiotherapy	  or	  chemotherapy	  [66].	  Since	  this	  patient	  group	  is	  generally	  immunocompetent,	  
immunotherapy	   is	   a	   promising	   option	   for	   these	   patients.	   Peptide	   vaccinations	   for	   glioma	  
patients	   using	   cocktails	   of	   several	   epitopes	   from	   glioma-­‐associated	   antigens	   have	   been	  
developed	   and	   are	   under	   investigation	   in	   clinical	   trials.	   An	   example	   for	  HLA-­‐A*02	  positive	  
GBM	  patients	  are	  the	  IMA950	  trials,	  which	  are	  phase	  1/2	  studies	  using	  11	  different	  specific	  
peptides	  [134].	  
An	  IDH1R132H-­‐targeting	  vaccine	  has	  the	  advantage	  of	  a	  single	  epitope	  being	  homogenously	  
expressed	  throughout	  the	  tumor.	  Moreover,	  IDH1R132H	  as	  a	  target	  is	  not	  prone	  to	  be	  lost,	  
but	   expression	   persists	   in	   recurrent	   tumors	   [172],	   making	   IDH1R132H-­‐targeted	  
immunotherapy	   an	   option	   even	   at	   recurrence.	   The	   finding	   that	   GBM	   of	   mesenchymal	  
subtype	  are	  more	  susceptible	  to	  DC	  vaccine	  using	  autologous	  tumor	  lysates	  than	  proneural	  –	  
hence	  mostly	   IDH1R132H	  positive	  –	  tumors	  [137]	  seems	  to	  be	  counteracting	  the	  suitability	  
of	  IDH1R132H	  vaccination,	  but	  has	  not	  been	  verified	  in	  low-­‐grade	  and	  anaplastic	  glioma.	  
Although	   the	   efficacy	   of	   the	   IDH1R132H-­‐specific	   vaccine	   was	   shown	   in	   a	  mouse	   sarcoma	  
model	  instead	  of	  an	  intracranial	  tumor	  model,	  the	  finding	  of	  spontaneous	  peripheral	  cellular	  
and	   humoral	   immune	   responses	   in	   patients	   (see	   3.3)	   supports	   the	   reasoning	   that	   such	   a	  
vaccine	   can	   be	   effective	   in	   glioma	   patients.	   It	   has	   been	   shown	   for	   NY-­‐ESO-­‐1	   that	  
spontaneously	  occurring	  antigen-­‐specific	   IgG	   increase	  the	  probability	   that	  T	  cell	   responses,	  
including	   CTL	   and	   Th	   responses,	   can	   be	   generated	   ex	   vivo	   [40,	   213],	   thus	  maybe	   also	   by	  
vaccination,	   although	   antigen-­‐binding	   IgG	   levels	   are	   not	   necessarily	   enhanced	   after	  
vaccination	   [30].	   A	   total	   of	   seven	   patients	   of	   the	   screened	   45	   patients	   (16	   %)	   with	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IDH1R132H-­‐mutated	   gliomas	   exhibited	   detectable	   peripheral	   specific	   immunity,	   of	   which	  
only	   one	   patient	   had	   both	   specific	   T	   cells	   and	   antibodies	   at	   the	   time	   analyzed.	   This	  
discrepancy	  and	  difference	   to	   the	  correlation	  of	  T	  cell	  and	  antibody	   responses	  against	  NY-­‐
ESO-­‐1	   in	  melanoma	  [40]	  most	   likely	  arises	  from	  T	  helper	  cell	  and	  antibody	  biology	  and	  the	  
therapeutic	   status	   of	   the	   patient	   at	   the	   time	   of	   blood	   withdrawal.	   B	   cells	   are	   commonly	  
stimulated	  by	  Th2-­‐derived	  IL-­‐4	  to	  differentiate	   into	  plasma	  cells	  to	  secrete	  IgG,	  particularly	  
IgG1	   and	   later	   class	   switch	   to	   IgE,	   whereas	   IFN-­‐γ-­‐producing	   Th1	   cells	   can	   inhibit	   IgG	  
production;	   alternatively,	   IFN-­‐γ	   is	   able	   to	   induce	   class	   switching	   to	   IgG2a	   [214,	   215].	  
Therefore,	  Th1	  responses,	  which	  were	  screened	  for	  by	  detecting	  IFN-­‐γ	  production,	  usually	  do	  
not	  correlate	  with	   IgG1,	  which	  were	  detected.	  Worth	  mentioning	   in	  this	  regard	   is	  that	  Th2	  
responses	  were	  not	  detected,	  because	   L-­‐4	  was	  not	  analyzed;	  however,	   Th2	   responses	   can	  
reduce	   Th1	   activity	   [216].	   In	   addition	   to	   these	   considerations,	   T	   cell	   responses	   and	  
antibodies	  have	  distinct	  kinetics	   in	  that	  IgG	  are	  more	  stable	  than	  T	  cell	  activities,	  the	  latter	  
being	  prone	  to	  influences	  of	  therapy.	  T	  cell	  numbers	  and	  activities	  can	  decline	  dramatically	  
when	  chemotherapy	  is	  applied.	  Since	  time	  of	  blood	  taking	  was	  not	  controlled	  with	  respect	  to	  
current	   therapy,	   these	   were	   unknown	   factors	   influencing	   detectable	   T	   cell	   responses.	   Of	  
note,	  when	  previously	  positive	  patients	  were	  repeatedly	  tested,	  at	  some	  time	  points,	  their	  T	  
cell	  responses	  fell	  under	  the	  detection	  level	  for	  positivity.	  Apart	  from	  therapy,	  the	  screened	  
patient	   cohort	   (see	   Appendix,	   Table	   6.1)	   was	   heterogeneous	   with	   respect	   to	   numerous	  
prognostic	   factors	   such	   as	   tumor	   grade	   and	   age,	   but	   also	  molecular	  markers,	   e.g.	  MGMT	  
status	  (L.	  Bunse,	  data	  not	  shown),	  not	  allowing	  for	  a	  correlation	  between	  immune	  response	  
and	   potentially	   favorable	   prognosis.	   Advantageously,	   a	   spontaneous	   immune	   response	   to	  
IDH1R132H	  was	  not	  associated	  with	  a	  distinct	  class	  II	  HLA-­‐DR	  type	  in	  patients	  (L.	  Bunse,	  data	  
not	   shown),	   nor	   in	   vaccinated	   mice	   (see	   3.2.4,	   Fig.	   3.9),	   making	   a	   vaccination	   therapy	  
applicable	  for	  IDH1R132H-­‐positive	  patients	  irrespective	  of	  their	  HLA-­‐type.	  This	  is	  in	  contrast	  
to	  other	  peptide	  vaccination	  trials	  such	  as	  IMA950	  [134].	  
In	   addition	   to	   the	   fact	   that	   gliomas	   are	   largely	   immunosuppressive	   tumors	   recruiting	  
suppressive	   immune	   cells	   such	   as	  MDSC	   and	   Treg	   into	   their	  microenvironment,	   the	   entire	  
peripheral	   immune	   system	   is	   characterized	   by	   suppression,	   in	   part	   due	   to	   radio-­‐	   and	  
chemotherapy,	  including	  anergic	  and	  dysfunctional	  T	  cells,	  impaired	  co-­‐stimulation	  and	  TCR	  
signaling,	   diminished	   IgG	   synthesis	   by	  B	   cells	   and	  general	   lymphopenia	   [217].	   Yet,	   at	   least	  
lymphopenia	  is	  in	  fact	  favorable	  during	  immunotherapy,	  because	  it	  allows	  the	  expansion	  of	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relevant	   clones	   [218],	   and	   for	   immunotherapeutic	   AT	   of	   tumor	   antigen-­‐specific	   T	   cells,	  
leukapheresis	   or	   other	   means	   of	   lymphodepletion,	   such	   as	   total	   body	   irradiation,	   are	  
commonly	  applied	  as	  pre-­‐treatments	  [29,	  219,	  220].	  
Several	   strategies	   are	   possible	   to	   increase	   the	   potential	   of	   immunotherapies	   during	  
combination	   therapy	   together	   with	   standard	   therapy	   in	   glioma	   patients.	   Radiotherapy	   in	  
itself	   can	  be	  beneficial	   for	   tumor	   antigen-­‐directed	   immune	   responses,	   because	   it	   not	  only	  
induces	   lymphodepletion	   and	   hence	   depletes	   immunosuppressive	   immune	   cells	   [29],	   but	  
also	   increases	   MHC	   expression	   on	   glioma	   cells,	   thereby	   facilitating	   recognition	   by	   T	   cells	  
[151].	   Immunomodulatory	   agents	   such	   as	   checkpoint	   blockers	   can	   be	   applied	   as	   adjuvant	  
therapy	  to	  overcome	  immunosuppression.	  For	  instance,	  CTLA-­‐4	  blockade	  using	  the	  antibody	  
ipilimumab	  has	  proven	  extremely	  efficient	  for	  patients	  with	  melanoma	  [25,	  26]	  and	  shown	  
encouraging	  results	   in	  other	  cancers	  such	  as	  lung	  and	  prostate	  cancer	  [221,	  222].	  Similarly,	  
PD1-­‐blocking	   antibodies	   lambrolizumab	   and	   nivolumab	   prolong	   survival	   in	   melanoma	  
patients	   [28,	   223]	   and	   are	   under	   investigation	   for	   treatment	   of	   lung	   cancer	   [224].	   Since	  
glioma	   cells	   express	   elevated	   levels	   of	   PD1L	   [114,	   225],	   which	   might	   correlate	   with	  
progression	  [226],	  PD1	  blockade	  might	  be	  a	  rational	  option	  for	  concomitant	  treatment.	  Also,	  
CTLA-­‐4	  blockade	  proved	  to	  be	  efficient	  in	  a	  mouse	  model	  for	  glioma	  [227],	  and	  a	  clinical	  trial	  
is	  currently	  under	  way	  comparing	  nivolumab	  and	  ipilimumab	  for	  glioma	  patient	  treatment.	  
Inhibition	  of	  TGF-­‐βR-­‐I	  is	  also	  under	  clinical	  investigation	  to	  target	  TGF-­‐β	  signaling	  in	  glioma,	  
and	  could	  potentially	  be	  combined	  with	  vaccination-­‐based	  immunotherapy.	  
The	  present	  study	  not	  only	  provides	  evidence	  for	  functional	  immunogenicity	  of	  IDH1R132H	  
in	   tumor-­‐bearing	  mice	  and	  spontaneously	  occurring	   immune	   responses	   in	  glioma	  patients,	  
but	  also	  the	  tools	  needed	  for	  monitoring	  immune	  responses	  during	  a	  possible	  clinical	  vaccine	  
trial.	   IFN-­‐γ	  ELISpot	  and	  peptide	  IgG	  ELISA	  were	  established	  to	  monitor	  T	  cell	  responses	  and	  
serum	   IgG	   levels,	   respectively.	   The	   development	   of	   the	   IDH1R132H-­‐peptide	   ELISA	   is	   of	  
particular	   importance	   for	   screening	   for	   specific	   IgG	   in	   multiple	   serum	   samples	   at	   a	   time,	  
allowing	  direct	   comparison	  between	  pre-­‐treatment,	   during	   treatment,	   and	  post-­‐treatment	  
samples	   of	   one	   patient.	   In	   addition,	  monitoring	   will	   involve	   general	   immunophenotyping,	  
including	  number,	  activation	  state,	  and	  phenotype	  of	  lymphocytes	  and	  other	  immune	  cells.	  
With	  these	  conclusions	  and	  techniques,	  a	  clinical	  vaccine	  trial	  in	  IDH1R132H-­‐positive	  glioma	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PBS	   	   	   phosphate-­‐buffered	  saline	  
PCR	   	   	   polymerase	  chain	  reaction	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PCV	   	   	   procarbazine,	  lomustine,	  and	  vincristine	  
PD1	   	   	   programmed	  cell	  death	  protein	  1	  
PDGFRA	   	   platelet-­‐derived	  growth	  factor	  receptor	  alpha	  
PFA	   	   	   paraformaldehyde	  
PHD	   	   	   prolyl	  hydroxylase	  domain-­‐containing	  protein	  
PI	   	   	   propidium	  iodide	  
PMA	   	   	   phorbol-­‐12-­‐myristate-­‐13-­‐acetate	  
PMSF	   	   	   phenylmethylsulphonyl	  fluoride	  
PNS	   	   	   peripheral	  nervous	  system	  
PTEN	   	   	   phosphatase	  and	  tensin	  homologue	  
RB	   	   	   retinoblastoma	  
RT	   	   	   radiotherapy	  /	  room	  temperature	  
s.	  c.	   	   	   subcutaneous(ly)	  
SEB	   	   	   staphylococcus-­‐derived	  enterotoxin	  B	  
secGBM	   	   secondary	  glioblastoma	  multiforme	  
TAA	   	   	   tumor-­‐associated	  antigen	  
TAP	   	   	   transporter	  associated	  with	  antigen	  processing	  
TBS	   	   	   Tris-­‐based	  saline	  
TCR	   	   	   T	  cell	  receptor	  
TDO	   	   	   tryptophan-­‐2,3-­‐dioxygenase	  
Teff	   	   	   effector	  T	  cell	  
TGF-­‐β	   	   	   transforming	  growth	  factor	  β	  
Th	   	   	   T	  helper	  cell	  
TIL	   	   	   tumor-­‐infiltrating	  lymphocyte	  
TLR	   	   	   Toll-­‐like	  receptor	  
TMZ	   	   	   temozolomide	  
TNF-­‐α	   	   	   tumor	  necrosis	  factor	  α	  
Treg	   	   	   regulatory	  T	  cell	  
TYRP1	   	   	   tyrosinase-­‐related	  protein	  1	  
VEGF	   	   	   vascular	  endothelial	  growth	  factor	  
WHO	   	   	   World	  Health	  Organization	  
WRS	   	   	   Wilcoxon	  rank-­‐sum	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wt	   	   	   wildtype	  
	  
6.2	  cDNA	  sequences	  
	  






























Sequence	  is	  shown	  from	  start	  codon	  to	  polyA.	  
	  
































Sequence	  is	  shown	  from	  start	  codon	  to	  polyA.	  
	  










Sequence	  is	  shown	  from	  start	  codon.	  
	  
6.3	  Amino	  acid	  sequences	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6.3.3	  Alignment	  of	  human	  and	  mouse	  IDH1	  proteins	  
	  
query,	  human	  IDH1;	  sbjct,	  subject,	  mouse	  IDH1;	  red	  box,	  IDH1	  p123-­‐142	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6.4	  Quantification	  of	  immunohistochemistry	  
	  
	  
Fig.	  6.1.	  Gating	  strategy	  and	  quantification	  of	  IDH1R132H+	  cells	  in	  syngeneic	  tumor	  slices.	  
IDH1R132H	  detection	  in	  tumor	  slices	  from	  IDH1R132H-­‐expressing	  and	  IDH1wt-­‐expressing	  tumors	  of	  
sham-­‐treated	  and	  vaccinated	  mice	  by	  DAB	  staining.	  IDH1R132H+	  A2.DR1	  tumor	  cells	  were	  counted	  
by	  ImageJ	  with	  an	  algorithm	  using	  background	  subtraction	  and	  colour	  deconvolution	  plugin.	  Red	  line-­‐
framed	  cells	  are	  recognized	  by	  established	  threshold.	  In	  addition	  cells	  marked	  with	  blue	  numbers	  
indicate	  IDH1R132H+	  cells	  gated	  positive	  based	  on	  defined	  cell	  morphology.	  An	  IDH1R132H-­‐
expressing	  tumor	  from	  a	  sham-­‐treated	  mouse	  is	  shown.	  Performed	  by	  L.	  Bunse.	  
	  
6.5	  Patient	  cohort	  
	  
patients gender age diagnosis IDHstatus ELISA sELISA ELISpot SA 
p001 m 50 GBM IDH1R132H x x x x 
p002 f 80 GBM IDH1wt x    
p003 m 68 GBM IDH1wt x    
p004 f 51 A°II IDH1wt x    
p005 m 71 GBM IDH1wt x    
p006 m 50 GBM IDH1wt x    
p007 m 48 O°II IDH1R132H x  x  
p008 m 79 GBM IDH1wt x    
p009 m 42 GBM IDH1R132H x x   
p010 m 41 GBM IDH1wt x    
p011 f 59 GBM IDH1wt x    
p012 m 28 GBM IDH1R132H x    
p013 m 73 GBM IDH1wt x    
p014 f 51 GBM IDH1wt x    
p015 f 60 GBM IDH1wt x    
p016 m 54 GBM IDH1wt x    
p017 m 56 A°III IDH1wt x    
p018 m 61 O°III IDH1R132H x    
p019 m 44 O°III IDH1R132H x  x  
p020 m 52 O°III IDH1R132H x x   
p021 f 71 GBM IDH1wt x    
p022 n.i. n.i. h.d. n.d. x    
p023 m 41 GBM IDH1R132H x x   
p024 m 48 O°II IDH1R132H x x   
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p025 m 47 O°III IDH1R132H x x   
p026 m 50 O°II IDH1R132H x    
p027 m 33 A°III IDH1R132H x x   
p028 m 59 GBM IDH1wt x    
p029 f 54 O°II IDH1R132H x    
p030 m 45 O°III IDH1R132H x    
p031 f 68 GBM IDH1wt x    
p032 f 78 GBM IDH1wt x    
p033 f 66 O°III IDH1R132H x    
p034 m 40 A°II IDH1R132H x  x  
p035 f 51 A°III IDH1R132H x    
p036 m 37 GBM IDH1R132H x x   
p037 m 27 A°III IDH1R132H x x x x 
p038 m 41 O°III IDH1R132H x    
p039 n.i. n.i. h.d. n.d. x    
p040 n.i. n.i. h.d. n.d. x    
p041 m 37 A°II IDH1R132H x x   
p042 m 56 A°III IDHR132C‡ x    
p043 m 34 GBM IDH1R132H x  x  
p044 f 63 GBM IDH1wt x    
p045 m 24 A°III IDH1R132H x  x  
p046 f 68 GBM IDH1wt x  x  
p047 m 46 OA°III IDH1R132H x  x  
p048 m 50 A°III IDH1R132H x  x  
p049 f 40 OA°III IDH1R132H x  x  
p050 f 31 A°III IDH1R132H x  x  
p051 f 57 A°II IDH1R132H x  x  
p052 m 39 OA°III IDH1R132H x  x  
p053 m 45 A°III IDH1R132H x  x  
p054 f 50 secGBM IDH1R132H x  x  
p055 f 60 GBM IDH1wt x  x  
p056 m 34 O°II IDH1R132H x  x  
p057 m 45 A°III IDH1R132H x  x  
p058 f 47 GBM IDH1R132H x  x  
p059 m 36 O°III IDH1R132H x  x  
p060 f 46 secGBM IDH1R132H x  x  
p061 f 44 O°III IDH1wt   x  
p062 m 65 A°III IDH1R132H x    
p063 m 34 A°II IDH1R132H x    
p064 m 43 A°III IDH1R132H x    
p065 m 53 O°III IDH1R132H x  x  
p066 f 51 A°III IDH1R132H x  x  
p067 m 66 GBM IDH1wt x  x  
p068 m 71 GBM IDH1wt x  x  
p069 f 47 A°II IDH1wt x  x  
p070 f 35 A°III IDH1wt x    
p071 m 67 GBM IDH1wt x  x  
p072 m 27 A°II IDH1wt x  x  
p073 f 54 GBM IDH1wt x  x  
p074 m 55 OA°III IDH1R132H   x  
p075 f 34 OA°II IDH1R132H   x  
p076 m 35 OA°II IDH1R132H   x  
p077 n.i. n.i. h.d. n.d. x    
p078 f 53 A°III IDH1R132H x    
p079 m 59 GBM IDH1wt x  x  
p080 m 56 GBM IDH1wt x  x  
p081 f 57 Gliosarcoma IDH1wt x  x  
p082 m 73 GBM IDH1wt x  x  
p083 m 58 GBM IDH1wt x  x  
p084 m 65 GBM IDH1wt x  x  
p085 m 34 GBM IDH1wt x  x  
p086 m 62 GBM IDH1wt x  x  
p087 m 70 GBM IDH1wt x  x  
p088 m 50 GBM IDH1wt x  x  
p089 m 47 GBM IDH1wt x  x  
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p090 f 62 A°II IDH1wt x  x  
p091 m 55 GBM IDH1wt x  x  
p092 f 54 A°III IDH1wt x  x  
p093 m 68 GBM IDH1wt x  x  
p094 m 54 GBM IDH1wt x  x  
p095 m 68 GBM IDH1wt x  x  
p096 m 64 Gliosarcoma IDH1wt x  x  
p097 m 70 GBM IDH1wt x  x  
Table	  6.1.	  Patient	  characteristics	  and	  analysis.	  GBM,	  glioblastoma	  multiforme;	  secGBM,	  secondary	  
GBM;	  A,	  astrocytoma;	  O,	  oligodendroglioma;	  OA,	  oligoastrocytoma;	  °II,	  WHO	  grade	  II;	  °III,	  WHO	  
grade	  III;	  ELISA,	  enzyme-­‐linked	  immuonadsorbent	  assay;	  sELISA,	  subtype	  ELISA;	  ELISpot,	  enzyme-­‐
linked	  immunoadsorbent	  spot	  assay;	  SA,	  secretion	  assay;	  n.i.,	  no	  information;	  h.d.,	  healthy	  donor;	  
n.d.,	  not	  determined;	  ‡,	  categorized	  as	  IDH1wt.	  Data	  collected	  and	  categorized	  by	  L.	  Bunse.	  
